"AHC","PY","nTotDoc","meanAUPerArt","meanAU_IN_PerArt","meanArtAU_IN","meanArtPer_AU_IN_FIRST","meanArtPer_AU_IN_LAST","meanArtPer_AU_IN_CORR","ArtOA","singleAuArt","Q1_nSJR","Q2_nSJR","Q3_nSJR","Q4_nSJR","Q1_percSJR","Q2_percSJR","Q3_percSJR","Q4_percSJR","meanTCperArt","mean_NTC","InternCoauthorship","AffCoauthorship","meanCitationTrend","GC_AUIN_wFractional","GC_AUIN_FIRSTname","GC_AUIN_LASTname","GC_AUIN_CORRESP","top_AU","top_AU_freq","top_AU_wFract","top_AU_freq_wFract","top_AUIN","top_AUIN_freq","top_AUIN_wFract","top_AUIN_freq_wFract","topAUbyCit","topAUbyCit_TC","topAUINbyCit","topAUINbyCit_TC","topAUINbyCit_norm_byYear","topAUINbyCit_TC_norm_byYear","topConcept_L0","topFreq_L0","topConcept_L1","topFreq_L1","topConcept_L2","topFreq_L2","topConcept_L3","topFreq_L3","topConcept_L4","topFreq_L4","topMESH","topMESH_n","topprimary_topic.display_name","topprimary_topic.display_name_n","topDE","topDE_n","topTI_TM","topTI_TM_n","topAB_TM","topAB_TM_n","nDoc_wALTM","percDoc_wALTM","altmetric_score_thirdQu","cited_by_accounts_count_thirdQu","cited_by_fbwalls_count_thirdQu","cited_by_feeds_count_thirdQu","cited_by_gplus_count_thirdQu","cited_by_msm_count_thirdQu","cited_by_patents_count_thirdQu","cited_by_peer_review_sites_count_thirdQu","cited_by_policies_count_thirdQu","cited_by_posts_count_thirdQu","cited_by_rdts_count_thirdQu","cited_by_rh_count_thirdQu","cited_by_tweeters_count_thirdQu","cited_by_videos_count_thirdQu","cited_by_wikipedia_count_thirdQu","cohorts.com_thirdQu","cohorts.doc_thirdQu","cohorts.pub_thirdQu","cohorts.sci_thirdQu","readers.citeulike_thirdQu","readers.connotea_thirdQu","readers.mendeley_thirdQu","readers_count_thirdQu","n_patentsDistinct","nPatentStatus_Abandoned","nPatentStatus_Granted","nPatentStatus_N/A","nPatentStatus_Pending","nPatentStatus_Active","nPatentStatus_Not-in-force","nPatentStatus_Expired - Fee Related","nPatentStatus_Withdrawn","nPatentStatus_Ceased","nPatentStatus_Revoked","nPatentStatus_Expired - Lifetime","nPatentPubType_Application","nPatentPubType_Grant","nPatentPubType_N/A","avg_citations_Patent","avg_Inventors_Patent","inventor_per_AUIN_100","avg_InstitutesInvolved_Patent","nPatent_singleInventor","n_Patents_CoAff","n_Jurisdiction_distinct","nJurisd_AU","nJurisd_CA","nJurisd_EP","nJurisd_IN","nJurisd_CN","nJurisd_US","nJurisd_DE","nJurisd_ES","nJurisd_IT","nJurisd_AT","nJurisd_BR","nJurisd_WO","nJurisd_JP","nJurisd_DK","nJurisd_IL","nJurisd_PT","nJurisd_PL","nJurisd_FR","nJurisd_SA","nJurisd_MY","nJurisd_KR","nJurisd_NL","nJurisd_CO","nJurisd_SM","nJurisd_SI","nJurisd_HR","nJurisd_RU","nJurisd_EA","nJurisd_MX","nJurisd_HK","nPatentKC_A1","nPatentKC_A","nPatentKC_A2","nPatentKC_B1","nPatentKC_D1","nPatentKC_T3","nPatentKC_B2","nPatentKC_T1","nPatentKC_A3","nPatentKC_C","nPatentKC_B","nPatentKC_C2","nPatentKC_C0","nPatentKC_A8","nPatentKC_E","nPatentKC_T4","nPatentKC_D0","nPatentKC_T2","nPatentKC_A0","nPatentKC_B8","nPatentKC_A4","nPatentKC_T8","nPatentKC_C1","nPatentKC_U1","nPatentKC_T5","nPatentKC_B3","nPatentKC_T7","nPatentKC_A9","top_Inventor names_Patent","top_Inventor names_Patent_n","top_Original assignee names_Patent","top_Original assignee names_Patent_n","top_Fields of Research (ANZSRC 2020)_Patent","top_Fields of Research (ANZSRC 2020)_Patent_n","top_RCDC Categories_Patent","top_RCDC Categories_Patent_n","top_HRCS RAC Categories_Patent","top_HRCS RAC Categories_Patent_n","top_IPCR_Patent","top_IPCR_Patent_n","top_CPC_Patent","top_CPC_Patent_n","n_clTrial","avg_durationYear_clTrial","avg_participants_clTrial","clTrial_perAUIN_100","nClTrial_w_AltmScore","cl_AltmS_rel","avg_sponsor_clTrial","nclTrialPhase_Phase 1","nclTrialPhase_Phase 1/2","nclTrialPhase_Phase 2","nclTrialPhase_Phase 2/3","nclTrialPhase_Phase 3","nclTrialPhase_Phase 3/4","nclTrialPhase_Phase 4","nclTrialPhase_N/A","nclTrialPhase_Post Authorisation Studies","nclTrial_StudyType_Interventional","nclTrial_StudyType_Observational","nclTrial_StudyType_Other","nclTrial_StudyType_Expanded access","nclTrial_StudyType_Active surveillance","nclTrial_StudyType_Non-interventional","nclTrial_StudyType_RCT","nclTrial_StudyType_CCT","nclTrial_Gender_All","nclTrial_Gender_Female","nclTrial_Gender_Male","nclTrial_Registry_ClinicalTrials.gov","nclTrial_Registry_EU-CTR","nclTrial_Registry_ENCePP","nclTrial_Registry_ISRCTN","nclTrial_Registry_ANZCTR","nclTrial_Registry_GCTR","nclTrial_Registry_PACTR","nclTrial_Registry_CTRI","nclTrial_Registry_ReBEC","nclTrial_Registry_UMIN-CTR","top_funder_country","top_funder_country_n","top_Fields of Research (ANZSRC 2020)_clTrial","top_Fields of Research (ANZSRC 2020)_clTrial_n","top_RCDC Categories_clTrial","top_RCDC Categories_clTrial_n","top_HRCS HC Categories_clTrial","top_HRCS HC Categories_clTrial_n","top_HRCS RAC Categories_clTrial","top_HRCS RAC Categories_clTrial_n","top_Cancer Types_clTrial","top_Cancer Types_clTrial_n","top_CSO Categories_clTrial","top_CSO Categories_clTrial_n","n_grants","avg_funding_EUR","avg_funding_EUR_perOrganization","avg_durationYear_grant","avg_Organization_per_grant","avg_countries_per_grant","perc_grant_internationalColl","avg_ResultingPublications_per_grant","totFundingOrgbyActivedGrant","avgPubByActivedFundingGrant_1000","top_Research Organization - standardized_Grants","top_Research Organization - standardized_n_Grants","top_Funder_Grants","top_Funder_n_Grants","top_Funder Group_Grants","top_Funder Group_n_Grants","top_Program_Grants","top_Program_n_Grants","top_Fields of Research (ANZSRC 2020)_Grants","top_Fields of Research (ANZSRC 2020)_n_Grants","top_RCDC Categories_Grants","top_RCDC Categories_n_Grants","top_HRCS HC Categories_Grants","top_HRCS HC Categories_n_Grants","top_HRCS RAC Categories_Grants","top_HRCS RAC Categories_n_Grants","top_Cancer Types_Grants","top_Cancer Types_n_Grants","top_CSO Categories_Grants","top_CSO Categories_n_Grants","top_Units of Assessment_Grants","top_Units of Assessment_n_Grants","top_Sustainable Development Goals_Grants","top_Sustainable Development Goals_n_Grants","n_dataset","top_Repository_Dataset","top_Repository_Dataset_n","top_Fields of Research (ANZSRC 2020)_Dataset","top_Fields of Research (ANZSRC 2020)_Dataset_n","top_RCDC Categories_Dataset","top_RCDC Categories_Dataset_n","top_HRCS HC Categories_Dataset","top_HRCS HC Categories_Dataset_n","top_HRCS RAC Categories_Dataset","top_HRCS RAC Categories_Dataset_n","top_Health Research Areas_Dataset","top_Health Research Areas_Dataset_n","top_Broad Research Areas_Dataset","top_Broad Research Areas_Dataset_n","top_Cancer Types_Dataset","top_Cancer Types_Dataset_n","top_Sustainable Development Goals_Dataset","top_Sustainable Development Goals_Dataset_n"
"AOU_GONZAGA",2000,26,7.15384615384615,3.69230769230769,0.270833333333333,0.730769230769231,0.423076923076923,0.192307692307692,0.230769230769231,2,8,4,4,8,0.31,0.15,0.15,0.31,31,0.683859065634256,0.230769230769231,0.5,NA,0.304043531331989,0.168067226890756,0.25,0,"GIUSEPPE SAGLIO;ALFREDO BERRUTI;LUIGI DOGLIOTTI;F. PORPIGLIA;ALBERTO ANGELI;DARIO FONTANA;U MAZZA;TAKEFUMI KAWATA;ADELE PARZIALE;DANIELA DE MICHELI;MARIO TIRIBELLI;G. GORZEGNO;P. PACCOTTI;G. OSELLA;GIUSEPPE REIMONDO;R. TARABUZZI;CLARA CAMASCHELLA;JAVIER GÓMEZ‐ROMÁN;NATASHA V. ZHUKOVSKAYA;M. TORTA","3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","STEFANO GEUNA;R POZZI;RAFFAELLA POZZI;R. GUGLIELMONE;G CORVETTI;LUCCHINA PG;TAKEFUMI KAWATA;NATASHA V. ZHUKOVSKAYA;SALVATORE BOZZARO;JAMES WILLIAMS;F. PORPIGLIA;U MAZZA;CLARA CAMASCHELLA;DARIO FONTANA;ALFREDO BERRUTI;LUIGI DOGLIOTTI;ALBERTO ANGELI;P. PACCOTTI;GIUSEPPE SAGLIO;PAVESE MARCELLA","1;1;0.5;0.5;0.5;0.5;0.4;0.4;0.4;0.4;0.39;0.33;0.33;0.32;0.31;0.31;0.31;0.29;0.26;0.25","GIUSEPPE SAGLIO;ALFREDO BERRUTI;LUIGI DOGLIOTTI;F. PORPIGLIA;ALBERTO ANGELI;DARIO FONTANA;U MAZZA;ADELE PARZIALE;DANIELA DE MICHELI;G. GORZEGNO;P. PACCOTTI;G. OSELLA;GIUSEPPE REIMONDO;R. TARABUZZI;M. TORTA;SALVATORE BOZZARO;ENRICO GOTTARDI;MAURIZIO BELLINA;F MOLLO;PAOLO DE GIULI","3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;1;1","STEFANO GEUNA;R POZZI;RAFFAELLA POZZI;R. GUGLIELMONE;G CORVETTI;SALVATORE BOZZARO;F. PORPIGLIA;U MAZZA;DARIO FONTANA;ALFREDO BERRUTI;LUIGI DOGLIOTTI;ALBERTO ANGELI;P. PACCOTTI;GIUSEPPE SAGLIO;PAVESE MARCELLA;CARMEN MORTELLARO;CORRENTE GIUSEPPE;ABUNDO ROBERTO;G. OSELLA;GIUSEPPE REIMONDO","1;1;0.5;0.5;0.5;0.4;0.39;0.33;0.32;0.31;0.31;0.31;0.29;0.26;0.25;0.25;0.25;0.25;0.24;0.24","ALBERTO ANGELI;ALFREDO BERRUTI;LUIGI DOGLIOTTI;DARIO FONTANA;M. TORTA;MAURIZIO BELLINA;G. GORZEGNO;F. PORPIGLIA;G. FASOLIS;RAFFAELLA BITOSSI;R. TARABUZZI;ALESSANDRA MOSCA;ENRICO BOLLITO;MAURO MARI;ANNA CASTELLÓ;ANTONIO BERTOLOTTO;EVA MILANO;MARCO CAPOBIANCO;ROBERTO MUTANI;SIMONA MALUCCHI","352;352;352;342;338;338;220;210;206;206;136;132;132;132;96;96;96;96;96;96","ALBERTO ANGELI;ALFREDO BERRUTI;LUIGI DOGLIOTTI;DARIO FONTANA;M. TORTA;MAURIZIO BELLINA;G. GORZEGNO;F. PORPIGLIA;G. FASOLIS;RAFFAELLA BITOSSI;ALESSANDRA MOSCA;ENRICO BOLLITO;MAURO MARI;R. TARABUZZI;ANNA CASTELLÓ;ANTONIO BERTOLOTTO;EVA MILANO;MARCO CAPOBIANCO;ROBERTO MUTANI;SIMONA MALUCCHI","352;352;352;338;338;338;220;210;206;206;132;132;132;132;96;96;96;96;96;96","GIUSEPPE SAGLIO;ALBERTO ANGELI;ALFREDO BERRUTI;LUIGI DOGLIOTTI;ADELE PARZIALE;DANIELA CILLONI;DANIELA DE MICHELI;DARIO FONTANA;ENRICO GOTTARDI;F. PORPIGLIA;G. GORZEGNO;G. OSELLA;GIUSEPPE REIMONDO;M. TORTA;MAURIZIO BELLINA;P. PACCOTTI;SALVATORE BOZZARO;U MAZZA;A ANGELI;A. PIA","3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1","MEDICINE;BIOLOGY;PHILOSOPHY;COMPUTER SCIENCE;PHYSICS;ENGINEERING;MATERIALS SCIENCE;PSYCHOLOGY","19;12;3;2;2;1;1;1","INTERNAL MEDICINE;SURGERY;IMMUNOLOGY;GENETICS;ENVIRONMENTAL HEALTH;MOLECULAR BIOLOGY;RADIOLOGY;BIOCHEMISTRY;ENDOCRINOLOGY;GASTROENTEROLOGY;PATHOLOGY;PSYCHIATRY;CANCER RESEARCH;DERMATOLOGY;HORTICULTURE;INTENSIVE CARE MEDICINE;LINGUISTICS;ONCOLOGY;OPTICS;PALEONTOLOGY;UROLOGY;VIROLOGY","15;7;6;5;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2","GENE;CANCER;POPULATION;ANTIBODY;LEUKEMIA;ADENOMA;ASTHMA;BINDING SITE;CIRRHOSIS;DISEASE;DNA;HORMONE;IMMUNOHISTOCHEMISTRY;INCIDENCE (GEOMETRY);LUNG;OSTEOPOROSIS;RECEPTOR;STALK;TRANSCRIPTION (LINGUISTICS);VIRUS","6;4;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ACTIVATOR (GENETICS);ANDROGEN;BREAKPOINT CLUSTER REGION;CHROMOSOMAL TRANSLOCATION;CHRONIC MYELOGENOUS LEUKEMIA;DICTYOSTELIUM;EXON;GENE EXPRESSION;INTRON;MUTANT;PROSTATE CANCER;RNA;TRANSCRIPTION FACTOR;TYROSINE KINASE;ADRENAL ADENOMA;ANTIPHOSPHOLIPID SYNDROME;AORTIC DISSECTION;ASBESTOSIS;BENIGNITY;BLOODLETTING;BONE DENSITY;BONE DISEASE;BONE MINERAL;BREAST CANCER;CALRETININ;CHROMOGRANIN A;CONVULSION;CROHN'S DISEASE;EMERGENCY PHYSICIAN;EPSTEIN–BARR VIRUS;FIXATION (POPULATION GENETICS);GENOTYPE;HEPATITIS C VIRUS;HEPCIDIN;HEREDITARY HEMOCHROMATOSIS;HOUNSFIELD SCALE;HYDROLASE;INFLAMMATORY BOWEL DISEASE;INTERFERON BETA;LIVER BIOPSY;LYMPHOBLASTIC LEUKEMIA;LYMPHOCELE;MOUTH BREATHING;NEUROBLAST;NEURORADIOLOGY;PHENOTYPE;PNEUMONECTOMY;PREMOLAR;PRIMARY EFFUSION LYMPHOMA;PROSTATE;PROTEOLYSIS;RETICULAR FORMATION;SAMPLING (SIGNAL PROCESSING);SIZE-EXCLUSION CHROMATOGRAPHY;TITER;TRYPSIN;ULCERATIVE COLITIS;VASCULITIS;VENOUS THROMBOSIS;VIRAL DISEASE","2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ABL;ALTERNATIVE SPLICING;DNA-BINDING PROTEIN;FUSION TRANSCRIPT;PHILADELPHIA CHROMOSOME;PROMOTER;REPRESSOR;RNA SPLICING;ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY;ANTIANDROGEN;BRONCHOPLEURAL FISTULA;CHYMOTRYPSIN;DEHYDROEPIANDROSTERONE;DEHYDROEPIANDROSTERONE SULFATE;DUAL-ENERGY X-RAY ABSORPTIOMETRY;HEPACIVIRUS;HERPESVIRIDAE;HORMONE THERAPY;INFLAMMATORY BOWEL DISEASES;INTERFERON BETA-1A;PROSTATECTOMY","2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;PROSTATIC NEOPLASMS;MALE;BONE NEOPLASMS;FEMALE;ADULT;MIDDLE AGED;ADRENAL GLAND NEOPLASMS;AGED;BETA-THALASSEMIA;INTERFERON-BETA;;ADJUVANTS, IMMUNOLOGIC;ADOLESCENT;ANTINEOPLASTIC AGENTS;CALCIUM;CYSTEINE ENDOPEPTIDASES;HEMOCHROMATOSIS;LYMPHOCELE;MULTIENZYME COMPLEXES","20;10;9;8;8;6;6;5;5;5;5;4;4;4;4;4;4;4;4;4","BISPHOSPHONATES IN CANCER TREATMENT AND BONE HEALTH;CELL MECHANICS AND EXTRACELLULAR MATRIX INTERACTIONS;EFFICACY AND RESISTANCE IN CML TREATMENT;PHEOCHROMOCYTOMA AND PARAGANGLIOMA;ADVANCED TECHNIQUES IN BIOIMAGE ANALYSIS AND MICROSCOPY;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;APPLICATIONS OF PLATELET-RICH PLASMA IN REGENERATIVE MEDICINE;DIAGNOSIS AND MANAGEMENT OF CHYLOTHORAX AND CHYLOUS ASCITES;DIAGNOSIS AND MANAGEMENT OF PLEURAL DISEASES;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;HEPATITIS C INFECTION AND TREATMENT;IMPACT OF CHILD CARE ON INFECTIOUS DISEASES;MALIGNANT PLEURAL MESOTHELIOMA RESEARCH;MOLECULAR MECHANISMS OF AXON GUIDANCE;PERIOPERATIVE CARDIAC RISK ASSESSMENT AND MANAGEMENT;PRENATAL EXPOSURE TO ANTIEPILEPTIC DRUGS;REGULATION OF IRON METABOLISM AND ANEMIA;STANDARDISATION AND MANAGEMENT OF COPD;SYSTEMIC LUPUS ERYTHEMATOSUS AND ANTIPHOSPHOLIPID SYNDROME","2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ABL;BCR-ABL;BONE METASTASIS;BREAKPOINT CLUSTER REGION;CAAT BOX;CHRONIC MYELOGENOUS LEUKEMIA;DNA BINDING SITE;FUSION TRANSCRIPT;METASTATIC BONE DISEASE;PHILADELPHIA CHROMOSOME;STALK;TRANSCRIPTION (LINGUISTICS);ADRENAL ADENOMA;ADRENAL INCIDENTALOMA;ADRENAL VEIN SAMPLING;ADVERSE EVENTS;ANTIPHOSPHOLIPID SYNDROME;ASBESTOS EXPOSURE;ASBESTOSIS;B CELL ABNORMALITIES","2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1","BONE MARROW;CELL-SPECIFIC GENE;CHRONIC MYELOGENOUS;DICTYOSTELIUM STALK;DIRECTS DICTYOSTELIUM;DNA SEQUENCE;GENE EXPRESSION;LEUKAEMIA PATIENT;MARROW TRANSPLANTATION;MYELOGENOUS LEUKAEMIA;NERVOUS SYSTEM;PATIENT RELAPSED;SEQUENCE ELEMENT;STALK CELL-SPECIFIC;ACUTE LYMPHOBLASTIC;ADRENAL MASSES;ADRENAL NODULES;ANTIPHOSPHOLIPID SYNDROME;AORTIC DISSECTION;ASBESTOS BODY;B-THALASSEMIA TREATED;BCR-ABL TRANSCRIPT;BCRABL TRANSCRIPT;BETA BLOCKERS;BLOCKERS PERIPHERAL;BODY BURDEN;BONE DENSITY;BONE METASTATIC;BONE RESORPTION;BONE SITES","2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HORMONE-REFRACTORY DISEASE;ADRENAL MASSES;BRONCHOPLEURAL FISTULA;BRONCHOPLEURAL FISTULAS;CGA VALUES;DHEAS LEVELS;DHEAS MEASUREMENT;ADRENAL CANCERS;ADRENAL MASS;ANDROGEN DEPRIVATION;DHEAS LEVEL;DISEASE STAGE;EBV TYPE-;ELEVATED CGA;ENDOSCOPIC APPLICATION;ENDOSCOPIC CLOSURE;HORMONE-NAIVE DISEASE;LMP- GENE;LOW DHEAS;MOLECULAR CHARACTERIZATION;POOR PROGNOSIS;POSTRESECTIONAL BRONCHOPLEURAL;SAMPLING STRATEGY;SUPRANORMAL NSE;TYPE- OCCURRED;AB DISEASE;ACTIVE UC;ACTIVITYMETHODS PATIENTS;ADDITIONAL SURGICAL;ADHESIVE METHYL--CYANOACRYLATE","4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1",2,0.08,5.25,4.25,0,0,0,0,4,0,1,4.25,0,0,0,0,0,0,0,0,0,0,0,29,29,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_GONZAGA",2001,26,6.73076923076923,2.73076923076923,0.366197183098592,0.5,0.461538461538462,0.0384615384615385,0.192307692307692,2,9,5,4,6,0.35,0.19,0.15,0.23,35.12,0.76851647782643,0.0384615384615385,0.692307692307692,NA,0.330981826708711,0.256410256410256,0.333333333333333,0,"ALBERTO ANGELI;SUSANNA CAPPIA;LUIGI DOGLIOTTI;PAOLO DE GIULI;STEFANO GEUNA;G. GORZEGNO;MARIA G. GIACOBINI‐ROBECCHI;MICHELE FORNARO;ALFREDO BERRUTI;DARIO FONTANA;EMMA DI CARLO;FEDERICA CAVALLO;FEDERICA GANI;MARIA GIUSEPPA SAROBBA;ELENA QUAGLINO;MICHELA DONADIO;PIERO MUSIANI;ALBERTO BOTTINI;DAVIDE GIANGRANDI;RAFFAELE CALOGERO","5;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2","ROBERTO MARIO SCARPA;CARLOS G. DOTTI;ALBERTO ANGELI;STEFANO GEUNA;MARIA G. GIACOBINI‐ROBECCHI;MICHELE FORNARO;SUSANNA CAPPIA;DAVIDE GIANGRANDI;LUIGI DOGLIOTTI;DARIO FONTANA;PAOLO DE GIULI;FEDERICA GANI;GIANENRICO SENNA;MAURIZIO DEGIULI;CAYETANO SEMPERE ORTEGA;MICHELA MINECCIA;ALFREDO BERRUTI;R. TARABUZZI;ALDO FASOLO;I. DESTEFANO","1;1;0.75;0.7;0.7;0.7;0.49;0.45;0.4;0.38;0.35;0.35;0.35;0.33;0.33;0.33;0.33;0.28;0.25;0.25","ALBERTO ANGELI;SUSANNA CAPPIA;LUIGI DOGLIOTTI;PAOLO DE GIULI;STEFANO GEUNA;G. GORZEGNO;MARIA G. GIACOBINI‐ROBECCHI;MICHELE FORNARO;ALFREDO BERRUTI;DARIO FONTANA;EMMA DI CARLO;FEDERICA CAVALLO;FEDERICA GANI;ELENA QUAGLINO;PIERO MUSIANI;DAVIDE GIANGRANDI;RAFFAELE CALOGERO;R. TARABUZZI;PAOLA BERNABEI;GUIDO FORNI","5;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2","CARLOS G. DOTTI;ALBERTO ANGELI;STEFANO GEUNA;MARIA G. GIACOBINI‐ROBECCHI;MICHELE FORNARO;SUSANNA CAPPIA;DAVIDE GIANGRANDI;LUIGI DOGLIOTTI;DARIO FONTANA;PAOLO DE GIULI;FEDERICA GANI;MICHELA MINECCIA;ALFREDO BERRUTI;R. TARABUZZI;I. DESTEFANO;PAOLO BORRIONE;VITTORIO FALCO;MARCO SCAGLIA;DE GIULI P;VINCENZO CARBONE","1;0.75;0.7;0.7;0.7;0.49;0.45;0.4;0.38;0.35;0.35;0.33;0.33;0.28;0.25;0.25;0.25;0.25;0.25;0.25","ALBERTO ANGELI;SUSANNA CAPPIA;PAOLO DE GIULI;DARIO FONTANA;ALFREDO BERRUTI;LUIGI DOGLIOTTI;R. TARABUZZI;ALESSANDRO MUSSA;ENRICO SAGGIORATO;FABIO ORLANDI;G PANCANI;P. CARACI;MARCELLO TUCCI;RAFFAELE CALOGERO;ADRIANA BOCCUZZI;ANNA ALÌ;F. PORPIGLIA;MASSIMO TERZOLO;P. PACCOTTI;SILVIA BOVIO","381;295;284;234;164;164;140;134;134;134;134;134;106;104;94;94;94;94;94;94","PAOLO DE GIULI;SUSANNA CAPPIA;ALBERTO ANGELI;ALFREDO BERRUTI;LUIGI DOGLIOTTI;DARIO FONTANA;MARCELLO TUCCI;R. TARABUZZI;RAFFAELE CALOGERO;ELENA QUAGLINO;EMMA DI CARLO;GUIDO FORNI;PIERO MUSIANI;SILVIA SAVIOZZI;FEDERICA GANI;ALESSANDRA ANDRÈ;FEDERICA CAVALLO;K BOGGIO;MICHELA SPADARO;PIER‐LUIGI LOLLINI","284;284;140;114;114;106;106;106;104;90;90;90;90;59;46;45;45;45;45;45","MARIA G. GIACOBINI‐ROBECCHI;MICHELE FORNARO;PAOLO DE GIULI;STEFANO GEUNA;SUSANNA CAPPIA;ALBERTO ANGELI;ALFREDO BERRUTI;DAVIDE GIANGRANDI;ELENA QUAGLINO;EMMA DI CARLO;FEDERICA GANI;GUIDO FORNI;LUIGI DOGLIOTTI;PIERO MUSIANI;RAFFAELE CALOGERO;A. LEONARDI;A. PONCINO;ALESSANDRA ANDRÈ;CARMEN MORTELLARO;DARIO FONTANA","3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;MATERIALS SCIENCE","20;11;1;1;1","INTERNAL MEDICINE;PATHOLOGY;IMMUNOLOGY;SURGERY;CELL BIOLOGY;GASTROENTEROLOGY;BIOCHEMISTRY;ONCOLOGY;GENETICS;NEUROSCIENCE;ANATOMY;ANESTHESIA;CANCER RESEARCH;DERMATOLOGY;ENDOCRINOLOGY;UROLOGY;ENVIRONMENTAL HEALTH;FISHERY;GYNECOLOGY;INFORMATION RETRIEVAL;LIBRARY SCIENCE;METALLURGY;MICROBIOLOGY;MOLECULAR BIOLOGY;NURSING;ORGANIC CHEMISTRY;PALEONTOLOGY;PHARMACOLOGY;PHYSICAL THERAPY;PROGRAMMING LANGUAGE;PSYCHIATRY;WORLD WIDE WEB","14;10;7;7;5;5;4;4;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;GENE;IMMUNOHISTOCHEMISTRY;CYTOKINE;DISEASE;RECEPTOR;ADENOMA;ANGIOGENESIS;CARCINOMA;CHEMOTHERAPY;HYPERPLASIA;IMMUNE SYSTEM;INTRACELLULAR;MESOTHELIOMA;NEURON;OVERALL SURVIVAL;SURVIVAL ANALYSIS;ABDOMINAL PAIN;ADJUVANT;ADRENOCORTICAL CARCINOMA;ALLERGY;ALTERNATIVE MEDICINE;AMINO ACID;ANESTHESIOLOGY;ANGIOEDEMA;APOPTOSIS;ASBESTOS;ASTHMA;BIOPSY;BONE REMODELING;BONE RESORPTION;CELL;CELL CULTURE;CELL GROWTH;CENTRAL NERVOUS SYSTEM;CITATION;CLINICAL TRIAL;COMMON COLD;CYSTIC FIBROSIS;DIARRHEA;DIFFERENTIAL DIAGNOSIS;DNA;DORSUM;DOWNLOAD;EMBRYO;ENTERIC NERVOUS SYSTEM;ENZYME;EOSINOPHILIA;EPIDEMIOLOGY;FIBROSIS;FISH <ACTINOPTERYGII>;FOLLICULAR PHASE;HELMINTHS;HEMORRHOIDS;HORMONE;ICON;LESION;LOGISTIC REGRESSION;MALIGNANCY;MAXILLA;MEDICAL ADVICE;MONOCYTE;NASAL ADMINISTRATION;NEUROGENESIS;NITRIC OXIDE;ODONTOGENIC;OLFACTORY SYSTEM;OSTEOLYSIS;OSTEOPOROSIS;OUTPATIENT CLINIC;PANCREAS;PATHOGEN;PHOSPHORYLATION;PLATELET;PLEURAL EFFUSION;POPULATION;PROPORTIONAL HAZARDS MODEL;QUALITY OF LIFE (HEALTHCARE);RANDOMIZED CONTROLLED TRIAL;REGIMEN;RHINORRHEA;SCLEROTHERAPY;SIGNAL TRANSDUCTION;SIGNIFICANT DIFFERENCE;SOMATOSTATIN;STAGE (STRATIGRAPHY);STEM CELL;SWALLOWING;TABLE OF CONTENTS;THYROID;TUBERCULOSIS;URINARY INCONTINENCE;URINARY SYSTEM;VEGF RECEPTORS;VERTIGO","7;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;PROSTATE;CELL CYCLE;INTERFERON GAMMA;INTERLEUKIN;METASTASIS;PROSTATE CANCER;ADRENOCORTICAL ADENOMA;AMELOBLASTOMA;ANAPHYLAXIS;ANISAKIS;ANISAKIS SIMPLEX;ARGININE;ATOPY;ATYPICAL HYPERPLASIA;BONE DISEASE;BRONCHODILATOR;CALMODULIN;CARCINOGENESIS;CYCLIC GUANOSINE MONOPHOSPHATE;CYSTEINE;DNA SYNTHESIS;DOWNREGULATION AND UPREGULATION;ECTOPIC EXPRESSION;FINE-NEEDLE ASPIRATION;GASTRIC CARCINOMA;GENE EXPRESSION;GROWTH FACTOR;GROWTH HORMONE;GUANYLATE CYCLASE;HEK 293 CELLS;INFLAMMATORY BOWEL DISEASE;IONOMYCIN;KI-67;LEUKOPENIA;LYMPHOKINE;MACKEREL;METABOLIC BONE DISEASE;MYCOBACTERIUM;MYCOBACTERIUM TUBERCULOSIS;MYENTERIC PLEXUS;NASAL SPRAY;NEURAL STEM CELL;NEUTROPENIA;NOCTURIA;ODONTOGENIC CYST;PAIN MEDICINE;PARACRINE SIGNALLING;PARATENIC;PHOSPHATASE;PHOSPHODIESTERASE;PLACEBO;PROGNOSTIC VARIABLE;PROLIFERATING CELL NUCLEAR ANTIGEN;PROTEIN SUBUNIT;SOMATIC CELL;SUPPRESSOR;TAMSULOSIN;THYROID CANCER;THYROID CARCINOMA;THYROID NODULES;TOXOCARA CANIS;TRANSCRIPTION FACTOR;TRANSFECTION;TRANSGENE;TUNEL ASSAY;VASCULAR ENDOTHELIAL GROWTH FACTOR;VERRUCOUS CARCINOMA","4;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ACROMEGALY;ADJUVANT CHEMOTHERAPY;ANTHRACYCLINE;BONE METASTASIS;CA15-3;DOUBLE BLIND;ESTROGEN RECEPTOR;FEBRILE NEUTROPENIA;GENETICALLY MODIFIED MOUSE;INSULIN-LIKE GROWTH FACTOR;IPRATROPIUM BROMIDE;LOWER URINARY TRACT SYMPTOMS;MAMMARY TUMOR;MESALAZINE;METASTATIC BREAST CANCER;MONOKINE;MYCOBACTERIUM BOVIS;NEUROEPITHELIAL CELL;ONCOGENE;PROSTATE-SPECIFIC ANTIGEN;PROTEIN PHOSPHATASE 1;SOLUBLE GUANYLYL CYCLASE;TAXANE;ZAPRINAST","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;ADULT;MALE;BONE NEOPLASMS;BREAST NEOPLASMS;MESOTHELIOMA;MIDDLE AGED;PLEURAL NEOPLASMS;ADENOMA;MAMMARY NEOPLASMS, EXPERIMENTAL;NEURONS;ADENOCARCINOMA;AGED;ANIMALS;T-LYMPHOCYTES;INTERFERON-GAMMA;INTERLEUKIN-12;KI-67 ANTIGEN;NERVE TISSUE PROTEINS","18;11;10;9;8;8;8;8;8;7;7;7;6;6;6;6;5;5;5;5","EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;MALIGNANT PLEURAL MESOTHELIOMA RESEARCH;ADULT NEUROGENESIS AND BRAIN DEVELOPMENT;ALLERGIC RHINITIS AND ITS IMPACT ON ASTHMA;BISPHOSPHONATES IN CANCER TREATMENT AND BONE HEALTH;BROWN ADIPOSE TISSUE FUNCTION AND PHYSIOLOGY;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;CLASSIFICATION AND MANAGEMENT OF ODONTOGENIC TUMORS;CLOSTRIDIUM DIFFICILE INFECTION AND TREATMENT;DIAGNOSIS AND MANAGEMENT OF TEMPOROMANDIBULAR DISORDERS;DIAGNOSIS, TREATMENT, AND EPIDEMIOLOGY OF NONTUBERCULOUS MYCOBACTERIAL DISEASES;ECOLOGICAL INTERACTIONS OF PARASITES IN ECOSYSTEMS;EMERGING ANIMAL PATHOGENS AND DISEASES;FUNCTIONAL BOWEL DISORDERS AND GASTROINTESTINAL HEALTH;GASTRIC CANCER RESEARCH AND TREATMENT;MOLECULAR MECHANISMS OF ANGIOGENESIS AND VASCULAR FUNCTION;NATURAL KILLER CELLS IN IMMUNITY;OLFACTORY DYSFUNCTION IN HEALTH AND DISEASE;PHEOCHROMOCYTOMA AND PARAGANGLIOMA;ROLE OF GALECTINS IN IMMUNITY AND DISEASE","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MALIGNANT PLEURAL MESOTHELIOMA;NEURONAL DIFFERENTIATION;TREATMENT;ADJUVANT CHEMOTHERAPY;ADJUVANT THERAPY;ADRENAL VEIN SAMPLING;ADRENOCORTICAL ADENOMA;ADRENOCORTICAL CARCINOMA;ALFUZOSIN;AMINO ACID TRANSPORTERS;ANISAKIS;ANISAKIS SIMPLEX;ATOPY;ATYPICAL HYPERPLASIA;BIOCHEMICAL DIAGNOSIS;BISPHOSPHONATES;BONE DISEASE;BONE METASTASIS;BONE REMODELING;CA 15-3","2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER PATIENTS;BREAST CANCER;PROSTATE CANCER;ACQUIRED IMMUNODEFICIENCY;ACTIVATED LYMPHOCYTES;ADJUVANT CHEMOTHERAPY;ADRENOCORTICAL TUMORS;ADULT DORSAL;ADULT FIBROSING;ADULT MYENTERIC;ADVANCED BREAST;ADVANCED PROSTATE;ANALOG LANREOTIDE;ANTHRACYCLINE-PRETREATED METASTATIC;ANTIAGGREGATING EFFECT;ARF INTERACTS;BALBC TRANSGENIC;BLOOD HUMAN;BONE DISEASE;BORDERLINE DISORDER;BROMIDE NASAL;CANCER RATIONALE;CARCINOMA DEVELOPING;CHICK EMBRYO;CHROMOGRANINA PROSTATESPECIFIC;CIRCULATING LEVELS;CLINICAL EVALUATION;COLD-INDUCED RHINITIS;CONTROLLED TRIAL;CULTURED BLOOD","3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","TRUE NEUROGENESIS;NEWLY GENERATED;CELL BLOCKS;CELL CYCLE;DORSAL ROOT;DRG NEURONS;SURVIVAL MONTHS;ADDED NEURONS;CELL LINEAGE;ECTOPIC EXPRESSION;FOLLICULAR ADENOMAS;GENERATED DRG;GENERATED NEURONS;IMMATURE NEURONS;LATE DIFFERENTIATION;LONG-TERM SURVIVAL;NEUROGENESIS OCCURRED;NEURON ADDITION;NEWLY ADDED;PRECURSORS BELONGING;SLIGHTLY IMMATURE;SPINOPHILINNEURABIN II;SURGICAL SPECIMENS;THYROID NODULES;ABORTIVELY CONNECTED;ACOUPHONIA VERTIGO;ACTIVATING ARF;ADDITIONAL PREDICTIVE;ADULT NEUROGENESIS;AGGRESSIVE TUMOR","5;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1",1,0.04,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,14,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_GONZAGA",2002,34,8.32352941176471,2.44117647058824,0.409638554216867,0.441176470588235,0.382352941176471,0.117647058823529,0.294117647058824,0,13,8,5,5,0.38,0.24,0.15,0.15,72.79,1.3194819484722,0.235294117647059,0.852941176470588,NA,0.358588117152923,0.231884057971015,0.240740740740741,0.15,"GIUSEPPE SAGLIO;MARIELLA TROVATI;CLARA CAMASCHELLA;ANTONELLA ROETTO;GIOVANNI ANFOSSI;DARIO FONTANA;ROBERTA LA STARZA;ROBERTO MARIO SCARPA;GIUSEPPE POLI;CRISTINA MECUCCI;ALDO CATALDI;PAOLA MASSUCCO;LUIGI MATTIELLO;PATRIZIA SCARAVAGLIO;FRANCO CAVALOT;LUIGI DOGLIOTTI;GIOVANNA REGE‐CAMBRIN;ANGELO GUERRASIO;ISABELLA RUSSO;EMILIA GIUGLIANO","6;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","GIUSEPPE SAGLIO;CLARA CAMASCHELLA;ANTONELLA ROETTO;STEFANO GEUNA;M.G. GIACOBINI‐ROBECCHI;MARIELLA TROVATI;GIOVANNI ANFOSSI;ALDO CATALDI;ANGELO GUERRASIO;GIUSEPPE POLI;MARCO DE GOBBI;PAOLA MASSUCCO;BARBARA SOTTERO;FRANCO CAVALOT;GABRIELLA LEONARDUZZI;ROBERTO TORCHIO;MARCO PARVIS;C. GULOTTA;DARIO FONTANA;LUIGI MATTIELLO","0.77;0.62;0.62;0.5;0.5;0.42;0.42;0.39;0.39;0.39;0.33;0.33;0.33;0.33;0.33;0.33;0.33;0.33;0.29;0.26","GIUSEPPE SAGLIO;MARIELLA TROVATI;CLARA CAMASCHELLA;ANTONELLA ROETTO;GIOVANNI ANFOSSI;DARIO FONTANA;ROBERTO MARIO SCARPA;GIUSEPPE POLI;ALDO CATALDI;PAOLA MASSUCCO;LUIGI MATTIELLO;PATRIZIA SCARAVAGLIO;FRANCO CAVALOT;LUIGI DOGLIOTTI;GIOVANNA REGE‐CAMBRIN;EMILIA GIUGLIANO;ANNA SERRA;DARIO COCITO;FEDERICA CAVALLO;STEFANO GEUNA","6;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1","GIUSEPPE SAGLIO;CLARA CAMASCHELLA;ANTONELLA ROETTO;STEFANO GEUNA;M.G. GIACOBINI‐ROBECCHI;MARIELLA TROVATI;GIOVANNI ANFOSSI;ALDO CATALDI;GIUSEPPE POLI;MARCO DE GOBBI;PAOLA MASSUCCO;BARBARA SOTTERO;FRANCO CAVALOT;ROBERTO TORCHIO;C. GULOTTA;DARIO FONTANA;LUIGI MATTIELLO;G PICCIOLO;STEFANIA RE;PATRIZIA BIANCUCCI","0.77;0.62;0.62;0.5;0.5;0.42;0.42;0.39;0.39;0.33;0.33;0.33;0.33;0.33;0.33;0.29;0.26;0.25;0.25;0.25","ANTONELLA ROETTO;CLARA CAMASCHELLA;DIMITRIS LOUKOPOULOS;DOMENICO GIRELLI;FEDERICA ALBERTI;GEORGE PAPANIKOLAOU;JOHN CHRISTAKIS;MARIANNA POLITOU;ADRIANO CHIÒ;DARIO COCITO;E. BOTTACCHI;GABRIELE MORA;LETIZIA MAZZINI;M. T. GIORDANA;MAURIZIO LEONE;ROBERTO MUTANI;GIUSEPPE POLI;BARBARA SOTTERO;GABRIELLA LEONARDUZZI;CESARE GREGORETTI","926;926;868;868;868;868;868;868;234;234;234;234;234;234;234;234;201;188;188;157","CLARA CAMASCHELLA;FEDERICA ALBERTI;ADRIANO CHIÒ;DARIO COCITO;E. BOTTACCHI;GABRIELE MORA;LETIZIA MAZZINI;M. T. GIORDANA;MAURIZIO LEONE;ROBERTO MUTANI;GIUSEPPE POLI;BARBARA SOTTERO;FEDERICA GAMNA;VINCENZO SQUADRONE;G. GORZEGNO;RAFFAELE CALOGERO;CARMEN MORTELLARO;G PICCIOLO;PATRIZIA BIANCUCCI;V VERCELLINO","885;868;234;234;234;234;234;234;234;234;201;188;157;157;121;92;90;90;90;90","GIOVANNI ANFOSSI;GIUSEPPE SAGLIO;CLARA CAMASCHELLA;EMILIA GIUGLIANO;FRANCO CAVALOT;GIUSEPPE POLI;MARIELLA TROVATI;PAOLA MASSUCCO;ADRIANO CHIÒ;ALBERTO ANGELI;ALESSIA DI SAPIO;ANNA SERRA;ANTONELLA ROETTO;BARBARA SOTTERO;C MOSSETTI;CARMEN MORTELLARO;CLAUDIA BANCONE;DANIELLA ZANETTI;DARIO COCITO;DARIO FONTANA","3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;CHEMISTRY;PSYCHOLOGY;COMPUTER SCIENCE;PHYSICS;ECONOMICS;ENGINEERING;MATHEMATICS;PHILOSOPHY","26;17;5;3;2;2;1;1;1;1","INTERNAL MEDICINE;GENETICS;PATHOLOGY;BIOCHEMISTRY;IMMUNOLOGY;SURGERY;ENDOCRINOLOGY;CANCER RESEARCH;GASTROENTEROLOGY;ONCOLOGY;RADIOLOGY;CELL BIOLOGY;MOLECULAR BIOLOGY;UROLOGY;ARTIFICIAL INTELLIGENCE;PALEONTOLOGY;ANATOMY;ANESTHESIA;COMPUTER HARDWARE;DATA MINING;DENTISTRY;ECOLOGY;EMBEDDED SYSTEM;GYNECOLOGY;INTENSIVE CARE MEDICINE;LINGUISTICS;MATHEMATICAL ECONOMICS;MATHEMATICS EDUCATION;MECHANICAL ENGINEERING;MEDICAL EDUCATION;MICROBIOLOGY;NEUROSCIENCE;NURSING;OBSTETRICS;OPERATING SYSTEM;OPTICS;ORTHODONTICS;PEDAGOGY;PEDIATRICS;PHARMACOLOGY;PURE MATHEMATICS;QUANTUM MECHANICS;REAL-TIME COMPUTING","19;12;10;9;8;8;7;6;4;4;4;3;3;3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","GENE;CANCER;CHEMOTHERAPY;MYELOID LEUKEMIA;RECEPTOR;BONE MARROW;LEUKEMIA;TRANSPLANTATION;ANTIBODY;CARCINOMA;DIABETES MELLITUS;DISEASE;ENZYME;HEMOCHROMATOSIS;HYPERPLASIA;IMMUNOHISTOCHEMISTRY;INFLAMMATION;INSULIN;NITRIC OXIDE;PLATELET;TRISOMY","13;7;4;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","CHROMOSOME;CHROMOSOMAL TRANSLOCATION;CYCLOPHOSPHAMIDE;MUTATION;GENE DUPLICATION;GENOTYPE;LOCUS (GENETICS);MDM2;ABORTION;ADENOCARCINOMA;ADRENOCORTICAL ADENOMA;ALKALINE PHOSPHATASE;ASTROCYTOMA;AUTOANTIBODY;AZATHIOPRINE;BIRTH WEIGHT;BLADDER CANCER;BREAKPOINT CLUSTER REGION;CARCINOGENESIS;CARCINOMA IN SITU;CELL CYCLE;CHEMOKINE;CHILDBIRTH;CISPLATIN;COSMID;CYCLIC GUANOSINE MONOPHOSPHATE;CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR;CYTOTOXIC T CELL;DACARBAZINE;DNA DAMAGE;DOXAZOSIN;ENDOCYTOSIS;EPOETIN ALFA;ESSENTIAL THROMBOCYTHEMIA;FUSION GENE;GEMCITABINE;GENE ISOFORM;GENE REARRANGEMENT;GINGIVAL AND PERIODONTAL POCKET;HAZARD RATIO;HEPCIDIN;HEREDITARY HEMOCHROMATOSIS;HYDROXYCARBAMIDE;INFECTIOUS DISEASE (MEDICAL SPECIALTY);INSULIN RESISTANCE;IRON HOMEOSTASIS;KIDNEY TRANSPLANTATION;LIPOPROTEIN;LIVER TRANSPLANTATION;LOW BIRTH WEIGHT;LOW-DENSITY LIPOPROTEIN;MESSENGER RNA;MINIMAL RESIDUAL DISEASE;MUTANT;MYELODYSPLASTIC SYNDROMES;NITRIC OXIDE SYNTHASE;NUCLEOTIDE;OXYSTEROL;P53 PROTEIN;PAGETOID;PANCREATIC DISEASE;PANCYTOPENIA;PARATHYROID HORMONE;PERIPHERAL NEUROPATHY;PHOSPHATIDYLINOSITOL;PLACEBO;PLATELET AGGREGATION;POSTPRANDIAL;PROSTATE;PROSTATE CANCER;REGULATOR;RESTRICTION ENZYME;SOUTHERN BLOT;SPLENECTOMY;SUPPRESSOR;TACROLIMUS;TAMSULOSIN;THROMBOCYTOSIS;TRANSCRIPTION FACTOR;TRANSFERRIN RECEPTOR;TRANSMEMBRANE PROTEIN;TRYPSIN;TYPE 2 DIABETES;TYROSINE KINASE;UBIQUITIN;UNIVARIATE ANALYSIS;UROTHELIUM","5;3;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CYTOGENETICS;FLUORESCENCE IN SITU HYBRIDIZATION;KARYOTYPE;CHROMOSOME 7 (HUMAN);ABL;ADENOSINE DIPHOSPHATE;ANAGRELIDE;BONE METASTASIS;BREAKPOINT;BUSULFAN;CHROMOSOME 21;CORONAVIRUS DISEASE 2019 (COVID-19);DYNAMIN;ETV6;FERROPORTIN;HAMP;INSULIN ASPART;NERVE BIOPSY;OSTEOCALCIN;PHARMACOGENETICS;PHILADELPHIA CHROMOSOME;PSTI;RNA-BINDING PROTEIN;SCAVENGER RECEPTOR;SPLENIC DISEASE;TRANSCRIPTIONAL ACTIVITY;TRANSCRIPTIONAL REGULATION;TRANSITIONAL CELL CARCINOMA;TRANSLATION (BIOLOGY);TRYPSINOGEN;UNTRANSLATED REGION;VINCRISTINE;WORTMANNIN","4;4;3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;ADULT;MIDDLE AGED;LEUKEMIA, MYELOID;AGED;NEOPLASMS;URINARY BLADDER NEOPLASMS;ADOLESCENT;INSULIN;HODGKIN DISEASE;KIDNEY DISEASES;RECEPTOR, ERBB-2;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;CARCINOMA, NON-SMALL-CELL LUNG;IN SITU HYBRIDIZATION, FLUORESCENCE;LUNG NEOPLASMS;NITRIC OXIDE;PROTO-ONCOGENE PROTEINS","29;19;18;15;12;11;10;8;8;7;7;6;6;6;5;5;5;5;5;5","ACUTE MYELOID LEUKEMIA;REGULATION OF IRON METABOLISM AND ANEMIA;LYMPHOID NEOPLASMS;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;APPLICATIONS OF PLATELET-RICH PLASMA IN REGENERATIVE MEDICINE;BISPHOSPHONATES IN CANCER TREATMENT AND BONE HEALTH;CHOLESTEROL METABOLISM AND ATHEROSCLEROSIS;CUTANEOUS ADNEXAL NEOPLASMS AND RELATED SYNDROMES;DIAGNOSIS AND MANAGEMENT OF PANCREATITIS;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;EFFECTS OF MEDICATION ON PREGNANCY OUTCOMES;EFFICACY AND RESISTANCE IN CML TREATMENT;ELONGATED STYLOID PROCESS SYNDROME: CLINICAL AND ANATOMICAL STUDY;GLYCOSYLATION IN HEALTH AND DISEASE;GUILLAIN-BARRÉ SYNDROME AND RELATED NEUROPATHIES;IMMUNOBIOLOGY OF DENDRITIC CELLS;INFLAMMATION AND OBESITY-RELATED METABOLIC DISORDERS;LIVER TRANSPLANTATION AND GRAFT SURVIVAL ANALYSIS;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS","4;3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","TRISOMY 8;ACUTE MYELOID LEUKEMIA;CANCER METABOLISM;CHROMOSOME ABNORMALITY;HEMOCHROMATOSIS;TRISOMY;ABL;ABVD;ACTIVE LEARNING;ACUTE LYMPHOBLASTIC LEUKEMIA;ADENOSINE DIPHOSPHATE;ADRENAL VEIN SAMPLING;ADRENOCORTICAL ADENOMA;AMPHIPHYSIN;ANAGRELIDE;ANTIGEN PRESENTATION;BARTHOLIN GLAND CYST;BENIGN PROSTATIC HYPERPLASIA;BIOMARKER ANALYSIS;BONE METASTASIS","3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ACUTE MYELOID;MYELOID LEUKEMIA;NITRIC OXIDE;ABELSON ONCOGENE;ABERRATIONS DETECTED;ACUTE LYMPHOBLASTIC;ADEQUATE SURGICAL;ADRENAL MASS;ADULT PERIODONTAL;ADVANCED TRANSITIONAL;AFFECT SAFETY;ALBUMIN EXCRETION;ALS OUTCOME;AMPHIPHYSIN II;ANALOG ASPART;ANTIMICROBIAL PEPTIDE;AUTOLOGOUS BONE;BENIGN PROSTATIC;BLADDER UROTHELIAL;BLOOD CELL;BLOOD STEM;BONE MARROW;BONE METASTASES;CANCER PATIENTS;CATARACT SYNDROME;CELL CANCER;CELL COUNT;CELL LUNG;CHOLESTEROL DIETARY;CHROMOSOME ABERRATIONS","3;3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","PATIENT COMFORT;SKIN BREAKDOWN;BONE RESORPTION;CYCLIC NUCLEOTIDES;EYE IRRITATION;CANCER PATIENTS;CNOS ACTIVITY;EPOETIN ALFA;INSULIN RESISTANCE;POSITIVE CELLS;RENAL LESIONS;WBC COUNT;BONE FORMATION;BONE METASTASES;BONE PAIN;CANCER-RELATED ANAEMIA;CANCER-SPECIFIC MEASURES;CAVERNOSAL SMOOTH;CELL PROTEIN;CHANGE SIGNIFICANTLY;CHOLESTEROL OXIDATION;CNOS MRNA;CNOS PROTEIN;COMFORT SKIN;COUNT CORRELATES;CT SCAN;CYCLASE ACTIVATION;CYCLIC MONOPHOSPHATE;FATIGUE SUBSCALE;FOURTH DAY","5;5;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2",8,0.24,5.51,3.25,1,0,0,0,8,1,1.5,3.25,0,0,2,0,1,0,0,2,0,0,0,95.25,95.25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_GONZAGA",2003,42,7.04761904761905,2.4047619047619,0.415841584158416,0.571428571428571,0.333333333333333,0.214285714285714,0.357142857142857,6,27,7,3,5,0.64,0.17,0.07,0.12,141.19,2.66760010541546,0.30952380952381,0.666666666666667,NA,0.479428826751237,0.234375,0.255555555555556,0.233766233766234,"FEDERICA GANI;ANTONIO BERTOLOTTO;GIUSEPPE SAGLIO;G. GORZEGNO;MARIELLA TROVATI;PAOLA MASSUCCO;B. PEZZULICH;SARA ORECCHIA;SILVIA NOVELLO;MICHELE DE SIMONE;IRENE TARDIVO;CARLO LOMBARDI;ARIANNA SALA;A PREVITI;PAOLA CACCIOTTI;GIORGIO WALTER CANONICA;R MINIERO;MASSIMO LANDI;G. VARALDA;SIMONA MALUCCHI","3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","B. PEZZULLICH;C. FAVA;B. PEZZULICH;B PEZZULICH;MARIELLA TROVATI;PAOLA MASSUCCO;FEDERICA GANI;SILVIA NOVELLO;GIUSEPPE POLI;A PREVITI;G. VARALDA;PIETRO GRECO LUCCHINA;SÍLVIA R.L. LADEIRA;C. NUMES;JÖRG R. SCHAUR;THIERRY LE CHEVALIER;G. PASSALACQUA;LUIGI MATTIELLO;GIOVANNI ANFOSSI;ISABELLA RUSSO","2;2;1.5;1;0.65;0.65;0.62;0.6;0.5;0.5;0.5;0.5;0.5;0.5;0.5;0.5;0.45;0.4;0.4;0.4","FEDERICA GANI;ANTONIO BERTOLOTTO;GIUSEPPE SAGLIO;G. GORZEGNO;MARIELLA TROVATI;PAOLA MASSUCCO;B. PEZZULICH;SILVIA NOVELLO;CARLO LOMBARDI;ARIANNA SALA;A PREVITI;GIORGIO WALTER CANONICA;MASSIMO LANDI;G. VARALDA;SIMONA MALUCCHI;B. PEZZULLICH;ALESSIA DI SAPIO;C. FAVA;LUIGI MATTIELLO;P. BORASIO","3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","B. PEZZULLICH;C. FAVA;B. PEZZULICH;B PEZZULICH;MARIELLA TROVATI;PAOLA MASSUCCO;FEDERICA GANI;SILVIA NOVELLO;GIUSEPPE POLI;A PREVITI;G. VARALDA;PIETRO GRECO LUCCHINA;SÍLVIA R.L. LADEIRA;C. NUMES;G. PASSALACQUA;LUIGI MATTIELLO;GIOVANNI ANFOSSI;ISABELLA RUSSO;ANTONIO BERTOLOTTO;CARLO LOMBARDI","2;2;1.5;1;0.65;0.65;0.62;0.6;0.5;0.5;0.5;0.5;0.5;0.5;0.45;0.4;0.4;0.4;0.38;0.37","GIUSEPPE SAGLIO;ALOÏS GRATWOHL;ANDREAS HOCHHAUS;ANN E. BOLTON;BENGT SIMONSSON;BRIAN J. DRUKER;FRANCISCO CERVANTES;FRANÇOIS GUILHOT;GREGOR VERHOEF;HAGOP M. KANTARJIAN;INSA GATHMANN;JAN J. CORNELISSEN;JOHAN LANNG NIELSEN;JOHN D. SHEPHERD;JOHN M. GOLDMAN;JOSY REIFFERS;KERRY TAYLOR;KLAUS LECHNER;MICHELE BACCARANI;PHILIPPE ROUSSELOT","4457;3505;3505;3505;3505;3505;3505;3505;3505;3505;3505;3505;3505;3505;3505;3505;3505;3505;3505;3505","GIUSEPPE SAGLIO;ENRICO GOTTARDI;FRANCESCO ARDISSONE;P. BORASIO;C MOSSETTI;PAOLO OLIVO LAUSI;DARIO ANDREONE;ANTONIO BERTOLOTTO;ALESSIA DI SAPIO;ARIANNA SALA;FRANCESCA GILLI;MARCO CAPOBIANCO;R. BOTTERO;SIMONA MALUCCHI;EVA MILANO;FABIANA MARNETTO;FABIO MELIS;M. T. GIORDANA;RAIJA L.P. LINDBERG;ALFREDO BERRUTI","4457;878;397;397;280;280;276;214;199;199;199;199;199;199;173;173;173;173;173;152","ANTONIO BERTOLOTTO;FEDERICA GANI;G. GORZEGNO;GIUSEPPE SAGLIO;ALESSIA DI SAPIO;ALFREDO BERRUTI;ARIANNA SALA;FRANCESCA GILLI;FRANCESCO ARDISSONE;GIOVANNI ANFOSSI;ISABELLA RUSSO;LUIGI MATTIELLO;MARCO CAPOBIANCO;MARIELLA TROVATI;P. BORASIO;PAOLA MASSUCCO;R. BOTTERO;SIMONA MALUCCHI;A TEMPIA;ALBERTO PERBONI","3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;ENGINEERING;HISTORY;MATHEMATICS;PSYCHOLOGY;SOCIOLOGY","37;13;4;3;1;1;1;1;1;1","INTERNAL MEDICINE;IMMUNOLOGY;CARDIOLOGY;BIOCHEMISTRY;PATHOLOGY;SURGERY;INTENSIVE CARE MEDICINE;GENETICS;CELL BIOLOGY;ENDOCRINOLOGY;ONCOLOGY;PSYCHIATRY;RADIOLOGY;ANESTHESIA;GASTROENTEROLOGY;GYNECOLOGY;MECHANICS;MOLECULAR BIOLOGY;PALEONTOLOGY;PEDIATRICS;PHARMACOLOGY;PHYSICAL THERAPY;UROLOGY","31;10;9;8;8;7;6;5;4;4;4;3;3;2;2;2;2;2;2;2;2;2;2","CANCER;CHEMOTHERAPY;GENE;ABLATION;ASTHMA;HEART FAILURE;AERODYNAMICS;CARDIAC PACING;COMPLICATION;DIABETES MELLITUS;DISEASE;IMMUNE SYSTEM;MALIGNANCY;NEUROLOGY;SIGNAL TRANSDUCTION;ADVERSE EFFECT;ALLERGY;ANTIBODY;BIOPSY;BONE MARROW;CONFIDENCE INTERVAL;ELECTROPHYSIOLOGY;INSULIN;INTERFERON;LUNG CANCER;MESOTHELIOMA;MULTIPLE SCLEROSIS;MULTIVARIATE ANALYSIS;OXIDATIVE STRESS;PULMONARY FUNCTION TESTING;RANDOMIZED CONTROLLED TRIAL;RESPIRATORY SYSTEM;STAGE (STRATIGRAPHY);STEM CELL","10;6;6;4;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ATRIAL FLUTTER;BREAST CANCER;FLUTTER;NEURORADIOLOGY;CATHETER ABLATION;MELPHALAN;MINIMAL RESIDUAL DISEASE;RADIOFREQUENCY ABLATION;RECOMBINANT DNA;TOLERABILITY;UNIVARIATE ANALYSIS;VENTRICULAR PACING;AIRWAY OBSTRUCTION;ALLERGIC ASTHMA;ALPHA INTERFERON;CARDIOMYOPATHY;CASTRATION;CDC42;CELL MIGRATION;CELL SIGNALING;CEREBRUM;CHROMOSOMAL TRANSLOCATION;CHROMOSOME;CISPLATIN;CLINICAL ENDPOINT;COMPLETE REMISSION;COPOLYMER;CSF PLEOCYTOSIS;CYCLIC GUANOSINE MONOPHOSPHATE;CYTARABINE;CYTOSKELETON;DIABETIC RETINOPATHY;ENCEPHALITIS;EPIDERMAL GROWTH FACTOR RECEPTOR;FRESH GAS FLOW;FUSION GENE;GASTRECTOMY;GEMCITABINE;GENE EXPRESSION;GENOME;GENOTYPE;GOITER;GROWTH FACTOR;GUANINE NUCLEOTIDE EXCHANGE FACTOR;HAEMATOPOIESIS;HAZARD RATIO;HEMATOPOIETIC STEM CELL TRANSPLANTATION;HEREDITARY HEMOCHROMATOSIS;HUMAN INSULIN;IMATINIB;INFARCTION;INSULIN RESISTANCE;INTERIM ANALYSIS;LIPID MICRODOMAIN;LIPID PEROXIDATION;LIPID RAFT;LOCUS (GENETICS);LYSINE;MESSENGER RNA;MYELITIS;NEURAL STEM CELL;NEUROMYELITIS OPTICA;NEUTRALIZING ANTIBODY;OPTIC NEURITIS;PERIPHERAL BLOOD MONONUCLEAR CELL;PHASES OF CLINICAL RESEARCH;PLATELET ACTIVATION;PLEOCYTOSIS;POLYMERASE CHAIN REACTION;PROSTATE;PROSTATE CANCER;RAC1;RADICAL SURGERY;REAL-TIME POLYMERASE CHAIN REACTION;RESPIRATORY DISEASE;RETINOPATHY;SKIN BIOPSY;SODIUM NITROPRUSSIDE;SPLENOCYTE;SUPEROXIDE;SUPEROXIDE DISMUTASE;TAMSULOSIN;TIDAL VOLUME;TITER;TRANSVERSE MYELITIS;TYPE 1 DIABETES;TYROSINE KINASE","4;4;3;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","RF ABLATION;MAMMARY GLAND;4-HYDROXYNONENAL;ABL;ACTIN CYTOSKELETON;ACUTE TRANSVERSE MYELITIS;ANTIANDROGEN;BENIGN PROSTATIC HYPERPLASIA (BPH);FINASTERIDE;FUSION PROTEIN;GLYCERALDEHYDE 3-PHOSPHATE DEHYDROGENASE;GOSERELIN;HAPLOTYPE;HEMATOPOIETIC STEM CELL;HER2/NEU;IMATINIB MESYLATE;INSULIN LISPRO;LAMELLIPODIUM;LOWER URINARY TRACT SYMPTOMS;LYMPHOCYTIC PLEOCYTOSIS;MAMMOGRAPHY;MEMBRANE RUFFLING;METASTATIC BREAST CANCER;METHACHOLINE;NEOADJUVANT THERAPY;NEUROEPITHELIAL CELL;PHILADELPHIA CHROMOSOME;PLATELET-DERIVED GROWTH FACTOR RECEPTOR;PROSTATECTOMY;PSEUDOGENE;RAC GTP-BINDING PROTEINS;RAFT;REFERENCE GENES;REVERSE TRANSCRIPTASE;TAQMAN;VINORELBINE","4;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;ADULT;MIDDLE AGED;;AGED;ASTHMA;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;BRONCHIAL HYPERREACTIVITY;CARCINOMA, NON-SMALL-CELL LUNG;LUNG NEOPLASMS;INTERFERON-BETA;MULTIPLE SCLEROSIS;PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;ADOLESCENT;ANTINEOPLASTIC AGENTS;ASTHMA, EXERCISE-INDUCED;CYCLIC GMP;CYTOKINES","27;17;17;13;13;11;11;8;7;7;7;7;6;6;6;5;5;5;5;5","CATHETER ABLATION OF CARDIAC ARRHYTHMIAS;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;ADVANCEMENTS IN LUNG CANCER RESEARCH;ASTHMA;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;MALIGNANT PLEURAL MESOTHELIOMA RESEARCH;ADULT NEUROGENESIS AND BRAIN DEVELOPMENT;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;AETIOLOGY, DIAGNOSIS, AND MANAGEMENT OF MYOCARDITIS;ANESTHESIA AND SEDATION MANAGEMENT;BLOOD RHEOLOGY AND COAGULATION MECHANISMS;CELL MECHANICS AND EXTRACELLULAR MATRIX INTERACTIONS;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;COMPLICATIONS AND TECHNIQUES IN THYROID SURGERY;DIAGNOSIS AND TREATMENT OF HEART FAILURE;EFFICACY AND RESISTANCE IN CML TREATMENT;EPIDEMIOLOGY AND TREATMENT OF CHILDHOOD LEUKEMIA;GASTRIC CANCER RESEARCH AND TREATMENT;HEMATOPOIETIC STEM CELL BIOLOGY;HYPERGLYCEMIC CHOREA AND BASAL GANGLIA LESIONS","4;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ATRIAL FLUTTER;ELECTROANATOMIC MAPPING;RADIOFREQUENCY ABLATION;RF ABLATION;TREATMENT;CARDIAC PACING;FLUTTER;NEURORADIOLOGY;PACEMAKER THERAPY;ASTHMA;ATRIAL FIBRILLATION;CATHETER ABLATION;DIABETES;LEFT VENTRICULAR DYSFUNCTION;MALIGNANT PLEURAL MESOTHELIOMA;MELPHALAN;MINIMAL RESIDUAL DISEASE;RESPIRATORY;TOLERABILITY;UNIVARIATE ANALYSIS","4;4;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","ATRIAL FLUTTER;CAVOTRICUSPID ISTHMUS;RF ABLATION;TYPICAL ATRIAL;A- USEFULNESS;ABDOMINAL MALIGNANT;ALLERGIC ASTHMA;AUTOLOGOUS BONE;BONE MARROW;CHRONIC PACING;ELECTROPHYSIOLOGICAL MAPPING;LEFT VENTRICULAR;LUNG CANCER;MALIGNANT MESOTHELIOMA;MARROW TRANSPLANTATION;NON-SMALL-CELL LUNG;P- CHRONIC;PACING IDENTIFICATION;PACING THRESHOLD;SAFETY FACTOR;THERAPEUTIC ASPECTS;VENTRICULAR PACING;ACETATE ZOLADEX;ACTIN REORGANIZATION;ACUTE LYMPHOBLASTIC;ADULT ACUTE;ADVANCED DISEASE;ADVANCED PROSTATE;ANALOG LISPRO;ANESTHETIC CONSERVING","4;4;4;4;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1","NERVE STIMULATION;PACING THRESHOLD;PHRENIC NERVE;COOLED TIP;FINAL LEAD;SUBSEQUENT LEAD;CIRCLE SYSTEM;RATE VERSUS;ACCURATE INFORMATION;ANDOR PHRENIC;AWAS INTMOPERATIVE;DERIVED PACING;EUROPACEUNIPOLAR PACINGTHE;EXPERIENCED PHRENIC;FG TRANSCRIPT;GUIDEWIRE DERIVED;HEMODYMMIC OPTIMAL;IMPLANTATION FIGUREIN;IMPLANTATIONCONCLUSION TEMPORARY;IMPLANTATIONTHIS CONCEPT;INTMOPERATIVE HEMODYMMIC;ISOLATED GUIDEWIRE;LEAD IMPLANTATION;LEAD IMPLANTATIONCONCLUSION;LEAD IMPLANTATIONRESULTS;LEAD IMPLANTATIONTHERE;LEAD IMPLANTATIONTHIS;LV LEAD;OPTIMAL PACING;OUTPUT THRESHOLD","12;12;12;6;6;6;5;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3",8,0.19,6.75,5,1,3,0,6,3.5,0,3,5,0,0,19,0,4,0,4,12,3,1,0.25,137.5,138.75,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_GONZAGA",2004,50,8.72,2.82,0.354609929078014,0.52,0.32,0.12,0.32,3,26,10,2,6,0.52,0.2,0.04,0.12,38.9,0.826716536213216,0.2,0.68,NA,0.38403678426456,0.25997425997426,0.277056277056277,0.285714285714286,"ANTONIO BERTOLOTTO;FRANCESCA GILLI;GIUSEPPE SAGLIO;ARIANNA SALA;G. CIMINO;MARIELLA TROVATI;LUIGI MATTIELLO;ENRICO BOLLITO;ALFREDO BERRUTI;GIOVANNA MELONI;MARCO CAPOBIANCO;LUIGI DOGLIOTTI;ALFREDO BERRUTI;MASSIMO TERZOLO;FEDERICA GANI;MARCO TUCCI;SUSANNA CAPPIA;IRENE TARDIVO;ALBERTO ROSATI;ROBERTO MARIO SCARPA","4;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2","ANTONIO BERTOLOTTO;FRANCESCA GILLI;CARMELA LANZARA;ENRICO BOLLITO;MICHELA SPADARO;GUIDO FORNI;MARIELLA TROVATI;LUIGI MATTIELLO;FEDERICA GANI;ARIANNA SALA;MARCO CAPOBIANCO;CLAUDIO FOGLIATI;GIUSEPPE POLI;FIORELLA BIASI;GABRIELLA LEONARDUZZI;ELENA CHIARPOTTO;ANDREA DOVIO;D GATTULLO;ALDO CATALDI;PASQUALE PAGLIARO","1.37;1.37;1;0.71;0.5;0.5;0.42;0.42;0.39;0.37;0.37;0.36;0.35;0.35;0.35;0.35;0.33;0.33;0.33;0.33","ANTONIO BERTOLOTTO;FRANCESCA GILLI;GIUSEPPE SAGLIO;ARIANNA SALA;MARIELLA TROVATI;LUIGI MATTIELLO;ENRICO BOLLITO;ALFREDO BERRUTI;MARCO CAPOBIANCO;LUIGI DOGLIOTTI;ALFREDO BERRUTI;MASSIMO TERZOLO;FEDERICA GANI;MARCO TUCCI;SUSANNA CAPPIA;IRENE TARDIVO;ROBERTO MARIO SCARPA;GAETANO LA MANNA;GIUSEPPE POLI;CLAUDIO FOGLIATI","4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2","ANTONIO BERTOLOTTO;FRANCESCA GILLI;CARMELA LANZARA;ENRICO BOLLITO;MICHELA SPADARO;GUIDO FORNI;MARIELLA TROVATI;LUIGI MATTIELLO;FEDERICA GANI;ARIANNA SALA;MARCO CAPOBIANCO;CLAUDIO FOGLIATI;GIUSEPPE POLI;FIORELLA BIASI;GABRIELLA LEONARDUZZI;ELENA CHIARPOTTO;ANDREA DOVIO;PASQUALE PAGLIARO;PAOLA GOLLINI;LUIGI DOGLIOTTI","1.37;1.37;1;0.71;0.5;0.5;0.42;0.42;0.39;0.37;0.37;0.36;0.35;0.35;0.35;0.35;0.33;0.33;0.33;0.33","FRANCESCA GILLI;ANTONIO BERTOLOTTO;ARIANNA SALA;MARCO CAPOBIANCO;ALESSIA DI SAPIO;CARMELA LANZARA;CLAUDIO FOGLIATI;CESARE GREGORETTI;ENZO SQUADRONE;GIORGIO CONTI;MASSIMO ANTONELLI;PAMELA FRIGERIO;PAOLA BAIARDI;PAOLO NAVALESI;ROBERTA COSTA;SIMONA MALUCCHI;R. BOTTERO;LUIGI MATTIELLO;MARIELLA TROVATI;CLARA CAMASCHELLA","287;276;219;219;208;190;189;176;176;176;176;176;176;176;176;164;153;148;148;140","FRANCESCA GILLI;ANTONIO BERTOLOTTO;ARIANNA SALA;MARCO CAPOBIANCO;ALESSIA DI SAPIO;CARMELA LANZARA;CLAUDIO FOGLIATI;ENZO SQUADRONE;SIMONA MALUCCHI;R. BOTTERO;ELENA CHIARPOTTO;FIORELLA BIASI;GABRIELLA LEONARDUZZI;GIUSEPPE POLI;BARBARA SOTTERO;BARBARA VIZIO;BARBARA ZINGARO;DANIELLA ZANETTI;ROBERTO MARIO SCARPA;VERONICA VERDE","287;276;219;219;208;190;189;176;164;153;134;134;134;134;98;98;98;98;98;98","ALFREDO BERRUTI;ANTONIO BERTOLOTTO;FRANCESCA GILLI;ARIANNA SALA;ENRICO BOLLITO;GIUSEPPE SAGLIO;LUIGI DOGLIOTTI;MARCO CAPOBIANCO;ALESSANDRA MOSCA;ALESSIA DI SAPIO;CARLO TERRONE;CLAUDIO FOGLIATI;ELENA CHIARPOTTO;EZIO GAIA;FABIANA MARNETTO;FEDERICA VANA;FIORELLA BIASI;G. GORZEGNO;GABRIELLA LEONARDUZZI;GAETANO LA MANNA","5;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;ECONOMICS;ENGINEERING","44;18;8;3;1;1;1","INTERNAL MEDICINE;SURGERY;IMMUNOLOGY;BIOCHEMISTRY;GASTROENTEROLOGY;GENETICS;ENDOCRINOLOGY;ONCOLOGY;PATHOLOGY;ANATOMY;CELL BIOLOGY;PHARMACOLOGY;UROLOGY;ANESTHESIA;CANCER RESEARCH;ORGANIC CHEMISTRY;PEDIATRICS;DERMATOLOGY;MOLECULAR BIOLOGY;OBSTETRICS;RADIOLOGY","30;16;14;11;9;9;5;5;5;4;4;4;4;3;3;3;3;2;2;2;2","GENE;CANCER;ANTIBODY;CHEMOTHERAPY;MULTIPLE SCLEROSIS;INFLAMMATION;COMPLICATION;DISEASE;IMMUNE SYSTEM;IN VITRO;REACTIVE OXYGEN SPECIES;RECEPTOR;TRANSPLANTATION;ALTERNATIVE MEDICINE;APOPTOSIS;ASYMPTOMATIC;BONE MARROW;BONE PAIN;CARCINOMA;CHOLESTEROL;CYTOKINE;HEMOCHROMATOSIS;HORMONE;IMMUNOHISTOCHEMISTRY;INTERFERON;INTRACELLULAR;MECHANICAL VENTILATION;MYELOID LEUKEMIA;NITRIC OXIDE;OSTEOPOROSIS;PLATELET;PREGNANCY;RANDOMIZED CONTROLLED TRIAL;REGIMEN;RETROSPECTIVE COHORT STUDY","11;9;5;5;5;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","BREAST CANCER;PROSTATE;PROSTATE CANCER;ALLELE;BONE DISEASE;CISPLATIN;HEPCIDIN;IMATINIB;INTERFERON BETA;KIDNEY TRANSPLANTATION;LIVE BIRTH;LOCUS (GENETICS);MUTATION;NITRIC OXIDE SYNTHASE;ORGAN TRANSPLANTATION;OXYSTEROL;PERIPHERAL BLOOD MONONUCLEAR CELL;POLYMERASE CHAIN REACTION;PROINFLAMMATORY CYTOKINE;PROTEIN KINASE A;REAL-TIME POLYMERASE CHAIN REACTION;TRANSGENE","4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ANDROGEN DEPRIVATION THERAPY;ANTHRACYCLINE;EPIRUBICIN;HAMP;IMATINIB MESYLATE;INTERFERON BETA-1A;METASTATIC BREAST CANCER;VINORELBINE;BREAST CARCINOMA;CALNEXIN;COMPOUND HETEROZYGOSITY;EVANS SYNDROME;FEBRILE NEUTROPENIA;FERROPORTIN;GENETICALLY MODIFIED MOUSE;HER2/NEU;HOUSE DUST MITE;INTERFERON BETA-1B;LOSS OF HETEROZYGOSITY;LOWER URINARY TRACT SYMPTOMS;MEN1;METHYLENETETRAHYDROFOLATE REDUCTASE;MISSENSE MUTATION;NEUROENDOCRINE DIFFERENTIATION;OMALIZUMAB;OSTEOPROTEGERIN;PENETRANCE;RANKL;REVERSE TRANSCRIPTASE;REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;SUBLINGUAL IMMUNOTHERAPY;TAMOXIFEN;TRASTUZUMAB","2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;INTERFERON-BETA;ADULT;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;MIDDLE AGED;AGED;BREAST NEOPLASMS;MULTIPLE SCLEROSIS, RELAPSING-REMITTING;RNA, MESSENGER;;GTP-BINDING PROTEINS;MULTIPLE SCLEROSIS;TREATMENT OUTCOME;CYTOKINES;CARRIER PROTEINS;IMMUNOLOGIC FACTORS;VINBLASTINE;ANIMALS","36;26;23;21;16;16;16;13;11;11;11;10;10;10;9;8;7;7;7;6","DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;BISPHOSPHONATES IN CANCER TREATMENT AND BONE HEALTH;CHOLESTEROL METABOLISM AND ATHEROSCLEROSIS;EFFECTS OF MEDICATION ON PREGNANCY OUTCOMES;EFFICACY AND RESISTANCE IN CML TREATMENT;PHEOCHROMOCYTOMA AND PARAGANGLIOMA;REGULATION OF IRON METABOLISM AND ANEMIA;ROLE OF NITRIC OXIDE IN HEALTH AND DISEASE;ADVANCEMENTS IN LUNG CANCER RESEARCH;AETIOLOGY, DIAGNOSIS, AND MANAGEMENT OF MYOCARDITIS;ALLERGIC RHINITIS AND ITS IMPACT ON ASTHMA;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;ASTHMA;BREAST PATHOLOGY AND IMAGING TECHNIQUES;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;DIAGNOSIS AND MANAGEMENT OF PANCREATITIS;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;EPIDEMIOLOGY AND TREATMENT OF CHILDHOOD LEUKEMIA;ESOPHAGEAL INTERVENTION TECHNIQUES;FACTORS AND RISKS IN RESTRAINT-RELATED DEATHS","5;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;ADRENOCORTICAL CARCINOMA;BIRTH OUTCOMES;BONE DISEASE;BONE PAIN;EPIRUBICIN;HAMP;HEMOCHROMATOSIS;IMATINIB;IMATINIB MESYLATE;INTERFERON BETA-1A;LIVE BIRTH;METASTATIC BONE DISEASE;OXYSTEROL;PHYTOSTEROLS;PREGNANCY;PROINFLAMMATORY CYTOKINE;REGIMEN;TREATMENT;TREATMENT OUTCOMES","3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","MULTIPLE SCLEROSIS;CANCER PATIENTS;ACUTE LYMPHOBLASTIC;ANDROGEN DEPRIVATION;BIOLOGICAL ACTIVITY;BREAST CANCER;DEPRIVATION THERAPY;HORMONE REFRACTORY;INTERFERON BETA;NEUTRALIZING ANTIBODIES;NITRIC OXIDE;ORGAN TRANSPLANTATION;PROSTATE CANCER;REFRACTORY PROSTATE;RETROSPECTIVE SURVEY;SKELETAL COMPLICATIONS;ABSORPTION SYSTEM;ACTIVE COMPARATOR;ACUTE RESPIRATORY;ADMINISTERED INTERFERON;ADRENAL CORTEX;ADRENOCORTICAL ADENOMA;ADULT PATIENT;ADULT PATIENTS;ADVANCED BREAST;ADVANCED NON-SMALL-CELL;AGENTS SIBLINGS;AIRWAY PRESSURE;ALL-AF FUSION;ALLELIC LOSS","6;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","IFN BETA;MULTIPLE SCLEROSIS;BIOLOGICAL ACTIVITY;MECHANICAL VENTILATION;AUTOLOGOUS ALLOGENEIC;BETA BIOLOGICAL;CELL VACCINE;COPD PATIENTS;IL--ENGINEERED CELL;ORGAN TRANSPLANTATION;BALB-NEUT MICE;DIFFERENTIATED BREAST;GENE EXPRESSION;NEUROENDOCRINE DIFFERENTIATED;PATIENTS RECEIVING;RESIDUAL Β-CELL;SCLEROSIS PATIENTS;TYPE DIABETIC;ACUTE RESPIRATORY;ALLOGENEIC HSCT;APLASIA AUTOLOGOUS;AUTOIMMUNE CYTOPENIA;BABIES INCLUDING;BIOLOGICAL NON-RESPONDERS;BIOLOGICAL RESPONDERS;BREAST CARCINOMA;CALCIUM LEVELS;CALORIC INTAKE;CARD GENOTYPE;CELL APLASIA","8;8;6;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2",3,0.06,6.5,7,0,0,0,0,8.25,1,1,7,0,0,0,0,0,0,0,0,0,0,0,32.5,32.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_GONZAGA",2005,59,10.7627118644068,3.23728813559322,0.308900523560209,0.491525423728814,0.271186440677966,0.0847457627118644,0.288135593220339,2,36,13,4,4,0.61,0.22,0.07,0.07,92.2,1.74153563051192,0.288135593220339,0.779661016949153,NA,0.375480721210558,0.33717834960071,0.447368421052632,0.307692307692308,"GIUSEPPE SAGLIO;DANIELA CILLONI;ROBERTO MARIO SCARPA;ENRICO BOLLITO;LUIGI DOGLIOTTI;ENRICO GOTTARDI;CARLO TERRONE;SONIA CARTURAN;MARCO TAMPELLINI;GIOVANNI MARTINELLI;F. PORPIGLIA;FRANCESCA MESSA;ILARIA DEFILIPPI;ALFREDO BERRUTI;FABRIZIO PANE;PIER GIUSEPPE PELICCI;FRANCESCA ARRUGA;ALESSANDRA MOSCA;FRANCESCO LO‐COCO;VALENTINA ROSSO","11;7;6;6;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4","FEDERICA CAVALLO;ALBERTO BOTTINI;GIUSEPPE SAGLIO;ENRICO BOLLITO;PIETRO GRECO LUCCHINA;B. PEZZULICH;MARCO TAMPELLINI;ROBERTO MARIO SCARPA;LAURA CASTELLO;LUCIANA TESSITORE;ENRICO GOTTARDI;DANIELA CILLONI;LUIGI DOGLIOTTI;R. SCIOLLA;MAURIZIO LEONE;CARLO TERRONE;F. PORPIGLIA;SONIA CARTURAN;GABRIELLA DORONZO;MARIELLA TROVATI","1.12;1.08;0.76;0.72;0.58;0.58;0.53;0.52;0.5;0.5;0.49;0.47;0.47;0.46;0.46;0.42;0.41;0.4;0.4;0.4","GIUSEPPE SAGLIO;DANIELA CILLONI;ROBERTO MARIO SCARPA;ENRICO BOLLITO;LUIGI DOGLIOTTI;ENRICO GOTTARDI;CARLO TERRONE;SONIA CARTURAN;MARCO TAMPELLINI;F. PORPIGLIA;FRANCESCA MESSA;ILARIA DEFILIPPI;ALFREDO BERRUTI;FRANCESCA ARRUGA;ALESSANDRA MOSCA;VALENTINA ROSSO;EMANUELA MESSA;ALFREDO BERRUTI;SUSANNA CAPPIA;MAURO PAPOTTI","11;7;6;6;6;6;5;5;5;5;5;4;4;4;4;4;4;3;3;3","FEDERICA CAVALLO;ALBERTO BOTTINI;GIUSEPPE SAGLIO;ENRICO BOLLITO;PIETRO GRECO LUCCHINA;B. PEZZULICH;MARCO TAMPELLINI;ROBERTO MARIO SCARPA;LAURA CASTELLO;ENRICO GOTTARDI;DANIELA CILLONI;LUIGI DOGLIOTTI;R. SCIOLLA;CARLO TERRONE;F. PORPIGLIA;SONIA CARTURAN;GABRIELLA DORONZO;MARIELLA TROVATI;LUIGI MATTIELLO;GIOVANNI ANFOSSI","1.12;1.08;0.76;0.72;0.58;0.58;0.53;0.52;0.5;0.49;0.47;0.47;0.46;0.42;0.41;0.4;0.4;0.4;0.4;0.4","FRANCESCO LO‐COCO;PIER GIUSEPPE PELICCI;GIUSEPPE SAGLIO;DANIELA DIVERIO;MARCO VIGNETTI;CRISTINA MECUCCI;ALESSANDRA PUCCIARINI;ANTONELLA SANTUCCI;ARCANGELO LISO;BARBARA BIGERNA;BRUNANGELO FALINI;EMANUELA COLOMBO;ENRICO TIACCI;FRANCO MANDELLI;LAURA PASQUALUCCI;MARIA PAOLA MARTELLI;MYRIAM ALCALAY;NATALIA MEANI;PAOLA FAZI;ROBERTA LA STARZA","1919;1919;1903;1820;1792;1786;1782;1782;1782;1782;1782;1782;1782;1782;1782;1782;1782;1782;1782;1782","GIUSEPPE SAGLIO;ROBERTO MARIO SCARPA;DANIELA CILLONI;ANNALISA CARLUCCI;CESARE GREGORETTI;ENZO SQUADRONE;FABIO BELTRAME;FRANCESCO FANFULLA;MARIO GRASSI;PAOLO NAVALESI;STEFANO NAVA;F. PORPIGLIA;ENRICO BOLLITO;CARLO TERRONE;R. TARABUZZI;ALFREDO BERRUTI;MARCO CAPOBIANCO;CECILIA MARIA CRACCO;LUIGI DOGLIOTTI;ANTONIO BERTOLOTTO","1804;938;622;500;500;500;500;500;500;500;500;370;282;215;215;201;198;139;122;114","GIUSEPPE SAGLIO;ALFREDO BERRUTI;DANIELA CILLONI;ENRICO GOTTARDI;FRANCESCA MESSA;ENRICO BOLLITO;FRANCESCA ARRUGA;ILARIA DEFILIPPI;ROBERTO MARIO SCARPA;SONIA CARTURAN;VALENTINA ROSSO;LUIGI DOGLIOTTI;CARLO TERRONE;F. PORPIGLIA;MARCO TAMPELLINI;R. TARABUZZI;EMANUELA MESSA;RENATA CATALANO;ALESSANDRA MOSCA;ALESSANDRO MOROTTI","10;6;6;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;2;2","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;ENGINEERING;PHILOSOPHY;POLITICAL SCIENCE","52;27;8;6;1;1;1;1","INTERNAL MEDICINE;GASTROENTEROLOGY;GENETICS;SURGERY;ONCOLOGY;PATHOLOGY;UROLOGY;BIOCHEMISTRY;IMMUNOLOGY;CELL BIOLOGY;ENDOCRINOLOGY;PALEONTOLOGY;CANCER RESEARCH;INTENSIVE CARE MEDICINE;MOLECULAR BIOLOGY;PSYCHIATRY;ASTROBIOLOGY;CARDIOLOGY;RADIOLOGY;ANESTHESIA;DERMATOLOGY;ENVIRONMENTAL HEALTH;PEDIATRICS","47;17;13;13;12;12;11;10;10;8;8;6;5;5;5;5;4;3;3;2;2;2;2","CANCER;GENE;CHEMOTHERAPY;MYELOID LEUKEMIA;DISEASE;STAGE (STRATIGRAPHY);CYTOPLASM;IMMUNOHISTOCHEMISTRY;LUNG CANCER;REFRACTORY (PLANETARY SCIENCE);REGIMEN;SIGNAL TRANSDUCTION;TOXICITY;ADVERSE EFFECT;ANTIBODY;BONE MARROW;CARCINOMA;CELL;ENZYME;ISCHEMIA;LEUKEMIA;MULTIPLE SCLEROSIS;MULTIVARIATE ANALYSIS;NEUROLOGY;NEUROSURGERY","20;14;13;7;5;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3","PROSTATE CANCER;PROSTATE;COLORECTAL CANCER;ETOPOSIDE;IMATINIB;MUTATION;NEUTROPENIA;NUCLEOPHOSMIN;PHASES OF CLINICAL RESEARCH;ADENOCARCINOMA;BREAST CANCER;CHROMOGRANIN A;CHROMOSOME;CHRONIC MYELOGENOUS LEUKEMIA;CISPLATIN;CYCLOPHOSPHAMIDE;ENDOCYTOSIS;ENDOSOME;GEMCITABINE;GENE EXPRESSION;HYPEREOSINOPHILIC SYNDROME;MAPK/ERK PATHWAY;METALLOPROTEINASE;MUTANT;NEURORADIOLOGY;PERIPHERAL BLOOD MONONUCLEAR CELL;PI3K/AKT/MTOR PATHWAY;PROGRESSIVE DISEASE;TOLERABILITY;TYROSINE KINASE;UNIVARIATE ANALYSIS;VASCULAR SMOOTH MUSCLE;WESTERN BLOT","7;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","IMATINIB MESYLATE;EPIRUBICIN;KARYOTYPE;PROSTATECTOMY;ABL;ACTIN CYTOSKELETON;ACUTE PROMYELOCYTIC LEUKEMIA;ANTHRACYCLINE;ATYPICAL ADENOMATOUS HYPERPLASIA;BEPRIDIL;BONE METASTASIS;BREFELDIN A;CAPECITABINE;CHELERYTHRINE;CLATHRIN;COMPOUND HETEROZYGOSITY;CONTRACTILE VACUOLE;CYCLIN;DASATINIB;DNA VACCINATION;ENDOCYTIC CYCLE;ESTROGEN RECEPTOR;FEBRILE NEUTROPENIA;HOUSEKEEPING GENE;INTERFERON BETA-1A;LOSS OF HETEROZYGOSITY;LOWER URINARY TRACT SYMPTOMS;LY294002;METASTATIC BREAST CANCER;MODIFIED RANKIN SCALE;NATURAL KILLER CELL;NEUROENDOCRINE DIFFERENTIATION;NUCLEAR EXPORT SIGNAL;NUCLEOPLASM;ONCOGENE;OSTEOCALCIN;OXALIPLATIN;PDGFRA;PHOSPHOINOSITIDE 3-KINASE;PROSTATE DISEASE;PROSTATE-SPECIFIC ANTIGEN;RIBONUCLEOTIDE REDUCTASE;RNA EXTRACTION;SEMINAL VESICLE;TAMOXIFEN;TAQMAN;TAXANE;TRANSITIONAL CELL CARCINOMA;UROTHELIAL CELL;VINCRISTINE","3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;MIDDLE AGED;FEMALE;AGED;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;;LUNG NEOPLASMS;ADULT;PROSTATIC NEOPLASMS;NEOPLASMS;DEOXYCYTIDINE;NEOPLASMS, HORMONE-DEPENDENT;ANTINEOPLASTIC AGENTS;MULTIPLE SCLEROSIS;TREATMENT OUTCOME;ANIMALS;BONE NEOPLASMS;CARCINOMA, NON-SMALL-CELL LUNG;EPIRUBICIN","38;28;22;20;18;17;16;16;15;15;11;10;10;8;8;8;7;7;7;7","ACUTE MYELOID LEUKEMIA;EFFICACY AND RESISTANCE IN CML TREATMENT;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;DIAGNOSIS AND TREATMENT OF LUNG CANCER;HYPEREOSINOPHILIC SYNDROME AND RELATED DISORDERS;IMMUNOBIOLOGY OF DENDRITIC CELLS;PROSTATE CANCER RESEARCH AND TREATMENT;REGULATION OF IRON METABOLISM AND ANEMIA;ROLE OF MATRIX METALLOPROTEINASES IN CANCER AND PHYSIOLOGY;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN LUNG CANCER RESEARCH;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;ATP SYNTHASE FUNCTION AND REGULATION;ATRIAL FIBRILLATION;BISPHOSPHONATES IN CANCER TREATMENT AND BONE HEALTH;BRANCHIAL ANOMALIES AND THYROID ABNORMALITIES;CLINICAL AND PATHOLOGICAL ASPECTS OF URACHAL CARCINOMA;CLINICAL CHARACTERISTICS AND MANAGEMENT OF SARCOIDOSIS;DIAGNOSIS AND MANAGEMENT OF CEREBRAL VEIN THROMBOSIS","5;4;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","REFRACTORY (PLANETARY SCIENCE);REGIMEN;IMATINIB MESYLATE;NUCLEOPHOSMIN;PROSTATE CANCER;BREAST CANCER;CHROMOGRANIN A;CHRONIC MYELOGENOUS LEUKEMIA;EPIRUBICIN;HEMOCHROMATOSIS;HYPEREOSINOPHILIC SYNDROME;IMATINIB;LUNG CANCER;NEUROENDOCRINE TUMORS;NEURORADIOLOGY;NON-SMALL CELL LUNG CANCER;NPM1;NUCLEOCYTOPLASMIC TRANSPORT;PANCREATIC NEUROENDOCRINE TUMORS;RENAL CELL CARCINOMA","4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","PHASE II;CANCER PATIENTS;PROSTATE CANCER;CELL CARCINOMA;II TRIAL;LUNG CANCER;ACUTE MYELOGENOUS;ACUTE MYELOID;AUTOLOGOUS STEM;BREAST CANCER;CELL TRANSPLANTATION;CLINICAL TRIAL;CULTURED HUMAN;DOSE MG;HORMONE-REFRACTORY PROSTATE;HUMAN VASCULAR;II STUDY;INCREASES MATRIX;MATRIX METALLOPROTEINASE-;METALLOPROTEINASE- EXPRESSION;MG DAILY;MULTIPLE SCLEROSIS;MUSCLE CELLS;MYELOGENOUS LEUKEMIA;MYELOID LEUKEMIA;NPM MUTATIONS;RENAL CELL;RISK PATIENTS;SMOOTH MUSCLE;SOKAL RISK","6;5;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","GERMANY SEARCH;HEIDELBERG GERMANY;BIOLOGY LABORATORY;BIOPHYSICS PROGRAMME;CELL BIOLOGY;CELL BIOPHYSICS;EUROPEAN MOLECULAR;MOLECULAR BIOLOGY;NK CELL;PROGRAMME EUROPEAN;ANALYSIS GERMAN;CANCER RESEARCH;CENTRE HEIDELBERG;EMBL HEIDELBERG;GENOME ANALYSIS;GERMAN CANCER;LABORATORY EMBL;MOLECULAR GENOME;PROSTATE CANCER;RESEARCH CENTRE;SUPPLEMENTARY FIGURE;AUTHOR RAINER;CELL ACTIVITY;HELA CELLS;KI EXPRESSION;LUNG CANCER;MEMBRANE PROTEIN;NM GOLD;ANNEMARIE POUSTKA;CANCER PATIENTS","16;15;8;8;8;8;8;8;8;8;7;7;7;7;7;7;7;7;7;7;7;6;6;6;6;6;6;6;5;5",7,0.12,8.28,7,0,0,0,0,2,0,1,7.5,0,1,7,0,1.5,0,1,4,2,1.5,0,125.5,127,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_GONZAGA",2006,58,10.4137931034483,3.24137931034483,0.308510638297872,0.448275862068966,0.293103448275862,0.103448275862069,0.344827586206897,0,43,4,3,6,0.74,0.07,0.05,0.1,114.5,2.2416605108231,0.327586206896552,0.827586206896552,NA,0.420923947805056,0.262548262548262,0.418269230769231,0.363636363636364,"C. FAVA;MARCO VOLANTE;MAURO PAPOTTI;G. GAROFALO;LUIGI DOGLIOTTI;ALFREDO BERRUTI;GIUSEPPE SAGLIO;MICHELE BACCARANI;F. PEROTTO;ELISA BACILLO;MASSIMO TERZOLO;MARIO BOCCADORO;EZIO GAIA;MARIELLA TROVATI;ENRICO BOLLITO;A. DE PASCALE;GIOVANNI MARTINELLI;LUCIANO CARDINALE;FULVIA DAFFARA;FRANCESCA PALANDRI","8;6;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;2","C. FAVA;G. GAROFALO;MARCO VOLANTE;F. PEROTTO;MAURO PAPOTTI;A. DE PASCALE;ELISA BACILLO;NICOLA BELLOMO;GUIDO FORNI;FEDERICA SOLITRO;L. CARDINALE;LUCIANO CARDINALE;SARA SCUTERA;LUCA DURELLI;DIANELLA SAVOIA;MARIELLA TROVATI;EZIO GAIA;ENRICO BOLLITO;MASSIMO TERZOLO;FULVIA DAFFARA","1.61;0.81;0.67;0.61;0.55;0.54;0.52;0.5;0.5;0.44;0.44;0.43;0.42;0.42;0.42;0.4;0.39;0.37;0.37;0.37","C. FAVA;MARCO VOLANTE;MAURO PAPOTTI;G. GAROFALO;LUIGI DOGLIOTTI;ALFREDO BERRUTI;GIUSEPPE SAGLIO;F. PEROTTO;ELISA BACILLO;MASSIMO TERZOLO;EZIO GAIA;MARIELLA TROVATI;ENRICO BOLLITO;A. DE PASCALE;LUCIANO CARDINALE;FULVIA DAFFARA;MAURO F. FRASCISCO;MARCO ALLASIA;RAFFAELE CALOGERO;DANIELA CILLONI","8;6;5;5;5;4;4;4;4;3;3;3;3;3;3;3;2;2;2;2","C. FAVA;G. GAROFALO;MARCO VOLANTE;F. PEROTTO;MAURO PAPOTTI;A. DE PASCALE;ELISA BACILLO;GUIDO FORNI;FEDERICA SOLITRO;L. CARDINALE;LUCIANO CARDINALE;SARA SCUTERA;LUCA DURELLI;DIANELLA SAVOIA;MARIELLA TROVATI;EZIO GAIA;ENRICO BOLLITO;MASSIMO TERZOLO;FULVIA DAFFARA;LUIGI DOGLIOTTI","1.61;0.81;0.67;0.61;0.55;0.54;0.52;0.5;0.44;0.44;0.43;0.42;0.42;0.42;0.4;0.39;0.37;0.37;0.37;0.34","ALOÏS GRATWOHL;GIUSEPPE SAGLIO;MICHELE BACCARANI;BENGT SIMONSSON;JOHAN LANNG NIELSEN;ANDREAS HOCHHAUS;BAYARD L. POWELL;BRIAN J. DRUKER;CHARLENE SO;FRANCISCO CERVANTES;FRANÇOIS GUILHOT;GREGOR VERHOEF;HAGOP M. KANTARJIAN;HERMINE AGIS;INSA GATHMANN;JAN J. CORNELISSEN;JANICE GABRILOVE;JERALD P. RADICH;JOHN D. SHEPHERD;JOHN M. GOLDMAN","3639;3467;3434;3427;3427;3420;3420;3420;3420;3420;3420;3420;3420;3420;3420;3420;3420;3420;3420;3420","GIUSEPPE SAGLIO;FRANCO CAVALOT;ALESSANDRO MUSSA;GIOVANNA CASOLI;GIOVANNI VOLPICELLI;MAURO F. FRASCISCO;ALFREDO BERRUTI;LUIGI DOGLIOTTI;MARCO TAMPELLINI;MARIA PIA BRIZZI;RAFFAELE CALOGERO;MARCO CAPOBIANCO;ANTOINE ADENIS;BENOÎT BARON;BRUNO COUDERT;C. FOCAN;CARLO GARUFI;CARLOS CARVALHO;DOMINIQUE GENET;FRANÇIS LÉVI","3431;550;548;548;548;548;276;276;241;233;223;219;205;205;205;205;205;205;205;205","ALFREDO BERRUTI;LUIGI DOGLIOTTI;C. FAVA;G. GAROFALO;MAURO PAPOTTI;F. PEROTTO;GIUSEPPE SAGLIO;A. DE PASCALE;ENRICO BOLLITO;EZIO GAIA;MARCO VOLANTE;ALBERTO PERBONI;ALESSANDRO MUSSA;CARLO GULOTTA;ELISA BACILLO;ENRICO SAGGIORATO;FABIO ORLANDI;G. GORZEGNO;GIOVANNA CASOLI;GIOVANNI VOLPICELLI","5;5;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;COMPUTER SCIENCE;CHEMISTRY;PHYSICS;ENGINEERING;PHILOSOPHY;ECONOMICS;MATHEMATICS;POLITICAL SCIENCE;SOCIOLOGY","52;23;6;4;4;2;2;1;1;1;1","INTERNAL MEDICINE;PATHOLOGY;GASTROENTEROLOGY;SURGERY;BIOCHEMISTRY;GENETICS;IMMUNOLOGY;RADIOLOGY;CELL BIOLOGY;ENDOCRINOLOGY;CANCER RESEARCH;ONCOLOGY;PALEONTOLOGY;ANESTHESIA;ARTIFICIAL INTELLIGENCE;CARDIOLOGY;ENVIRONMENTAL HEALTH;MICROBIOLOGY;INTENSIVE CARE MEDICINE;MECHANICAL ENGINEERING;PHARMACOLOGY;PSYCHIATRY;QUANTUM MECHANICS;UROLOGY;VIROLOGY","39;17;13;11;10;10;10;10;7;7;6;6;5;4;3;3;3;3;2;2;2;2;2;2;2","GENE;CANCER;CHEMOTHERAPY;MYELOID LEUKEMIA;ADENOMA;RECEPTOR;ULTRASOUND;CARCINOMA;CONTEXT (ARCHAEOLOGY);DIAGNOSTIC ACCURACY;DISEASE;HEART FAILURE;HYPERPLASIA;IMMUNOHISTOCHEMISTRY;LUNG;LYMPHOMA;MULTIPLE SCLEROSIS;POPULATION;STEM CELL;SUPINE POSITION;TRANSPLANTATION","13;12;7;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3","IMATINIB;METASTASIS;BREAST CANCER;CD34;CHROMOSOMAL TRANSLOCATION;CHROMOSOME;CYCLOPHOSPHAMIDE;CYTARABINE;EJECTION FRACTION;ESCHERICHIA COLI;ETOPOSIDE;GENE EXPRESSION;GENOTYPE;INTERSTITIAL LUNG DISEASE;NEURORADIOLOGY;PARATHYROID ADENOMA;PARATHYROID CARCINOMA;PROSTATE;SPIROMETRY;THALIDOMIDE;THYROID CARCINOMA;TYPE 2 DIABETES","5;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","IMATINIB MESYLATE;ANTHRACYCLINE;FLUORESCENCE IN SITU HYBRIDIZATION;PARATHYROID NEOPLASM;PHILADELPHIA CHROMOSOME;SOLITARY FIBROUS TUMOR;4-HYDROXYNONENAL;ABL;ACTIN CYTOSKELETON;ASPIRATION BIOPSY;BURKHOLDERIA CEPACIA COMPLEX;C-JUN;CARDIAC RESYNCHRONIZATION THERAPY;CARMUSTINE;CD3;CELL ENVELOPE;COMET TAIL;COMPUTED RADIOGRAPHY;CYCLIN;CYSTECTOMY;CYTOGENETICS;DIFFUSE ALVEOLAR DAMAGE;DNA FRAGMENTATION;EPIRUBICIN;ESCHERICHIA COLI PROTEINS;ESTROGEN RECEPTOR;FEBRILE NEUTROPENIA;FLUDARABINE;HEAT SHOCK;HISTONE DEACETYLASE;IN SITU HYBRIDIZATION;INDOLE-3-ACETIC ACID;INSULIN RECEPTOR;INTERLEUKIN 12;INTERLEUKIN 21;LEISHMANIA INFANTUM;MEDIASTINAL LYMPH NODE;METABOTROPIC GLUTAMATE RECEPTOR;METASTATIC BREAST CANCER;MICROCHIMERISM;MMP2;NATURAL KILLER CELL;NEUROENDOCRINE DIFFERENTIATION;OXALIPLATIN;PROSTATECTOMY;PULSED-FIELD GEL ELECTROPHORESIS;RAPD;RIBAVIRIN;SUPERANTIGEN;SURGICAL NURSING;T-CELL RECEPTOR;TAMOXIFEN;TRANSCRIPTOME;TRANSITIONAL CELL CARCINOMA","5;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;MIDDLE AGED;;ADULT;AGED;FOLLOW-UP STUDIES;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;BIOMARKERS, TUMOR;LUNG NEOPLASMS;BREAST NEOPLASMS;ADOLESCENT;ANTINEOPLASTIC AGENTS;PLEURAL NEOPLASMS;RESPIRATORY INSUFFICIENCY;RETROSPECTIVE STUDIES;TREATMENT OUTCOME;ADENOMA;AGED, 80 AND OVER","36;24;23;22;17;15;15;12;9;9;9;8;7;7;7;7;7;7;6;6","EFFICACY AND RESISTANCE IN CML TREATMENT;ROLE OF LUNG ULTRASOUND IN CRITICAL CARE;CLINICOPATHOLOGY OF FIBROUS TUMORS AND TREATMENT STRATEGIES;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;METABOLIC REPROGRAMMING IN CANCER BIOLOGY;STANDARDISATION AND MANAGEMENT OF COPD;;ACUTE MYELOID LEUKEMIA;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN LUNG CANCER RESEARCH;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;BACTERIAL PHYSIOLOGY AND GENETICS;BREAST CANCER SCREENING TECHNOLOGY;CHIRAL SEPARATION IN CHROMATOGRAPHY;DEVELOPMENT AND APPLICATIONS OF RADIOPHARMACEUTICALS;DIAGNOSIS AND MANAGEMENT OF PANCREATITIS;DIAGNOSIS AND MANAGEMENT OF PITUITARY DISORDERS;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE","4;4;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","IMATINIB MESYLATE;CARDIAC ULTRASOUND;IMATINIB;LUNG ULTRASOUND;POINT-OF-CARE ULTRASONOGRAPHY;SUPINE POSITION;TREATMENT;DIABETES;INSULIN SIGNALING;INTERNATIONAL MYELOMA WORKING GROUP;NEURORADIOLOGY;PARATHYROID CARCINOMA;PARATHYROID HORMONE;PARATHYROID NEOPLASM;PHILADELPHIA CHROMOSOME;POSITIVE END-EXPIRATORY PRESSURE;REGIMEN;SOLITARY FIBROUS TUMOR;;4-HYDROXYNONENAL","5;4;4;4;4;3;3;2;2;2;2;2;2;2;2;2;2;2;1;1","CANCER PATIENTS;CHRONIC MYELOID;DOSE MG;MULTIPLE SCLEROSIS;MYELOID LEUKEMIA;ALVEOLAR-INTERSTITIAL SYNDROME;BLOOD GLUCOSE;BREAST CANCER;CHRONIC HEART;HEART FAILURE;HYPOXIA-INDUCIBLE FACTOR-Α;II TRIAL;INDOLE--ACETIC ACID;KI- EXPRESSION;MG DAILY;MULTIGLANDULAR PARATHYROID;PARATHYROID LESIONS;PHASE II;RANDOMIZED TRIAL;RISK PATIENTS;SOKAL RISK;SOLITARY FIBROUS;TYPE DIABETES;ACID IMPROVES;ACID REGULATES;ACTIVATES HYPOXIA-INDUCIBLE;ACUTE MONOBLASTIC;ACUTE RESPIRATORY;ADJUVANT MODULATES;ADRENAL ADENOMA","4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1","A-NK CELLS;LUNG ULTRASOUND;ALVEOLAR-INTERSTITIAL SYNDROME;HYPERPLASTIC LESIONS;MEDIAN SURVIVAL;PARATHYROID ADENOMAS;PARATHYROID DISEASES;BLOOD GLUCOSE;BREAST CANCER;COMET-TAIL ARTIFACTS;GENOMOVAR III-A;HIF-Α EXPRESSION;INSULIN SIGNALLING;RENAL CELL;SURVIVAL TIMES;ACID CYCLE;ACTIN CYTOSKELETON;ADDITION SECONDARY;AORTIC VSMC;BEDSIDE LUNG;CANCER ENROLLED;CELL CARCINOMA;CELL NEUROENDOCRINE;CELL VARIANT;CF PATIENTS;CYSTIC RENAL;DIABETES CONTROL;DIABETES DURATION;DIAGNOSTIC ROLE;DIFFERENTIATING BENIGN","7;5;4;4;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2",14,0.24,8.96,8.75,2,2,0,6.5,10.5,1,1.75,8.75,0,1,8,1,8,1,3,7,1,0,0,128.5,128.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_GONZAGA",2007,40,10.375,3.55,0.28169014084507,0.425,0.325,0.125,0.375,0,19,10,3,5,0.48,0.25,0.07,0.12,50.97,0.965874805798993,0.325,0.75,NA,0.386465770272398,0.287179487179487,0.317391304347826,0.25,"GIUSEPPE SAGLIO;ALBERTO ANGELI;ANTONIO BERTOLOTTO;MARCO VOLANTE;MARCO CAPOBIANCO;ANDREA DOVIO;L. SABA;ARIANNA SALA;MAURO PAPOTTI;GABRIELLA DORONZO;MARIELLA TROVATI;SIMONA MALUCCHI;MICHELE BACCARANI;PAOLA DEL MESE;GIOVANNI VOLPICELLI;FRANCESCA GILLI;GIOVANNI MARTINELLI;GIOVANNI ANFOSSI;FABIANA MARNETTO;ISABELLA RUSSO","5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","GIOVANNI VOLPICELLI;MAURO F. FRASCISCO;LUIGI DOGLIOTTI;EZIO GAIA;PAOLA SALACONE;ALESSANDRA MOSCA;WALTER SARACCO;ALBERTO ANGELI;MARCO VOLANTE;ANTONIO BERTOLOTTO;GABRIELLA DORONZO;MARIELLA TROVATI;PAOLA DEL MESE;GIOVANNI ANFOSSI;ISABELLA RUSSO;MARCO CAPOBIANCO;ARIANNA SALA;SIMONA MALUCCHI;FRANCESCA GILLI;FABIANA MARNETTO","1.25;0.75;0.57;0.5;0.5;0.5;0.5;0.49;0.44;0.42;0.41;0.41;0.41;0.41;0.41;0.4;0.34;0.34;0.34;0.34","GIUSEPPE SAGLIO;ALBERTO ANGELI;ANTONIO BERTOLOTTO;MARCO VOLANTE;MARCO CAPOBIANCO;ANDREA DOVIO;L. SABA;ARIANNA SALA;MAURO PAPOTTI;GABRIELLA DORONZO;MARIELLA TROVATI;SIMONA MALUCCHI;PAOLA DEL MESE;GIOVANNI VOLPICELLI;FRANCESCA GILLI;GIOVANNI ANFOSSI;FABIANA MARNETTO;ISABELLA RUSSO;SILVIA NOVELLO;SUSANNA CAPPIA","5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2","GIOVANNI VOLPICELLI;MAURO F. FRASCISCO;LUIGI DOGLIOTTI;EZIO GAIA;ALBERTO ANGELI;MARCO VOLANTE;ANTONIO BERTOLOTTO;GABRIELLA DORONZO;MARIELLA TROVATI;PAOLA DEL MESE;GIOVANNI ANFOSSI;ISABELLA RUSSO;MARCO CAPOBIANCO;ARIANNA SALA;SIMONA MALUCCHI;FRANCESCA GILLI;FABIANA MARNETTO;GIUSEPPE SAGLIO;G RADESCHI;MAURO PAPOTTI","1.25;0.75;0.57;0.5;0.49;0.44;0.42;0.41;0.41;0.41;0.41;0.41;0.4;0.34;0.34;0.34;0.34;0.33;0.3;0.29","MAURO PAPOTTI;MARCO VOLANTE;GIUSEPPE SAGLIO;ATSUHIKO SAKAMOTO;GIANNI BUSSOLATI;JUAN ROSAÍ;KENNICHI KAKUDO;MANUEL SOBRINHO–SIMÕES;PAOLA COLLINI;RICARDO V. LLOYD;RYOHEI KATOH;VIRGINIA A. LIVOLSI;YURI E. NIKIFOROV;NORBERT GATTERMANN;ANDREAS HOCHHAUS;OLIVER G. OTTMANN;GIOVANNI MARTINELLI;MICHELE BACCARANI;DONG‐WOOK KIM;ELISABETTA ABRUZZESE","665;659;600;561;561;561;561;561;561;561;561;561;561;539;347;347;308;308;294;294","GIUSEPPE SAGLIO;MAURO PAPOTTI;ANTONIO BERTOLOTTO;MARCO CAPOBIANCO;ARIANNA SALA;FABIANA MARNETTO;FRANCESCA GILLI;SIMONA MALUCCHI;ALESSIA DI SAPIO;ISABELLA RUSSO;MARZIA CALDANO;TOMMASINA GUGLIELMELLI;EUGENIO LEONARDO;CARLOS G. DOTTI;VANESSA SCHUBERT;GABRIELLA DORONZO;MARIELLA TROVATI;PAOLA DEL MESE;ENRICO GOTTARDI;C FERRERO","600;586;218;203;146;146;146;146;86;85;83;82;79;74;74;69;69;69;63;59","GIUSEPPE SAGLIO;ANTONIO BERTOLOTTO;MARCO CAPOBIANCO;MAURO PAPOTTI;ARIANNA SALA;FABIANA MARNETTO;FRANCESCA GILLI;GIOVANNI VOLPICELLI;ISABELLA RUSSO;SIMONA MALUCCHI;ALBERTO ANGELI;ALESSIA DI SAPIO;ANDREA DOVIO;DANIELA CILLONI;EMILIANO AROASIO;ENRICO GOTTARDI;FAUSTO FANTÒ;G RADESCHI;GABRIELLA DORONZO;GIORGIO V. SCAGLIOTTI","5;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;PSYCHOLOGY;SOCIOLOGY","36;16;11;3;1;1","INTERNAL MEDICINE;IMMUNOLOGY;BIOCHEMISTRY;SURGERY;GASTROENTEROLOGY;ONCOLOGY;PATHOLOGY;RADIOLOGY;ENDOCRINOLOGY;PSYCHIATRY;GENETICS;CANCER RESEARCH;MOLECULAR BIOLOGY;ORGANIC CHEMISTRY;ANESTHESIA;BIOINFORMATICS;CELL BIOLOGY;ENVIRONMENTAL HEALTH;INTENSIVE CARE MEDICINE;NUCLEAR MEDICINE;PALEONTOLOGY;PHARMACOLOGY;PHYSICAL THERAPY;UROLOGY","28;13;12;9;8;8;8;7;6;6;4;3;3;3;2;2;2;2;2;2;2;2;2;2","DISEASE;GENE;CANCER;ADVERSE EFFECT;MULTIPLE SCLEROSIS;MYELOID LEUKEMIA;ANTIBODY;CHEMOTHERAPY;EMERGENCY DEPARTMENT;IMMUNOHISTOCHEMISTRY;IN VITRO;KINASE;MAGNETIC RESONANCE IMAGING;PHOSPHORYLATION;ALTERNATIVE MEDICINE;BONE MARROW;CLINICAL TRIAL;ENZYME;LEUKEMIA;LUNG CANCER;NEUROLOGY;NEUROSURGERY;NITRIC OXIDE;PLATELET;PNEUMOTHORAX;POPULATION;RECEPTOR;ULTRASOUND;VASODILATION","8;8;6;5;5;5;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","IMATINIB;TOLERABILITY;ALZHEIMER'S DISEASE;CYCLIC GMP;CYCLIC GUANOSINE MONOPHOSPHATE;NEURORADIOLOGY;PLATELET ACTIVATION;PROTEIN KINASE A;REAL-TIME POLYMERASE CHAIN REACTION;ACTIVATOR (GENETICS);ACUTE ABDOMINAL PAIN;ACUTE LEUKEMIA;ACUTE-PHASE PROTEIN;ADENOCARCINOMA;AMIDOAMINE;AUTOCRINE SIGNALLING;AUTOLOGOUS STEM-CELL TRANSPLANTATION;BORTEZOMIB;BREAST CANCER;C-REACTIVE PROTEIN;CGMP-SPECIFIC PHOSPHODIESTERASE TYPE 5;CHROMOSOMAL TRANSLOCATION;CHRONIC MYELOGENOUS LEUKEMIA;CLINICAL ENDPOINT;CLONE (JAVA METHOD);COPOLYMER;CORNEAL TOPOGRAPHY;CYTARABINE;CYTOPENIA;CYTOTOXIC T CELL;DEFERASIROX;DEFERIPRONE;DIFFUSION MRI;DNA REPAIR;EFFECTIVE DIFFUSION COEFFICIENT;EPIDERMAL GROWTH FACTOR;EPIDERMAL GROWTH FACTOR RECEPTOR;EPIGENETICS;EPITOPE;ETOPOSIDE;FUSION GENE;HEMOTHORAX;HYPERHOMOCYSTEINEMIA;HYPOXIA (ENVIRONMENTAL);INFORMED CONSENT;INTERFERON BETA;LIPID PEROXIDATION;LUNG ULTRASOUND;MANTLE CELL LYMPHOMA;MONOCLONAL ANTIBODY;MYELODYSPLASTIC SYNDROMES;NEUROFIBROMA;NEUROMYELITIS OPTICA;NEUTRALIZING ANTIBODY;NEUTROPENIA;NUCLEOTIDE;PANCREATECTOMY;PANCREATIC CANCER;PEPTIDE SEQUENCE;PERIPHERAL EDEMA;PHOSPHOPROTEIN;PLASMA CELL LEUKEMIA;POLYMERASE CHAIN REACTION;PROGRESSIVE DISEASE;PROSTATE;PROSTATE CANCER;PROTEASOME INHIBITOR;RARE DISEASE;RECEPTOR TYROSINE KINASE;RECOMBINANT DNA;RELAPSING REMITTING;RENAL PARENCHYMA;RITUXIMAB;SERIAL DILUTION;SOMNOLENCE;STAIN;SUPEROXIDE;SYSTEMIC MASTOCYTOSIS;THALIDOMIDE;THYROID CARCINOMA;TITER;TUMOR HYPOXIA;TYROSINE KINASE;TYROSINE-KINASE INHIBITOR;UNIVARIATE ANALYSIS;VASCULAR SMOOTH MUSCLE;WHITE MATTER","4;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","IMATINIB MESYLATE;4-HYDROXYNONENAL;AMYLOID PRECURSOR PROTEIN;BREAKPOINT;CYCLIC NUCLEOTIDE;DASATINIB;DIFFUSION-WEIGHTED MAGNETIC RESONANCE IMAGING;EPIRUBICIN;HELSINKI DECLARATION;HUMAN BREAST;IMMUNOPEROXIDASE;INTERFERON BETA-1A;MITOGEN-ACTIVATED PROTEIN KINASE KINASE;MONOCLONAL;MULTIPLEX POLYMERASE CHAIN REACTION;NATURAL KILLER CELL;NILOTINIB;NUCLEOTIDE EXCISION REPAIR;OSTEOPROTEGERIN;PAPILLARY CARCINOMA;POLY(AMIDOAMINE);PROSTATE CARCINOMA;SOLUBLE GUANYLYL CYCLASE;TAMOXIFEN;TAQMAN;TGF ALPHA;ZAPRINAST","3;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;ADULT;INTERFERON-BETA;MIDDLE AGED;THYROID NEOPLASMS;;AGED;MULTIPLE SCLEROSIS;BRAIN;BREAST NEOPLASMS;CELL ADHESION MOLECULES;ANTIBODIES;CARDIOVASCULAR DISEASES;CYCLIC GMP;AMYLOID BETA-PEPTIDES;ANTINEOPLASTIC AGENTS;BIOMARKERS, TUMOR;CYCLIC GMP-DEPENDENT PROTEIN KINASES","29;20;19;15;15;11;10;9;9;9;8;8;8;7;7;7;6;6;6;6","DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;EFFICACY AND RESISTANCE IN CML TREATMENT;NEUROIMMUNE INTERACTION IN PSYCHIATRIC DISORDERS;ACUTE MYELOID LEUKEMIA;ADVANCEMENTS IN LUNG CANCER RESEARCH;AETIOLOGY, DIAGNOSIS, AND MANAGEMENT OF MYOCARDITIS;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;BIOMECHANICAL PROPERTIES OF THE CORNEA AND RELATED DISEASES;DEVELOPMENT AND DISORDERS OF FETAL BRAIN;DIAGNOSIS AND MANAGEMENT OF IGG4-RELATED DISEASE;DIAGNOSIS AND MANAGEMENT OF PANCREATITIS;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;DIAGNOSIS AND TREATMENT OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA;EPIDEMIOLOGY AND TREATMENT OF URINARY TRACT INFECTIONS;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;HEMOSTATIC AGENTS AND TECHNIQUES;IMMUNOLOGICAL MECHANISMS IN ATHEROSCLEROSIS DEVELOPMENT;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;MANAGEMENT OF CARDIAC ARREST AND RESUSCITATION","5;4;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","IMATINIB;IMATINIB MESYLATE;TOLERABILITY;CYCLIC GUANOSINE MONOPHOSPHATE;NEUROINFLAMMATION;NEURORADIOLOGY;4-HYDROXYNONENAL;ACUTE ABDOMINAL PAIN;ACUTE MYELOID LEUKEMIA;ADRENAL VEIN SAMPLING;AMYLOID (MYCOLOGY);ANTIBODY PHARMACOKINETICS;ANTIESTROGEN;ASTIGMATISM;AUTOLOGOUS STEM-CELL TRANSPLANTATION;BCR-ABL;BREAKPOINT;CARDIAC ULTRASOUND;CGMP-DEPENDENT PROTEIN KINASE;CHILDHOOD MYOPIA","3;3;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MULTIPLE SCLEROSIS;ALZHEIMERS DISEASE;EMERGENCY DEPARTMENT;GROWTH FACTOR;LUNG CANCER;PROSPECTIVE STUDY;ACCELERATED-PHASE CHRONIC;ACTIVATED FACTOR;ACTIVATION PATTERN;ACTIVATOR INHIBITOR;ACUTE LEUKEMIA;ACUTE LYMPHOBLASTIC;ACUTE PYELONEPHRITIS;ACYCLOVIR COMPLEX;ADC MAPS;ADRENAL PSEUDOCYST;ADVANCED HORMONE;ADVERSE CARDIOVASCULAR;AGGRESSIVE SYSTEMIC;ALGORITHMIC DIAGNOSTIC;AMYLOID TOXICITY;ANIMAL MODEL;ANTI-INTERFERON-Β NEUTRALISING;ANTIAGGREGATORY CYCLIC;ANTIVIRAL ACTIVITY;ARTERY DISEASE;BACTERIOSTATIC PRESERVATIVE;BCR-ABL TRANSCRIPTS;BCR-ABL TYROSINE;BETA-A SLOWS","3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;ADVERSE EVENTS;CELL MEMBRANE;FAST PROGRESSION;GROWTH FACTOR;RENAL DAMAGE;SLOW PROGRESSION;CYCLIC NUCLEOTIDE;CYCLIC NUCLEOTIDES;ERCC RRM;ES SCLC;IRON INTAKE;LS PATIENTS;MEMBRANE REACTIVITY;MRNA LEVELS;OBESE INDIVIDUALS;PARTIAL RESPONSES;PDE ACTIVITY;PREDICTIVE ROLE;RESPONSES DEFINED;SERUM FERRITIN;STATISTICALLY SIGNIFICANT;TRANSFUSIONAL IRON;TYROSINE KINASE;VASP PHOSPHORYLATION;ACTIVATED AUTOCRINE;ACUTE PYELONEPHRITIS;ACUTE UNCOMPLICATED;ALZHEIMERS DISEASE;AMERICAN CANCER","6;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2",11,0.28,5,5,0,1,0,0,4,0,1,5,0,0,8,0,3,2,3,3,0,0,0,47.5,47.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_GONZAGA",2008,54,9.64814814814815,2.77777777777778,0.36,0.37037037037037,0.388888888888889,0.166666666666667,0.296296296296296,0,30,7,7,7,0.56,0.13,0.13,0.13,48.11,0.876790065800892,0.314814814814815,0.777777777777778,NA,0.413410609495187,0.277526395173454,0.313978494623656,0.315789473684211,"ANTONIO BERTOLOTTO;GIUSEPPE SAGLIO;F. PORPIGLIA;LUCIANO CARDINALE;ROBERTO MARIO SCARPA;FABRIZIO PANE;FRANCESCA GILLI;MARCO CAPOBIANCO;GIANANTONIO ROSTI;MAURO F. FRASCISCO;VALERIA CARAMELLO;SIMONA MALUCCHI;C. FAVA;MARZIA CALDANO;GIOVANNI VOLPICELLI;GIOVANNI MARTINELLI;LUIGI DOGLIOTTI;DIANELLA SAVOIA;FABIANA MARNETTO;FRANCESCA PALANDRI","7;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;2","LUCIANO CARDINALE;ANTONIO BERTOLOTTO;MAURO F. FRASCISCO;GIOVANNI VOLPICELLI;DIANELLA SAVOIA;C. FAVA;GIUSEPPE POLI;VALERIA CARAMELLO;GIOVANNI VOLPICELLI;FRANCESCA GILLI;MARCO CAPOBIANCO;F. PORPIGLIA;TIZIANA RASO;L. CARDINALE;FABIANA MARNETTO;ROBERTO MARIO SCARPA;SIMONA MALUCCHI;MARZIA CALDANO;ANTONIO PRATO;GIUSEPPE SAGLIO","1.03;0.84;0.83;0.75;0.65;0.59;0.58;0.58;0.53;0.51;0.46;0.42;0.4;0.39;0.39;0.37;0.35;0.35;0.34;0.34","ANTONIO BERTOLOTTO;GIUSEPPE SAGLIO;F. PORPIGLIA;LUCIANO CARDINALE;ROBERTO MARIO SCARPA;FRANCESCA GILLI;MARCO CAPOBIANCO;MAURO F. FRASCISCO;VALERIA CARAMELLO;SIMONA MALUCCHI;C. FAVA;MARZIA CALDANO;GIOVANNI VOLPICELLI;LUIGI DOGLIOTTI;DIANELLA SAVOIA;FABIANA MARNETTO;MARCO TUCCI;STEFANO GEUNA;LETIZIA GRANIERI;GIUSEPPE POLI","7;5;5;5;4;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2","LUCIANO CARDINALE;ANTONIO BERTOLOTTO;MAURO F. FRASCISCO;GIOVANNI VOLPICELLI;DIANELLA SAVOIA;C. FAVA;GIUSEPPE POLI;VALERIA CARAMELLO;GIOVANNI VOLPICELLI;FRANCESCA GILLI;MARCO CAPOBIANCO;F. PORPIGLIA;L. CARDINALE;FABIANA MARNETTO;ROBERTO MARIO SCARPA;SIMONA MALUCCHI;MARZIA CALDANO;ANTONIO PRATO;GIUSEPPE SAGLIO;FEDERICA GANI","1.03;0.84;0.83;0.75;0.65;0.59;0.58;0.58;0.53;0.51;0.46;0.42;0.39;0.39;0.37;0.35;0.35;0.34;0.34;0.33","GIOVANNI VOLPICELLI;LUCIANO CARDINALE;VALERIA CARAMELLO;MAURO F. FRASCISCO;ALESSANDRO MUSSA;FABRIZIO BAR;ALVIN S. TEIRSTEIN;CARLO ALBERA;CHARLES FOGARTY;DANIEL A. CULVER;DAVID S. WILKES;DOMINIQUE VALEYRE;DONAL MCNALLY;FRANK KANNIESS;GANESH RAGHU;GARY W. HUNNINGHAKE;GERALD S. DAVIS;H. PATRICK;HENK C. HOOGSTEDEN;HENRY YEAGER","408;386;385;354;331;331;300;300;300;300;300;300;300;300;300;300;300;300;300;300","LUCIANO CARDINALE;GIOVANNI VOLPICELLI;MAURO F. FRASCISCO;ALESSANDRO MUSSA;FABRIZIO BAR;VALERIA CARAMELLO;CARLO ALBERA;ANTONIO BERTOLOTTO;A. SAMBATARO;TOMMASINA GUGLIELMELLI;FRANCESCA GILLI;EZIO GAIA;STEFANO GEUNA;MARCO CAPOBIANCO;MARZIA CALDANO;FABIANA MARNETTO;ARIANNA SALA;LETIZIA GRANIERI;PAOLA VALENTINO;PEDRO BOAL CARVALHO","385;354;354;331;331;331;300;299;268;179;166;159;155;154;153;142;129;129;129;126","ANTONIO BERTOLOTTO;GIUSEPPE SAGLIO;FRANCESCA GILLI;LUCIANO CARDINALE;MARCO CAPOBIANCO;GIOVANNI VOLPICELLI;F. PORPIGLIA;MARZIA CALDANO;MAURO F. FRASCISCO;SIMONA MALUCCHI;FABIANA MARNETTO;ALBERTO ANGELI;ALESSANDRO MUSSA;ALFREDO BERRUTI;ANTONIO PRATO;ARIANNA SALA;C. FAVA;CARMEN FAVA;ENRICO BOLLITO;FABRIZIO BAR","7;5;4;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;PSYCHOLOGY;ECONOMICS;MATERIALS SCIENCE;PHYSICS;BUSINESS;ENGINEERING;HISTORY;MATHEMATICS;PHILOSOPHY;POLITICAL SCIENCE","48;15;11;4;3;2;2;2;1;1;1;1;1;1","INTERNAL MEDICINE;SURGERY;IMMUNOLOGY;BIOCHEMISTRY;RADIOLOGY;PATHOLOGY;GASTROENTEROLOGY;ENDOCRINOLOGY;GENETICS;ONCOLOGY;PSYCHIATRY;CANCER RESEARCH;CARDIOLOGY;NUCLEAR MEDICINE;PHARMACOLOGY;CELL BIOLOGY;ENVIRONMENTAL HEALTH;MICROBIOLOGY;ANATOMY;DERMATOLOGY;MEDICAL PHYSICS;NEUROSCIENCE;OPTICS;ORGANIC CHEMISTRY;PALEONTOLOGY;PHYSICAL THERAPY;UROLOGY;VIROLOGY","38;14;13;12;11;10;9;8;8;8;7;5;4;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2","CANCER;GENE;MULTIPLE SCLEROSIS;MYELOID LEUKEMIA;ADVERSE EFFECT;INTERFERON;ANTIBODY;CHEMOTHERAPY;CLINICAL TRIAL;CYTOKINE;LEUKEMIA;LUNG;BACTERIA;CONFIDENCE INTERVAL;IMMUNE SYSTEM;IMMUNOHISTOCHEMISTRY;NEUROLOGY;POPULATION;PROSPECTIVE COHORT STUDY;RECEPTOR","10;9;8;6;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3","IMATINIB;CHRONIC MYELOGENOUS LEUKEMIA;CLINICAL ENDPOINT;GENOTYPE;INTERFERON BETA;ALKALINE PHOSPHATASE;BREAST CANCER;CELL CYCLE;CYCLOPHOSPHAMIDE;DOWNREGULATION AND UPREGULATION;HAZARD RATIO;LUNG ULTRASOUND;METASTASIS;NEURORADIOLOGY;OCCULT;PHASES OF CLINICAL RESEARCH;PROSTATE CANCER;PSEUDOMONAS AERUGINOSA;ACHROMOBACTER XYLOSOXIDANS;ACUTE DECOMPENSATED HEART FAILURE;ANAPHYLAXIS;ANTIBIOTIC RESISTANCE;ANTIMICROBIAL PEPTIDES;AUTOCRINE SIGNALLING;BORTEZOMIB;CARCINOGENESIS;CERVICAL CANCER;CHEMOTHERAPY REGIMEN;CHEST RADIOGRAPH;CYTARABINE;CYTOTOXIC T CELL;DIFFUSION MRI;DYSLIPIDEMIA;ENDOCRINE SYSTEM;ESCHERICHIA COLI;EXOCRINE PANCREATIC INSUFFICIENCY;EZETIMIBE;GENE EXPRESSION;GENE ISOFORM;GLATIRAMER ACETATE;HEAD AND NECK CANCER;HEMOSTATICS;HUMAN FACTORS AND ERGONOMICS;HYPERLIPIDEMIA;IMMUNOGENICITY;IMMUNOSTAINING;INFECTIOUS DISEASE (MEDICAL SPECIALTY);INFLIXIMAB;INNATE IMMUNE SYSTEM;INTERLEUKIN;LIPOPROTEIN;LYTIC CYCLE;MDM2;METABOLIC SYNDROME;MITOXANTRONE;MULTICENTER STUDY;MULTIPLE DRUG RESISTANCE;MUTATION;MYELIN;NATRIURETIC PEPTIDE;NEPHRECTOMY;NERVE GUIDANCE CONDUIT;NEUROPSYCHOLOGY;ORGASM;PARATHYROID HORMONE;PERIPHERAL BLOOD MONONUCLEAR CELL;PERIPHERAL NERVE INJURY;PERIPHERAL NERVOUS SYSTEM;PET-CT;PHENOTYPE;PHOSPHATIDYLINOSITOL;PI3K/AKT/MTOR PATHWAY;PLEURISY;PNEUMONECTOMY;PRIMING (AGRICULTURE);PROINFLAMMATORY CYTOKINE;PROSTATE;PROTEASOME INHIBITOR;PROTEIN KINASE B;PSAMMOMA BODY;PSEUDOANEURYSM;RECOMBINANT DNA;RESPIRATORY TRACT;RHABDOMYOSARCOMA;SALVAGE THERAPY;SCIATIC NERVE INJURY;SEPTIC SHOCK;SOFT TISSUE SARCOMA;SPUTUM;STAT1;STROMA;THORACIC AORTA;THYROID CARCINOMA;TOLERABILITY;TRANSCRIPTION FACTOR;TRANSFECTION;TRIGLYCERIDE;TYPE 2 DIABETES MELLITUS;TYROSINE-KINASE INHIBITOR;WHITE MATTER;ZYMOSAN","5;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","IMATINIB MESYLATE;INTERFERON BETA-1B;OSTEOCALCIN;PULSED-FIELD GEL ELECTROPHORESIS;AROMATASE;CLOFARABINE;CORONAVIRUS DISEASE 2019 (COVID-19);CYCLIN D1;DASATINIB;EMBRYONAL RHABDOMYOSARCOMA;FLUDARABINE;FRACTIONAL ANISOTROPY;GERMLINE MUTATION;GRAM-NEGATIVE BACTERIA;HAPLOTYPE;HEAD AND NECK SQUAMOUS-CELL CARCINOMA;HPV INFECTION;IDARUBICIN;IMIPENEM;INTERFERON BETA-1A;INTERLEUKIN 12;MASS-CASUALTY INCIDENT;MULTICENTER TRIAL;NEOPLASTIC TRANSFORMATION;NEUROPSYCHOLOGICAL ASSESSMENT;NILOTINIB;ONCOGENE;PIPERACILLIN;POLYMORPHISM (COMPUTER SCIENCE);PRIMARY TUMOR;PROSTATE-SPECIFIC ANTIGEN;PROSTATECTOMY;PSEUDOMONADACEAE;REPORTER GENE;THYROID NEOPLASM;TLR2;TRACTOGRAPHY;VERY LOW-DENSITY LIPOPROTEIN","5;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;MIDDLE AGED;ADULT;AGED;INTERFERON-BETA;ADENOCARCINOMA;ANTIBODIES;;IMMUNOLOGIC FACTORS;MULTIPLE SCLEROSIS;ITALY;LUNG NEOPLASMS;MULTIPLE SCLEROSIS, RELAPSING-REMITTING;BREAST NEOPLASMS;KIDNEY NEOPLASMS;SCIATIC NERVE;DRUG RESISTANCE;PROSTATIC NEOPLASMS","39;27;25;25;21;20;16;15;13;12;12;12;10;10;10;9;9;9;8;8","DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;EFFICACY AND RESISTANCE IN CML TREATMENT;ROLE OF LUNG ULTRASOUND IN CRITICAL CARE;BISPHOSPHONATES IN CANCER TREATMENT AND BONE HEALTH;ACUTE MYELOID LEUKEMIA;RENAL CELL CARCINOMA;ANTIMICROBIAL PEPTIDES IN HOST DEFENSE AND THERAPY;CLINICAL CHARACTERISTICS AND MANAGEMENT OF SARCOIDOSIS;DIAGNOSIS AND MANAGEMENT OF BILIARY TRACT DISORDERS;DIAGNOSIS AND MANAGEMENT OF FOOD ALLERGY;DIAGNOSIS AND MANAGEMENT OF PANCREATITIS;DIAGNOSIS AND TREATMENT OF LUNG CANCER;DISASTER RESPONSE AND PUBLIC HEALTH PREPAREDNESS;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;GENETIC BASIS OF PRIMARY IMMUNODEFICIENCY DISORDERS;GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;HEALTH LOCUS OF CONTROL AND PROMOTING BEHAVIORS;LIPID METABOLISM IN CANCER PATHOGENESIS;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER","5;5;4;3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","IMATINIB;IMATINIB MESYLATE;LUNG ULTRASOUND;CARDIAC ULTRASOUND;CHRONIC MYELOGENOUS LEUKEMIA;CLINICAL ENDPOINT;IMMUNE RESPONSES;BONE METASTASIS;BONE REMODELING;DIAGNOSIS;ECHOCARDIOGRAPHY;INTERFERON BETA-1B;METASTATIC BONE DISEASE;METASTATIC PROSTATE CANCER;N-TERMINAL TELOPEPTIDE;NEURORADIOLOGY;OCCULT;TREATMENT;ZOLEDRONIC ACID;ACHROMOBACTER XYLOSOXIDANS","5;5;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;1","MULTIPLE SCLEROSIS;MYELOID LEUKEMIA;CHRONIC MYELOID;BREAST CANCER;CANCER PATIENTS;CELL CARCINOMA;CHRONIC PHASE;CYSTIC FIBROSIS;ELDERLY PATIENTS;FIBROSIS PATIENTS;LEUKEMIA CML;MOLECULAR RESPONSE;NEUTRALISING ANTIBODIES;PROSPECTIVE STUDY;PROSTATE CANCER;ZOLEDRONIC ACID;ABSTRACT HYDROXYNONENAL;ACID VERSUS;ACUTE DECOMPENSATED;ACUTE MYELOGENOUS;ACUTE MYELOID;ACUTE PYELONEPHRITIS;ADULT DIAGNOSTIC;AGGRESSIVE MULTIPLE;ALVEOLAR CONSOLIDATION;ANIMAL FAT;ANTIGEN ERA;ANTIINFLAMMATORY DRUG;ANTIMICROBIAL ACTIVITY;ASYMPTOMATIC MYELOMA","5;5;4;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ZOLEDRONIC ACID;IL- PRODUCTION;BREAST CANCER;LEISURE ACTIVITIES;MENTAL HEALTH;TIME STRUCTURE;BMS PATIENTS;BRCA GENES;BREAST CANCERS;COGNITIVE IMPAIRMENT;DIFFERENTIAL EFFECTS;FAMILIAL BREAST;MEDIASTINAL HAEMATOMA;TLR LIGANDS;TRANSFORMING GROWTH;ACUTE PYELONEPHRITIS;ANIMAL FAT;ARRHYTHMIC EVENTS;BONE TURNOVER;BRCA BRCA;BRCA TUMORS;BRCAX TUMORS;BRUGADA ECG;CANCER PATIENTS;CLINICAL PRESENTATION;COMMON HAPLOTYPES;DEPRESSIVE SYMPTOMS;DIAGNOSIS HISTOLOGICAL;DIETARY INTAKE;DIFFERENTIAL ABILITY","9;7;5;5;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2",16,0.3,6.25,3.25,0,0,0,2.5,2,0,1,4.25,0,1,7,0,1,3,4,11.5,5.5,0,0,87.5,88.25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_GONZAGA",2009,66,9.45454545454546,3.21212121212121,0.311320754716981,0.5,0.439393939393939,0.212121212121212,0.348484848484849,0,38,8,7,7,0.58,0.12,0.11,0.11,40.3,0.871280815553781,0.242424242424242,0.803030303030303,NA,0.449174612662673,0.404220779220779,0.386865671641791,0.339869281045752,"GIUSEPPE SAGLIO;GIOVANNI VOLPICELLI;MARINELLA CLERICO;LUCA DURELLI;GIOVANNI MARTINELLI;MASSIMO TERZOLO;ANTONIO BERTOLOTTO;SANDRO MASSIMO PRIOLA;DANIELA CILLONI;ALDO CATALDI;C. FAVA;GIULIA CONTESSA;ADRIANO MASSIMILIANO PRIOLA;ALBERTO ANGELI;MASSIMO FILIPPI;SIMONA SOVERINI;TOMMASINA GUGLIELMELLI;LAURA CONTI;GIOVANNA REGE CAMBRIN;UBALDO FAMILIARI","10;6;5;5;5;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3","GIOVANNI VOLPICELLI;SANDRO MASSIMO PRIOLA;ADRIANO MASSIMILIANO PRIOLA;GIUSEPPE SAGLIO;LUCIANO CARDINALE;ALESSANDRO MUSSA;FRANCESCO ARDISSONE;ALDO CATALDI;C. FAVA;ALBERTO ANGELI;MASSIMO TERZOLO;CLAUDIO FOGLIATI;LORENZO PELIZZA;PIERMARIA FURLAN;FEDERICA BONAZZI;WALTER SARACCO;R.L. PICCI;MARINELLA CLERICO;LUCA DURELLI;CARMEN FAVA","2.15;1.07;1.07;0.93;0.83;0.81;0.75;0.73;0.73;0.71;0.67;0.5;0.5;0.5;0.5;0.5;0.5;0.5;0.5;0.49","GIUSEPPE SAGLIO;GIOVANNI VOLPICELLI;MARINELLA CLERICO;LUCA DURELLI;GIOVANNI MARTINELLI;MASSIMO TERZOLO;ANTONIO BERTOLOTTO;SANDRO MASSIMO PRIOLA;DANIELA CILLONI;ALDO CATALDI;C. FAVA;GIULIA CONTESSA;ADRIANO MASSIMILIANO PRIOLA;ALBERTO ANGELI;SIMONA SOVERINI;TOMMASINA GUGLIELMELLI;GIOVANNA REGE CAMBRIN;UBALDO FAMILIARI;MICHELE BACCARANI;STEFANO ULISCIANI","10;6;5;5;5;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3","GIOVANNI VOLPICELLI;SANDRO MASSIMO PRIOLA;ADRIANO MASSIMILIANO PRIOLA;GIUSEPPE SAGLIO;LUCIANO CARDINALE;ALESSANDRO MUSSA;FRANCESCO ARDISSONE;ALDO CATALDI;C. FAVA;ALBERTO ANGELI;MASSIMO TERZOLO;CLAUDIO FOGLIATI;PIERMARIA FURLAN;FEDERICA BONAZZI;R.L. PICCI;MARINELLA CLERICO;LUCA DURELLI;CARMEN FAVA;GIUSEPPE REIMONDO;UBALDO FAMILIARI","2.15;1.07;1.07;0.93;0.83;0.81;0.75;0.73;0.73;0.71;0.67;0.5;0.5;0.5;0.5;0.5;0.5;0.49;0.46;0.44","CARLO ALBERA;DOMINIQUE VALEYRE;JAVIER SZWARCBERG;LISA LANCASTER;MICHIEL THOMEER;PAUL W. NOBLE;PHIL HORMEL;ROLAND M. DU BOIS;STEVEN A. SAHN;TALMADGE E. KING;ULRICH COSTABEL;WILLIAMSON Z. BRADFORD;LUCA DURELLI;MARINELLA CLERICO;BRUNO FERRERO;GIULIA CONTESSA;PAOLO RIPELLINO;DANIELA BOSELLI;FRANCESCO NOVELLI;LAURA CONTI","503;503;503;503;503;503;503;503;503;503;503;503;389;389;358;358;358;353;353;353","CARLO ALBERA;LUCA DURELLI;MARINELLA CLERICO;BRUNO FERRERO;GIULIA CONTESSA;PAOLO RIPELLINO;GIUSEPPE SAGLIO;MARCO TAMPELLINI;ALFREDO BERRUTI;ANDREA CIVRA;DAVID LEMBO;LUIGI DOGLIOTTI;MARIA PIA BRIZZI;ELISA PIRRO;FRANCESCA MARTINO;FRANCESCO DI CARLO;SILVIA DE FRANCIA;SILVIA RACCA;ANTONIO BERTOLOTTO;MASSIMO TERZOLO","503;389;389;358;358;358;331;213;203;201;201;201;201;112;112;112;112;112;110;109","GIUSEPPE SAGLIO;GIOVANNI VOLPICELLI;LUCA DURELLI;MARINELLA CLERICO;ANTONIO BERTOLOTTO;GIULIA CONTESSA;MASSIMO TERZOLO;ADRIANO MASSIMILIANO PRIOLA;ALBERTO ANGELI;ALDO CATALDI;L. CARDINALE;SANDRO MASSIMO PRIOLA;ALFREDO BERRUTI;CARMEN FAVA;GIOVANNA REGE CAMBRIN;TOMMASINA GUGLIELMELLI;ALESSANDRO MUSSA;C. FAVA;DANIELA CILLONI;FRANCESCO ARDISSONE","10;7;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;PSYCHOLOGY;ENGINEERING;MATERIALS SCIENCE;MATHEMATICS;PHILOSOPHY;ECONOMICS;POLITICAL SCIENCE;GEOGRAPHY","59;16;5;5;4;3;3;3;3;2;2;1","INTERNAL MEDICINE;SURGERY;RADIOLOGY;PATHOLOGY;PSYCHIATRY;GASTROENTEROLOGY;IMMUNOLOGY;ONCOLOGY;GENETICS;CANCER RESEARCH;BIOCHEMISTRY;ENDOCRINOLOGY;ANATOMY;ANESTHESIA;CELL BIOLOGY;MOLECULAR BIOLOGY;PEDIATRICS;CHROMATOGRAPHY;FAMILY MEDICINE;INTENSIVE CARE MEDICINE;NURSING","46;18;15;14;14;13;13;11;9;8;6;6;5;4;4;4;4;3;3;3;3","CANCER;GENE;MULTIPLE SCLEROSIS;MYELOID LEUKEMIA;CHEMOTHERAPY;ANTIBODY;DISEASE;ADVERSE EFFECT;CLINICAL TRIAL;COMPLICATION;EMERGENCY DEPARTMENT;LUNG;MAGNETIC RESONANCE IMAGING;MULTIPLE MYELOMA;APOPTOSIS;CONFIDENCE INTERVAL;IMMUNE SYSTEM;LESION;LEUKEMIA;QUALITY OF LIFE (HEALTHCARE);SIGNAL TRANSDUCTION","10;9;8;8;7;6;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3","IMATINIB;GENE ISOFORM;HAZARD RATIO;LENALIDOMIDE;TYROSINE KINASE;TYROSINE-KINASE INHIBITOR;BREAKPOINT CLUSTER REGION;CD34;CHRONIC MYELOGENOUS LEUKEMIA;CLINICAL ENDPOINT;CYCLOPHOSPHAMIDE;EXPANDED DISABILITY STATUS SCALE;FOXP3;MESSENGER RNA;NEUROMYELITIS OPTICA;PHASES OF CLINICAL RESEARCH;PROSTATE CANCER;PULMONARY EDEMA;SALVAGE THERAPY;T CELL;THALIDOMIDE;TOLERABILITY;TRACHEAL INTUBATION","7;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","IMATINIB MESYLATE;NILOTINIB;DASATINIB;IL-2 RECEPTOR;SOLITARY FIBROUS TUMOR;ABL;ACROMEGALY;ALTERNATIVE SPLICING;AMPHIPHILE;AROMATASE;CD135;CONTINUOUS GLUCOSE MONITORING;DIFFUSING CAPACITY;DYSKINESIA;ESTROGEN RECEPTOR;EXTERNAL ANAL SPHINCTER;FRACTIONAL ANISOTROPY;GENETICALLY MODIFIED MOUSE;INSULIN SENSITIVITY;KAPOSI'S SARCOMA;MYELIN BASIC PROTEIN;NEUROENDOCRINE DIFFERENTIATION;OMALIZUMAB;OXALIPLATIN;PERIVASCULAR EPITHELIOID CELL;PROSTATECTOMY;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;RETICULOCYTE;RHODAMINE B;SOMATIC HYPERMUTATION;STAT PROTEIN","5;5;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;FEMALE;MALE;MIDDLE AGED;ADULT;AGED;MULTIPLE SCLEROSIS;ANTINEOPLASTIC AGENTS;INTERFERON-BETA;YOUNG ADULT;ANIMALS;ANTIBODIES, MONOCLONAL;BRAIN;MUSCLE, SKELETAL;NEOPLASM RECURRENCE, LOCAL;NEUROMYELITIS OPTICA;POSTOPERATIVE COMPLICATIONS;THYMOMA;THYMUS NEOPLASMS","34;29;24;24;22;19;16;15;10;9;9;7;7;7;7;7;7;7;7;7","EFFICACY AND RESISTANCE IN CML TREATMENT;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;MYASTHENIA GRAVIS AND THYMIC TUMORS RESEARCH;CLINICOPATHOLOGY OF FIBROUS TUMORS AND TREATMENT STRATEGIES;MANAGEMENT OF RIB FRACTURES IN TRAUMA PATIENTS;;ASSESSMENT OF DECISIONAL CAPACITY IN PSYCHIATRY;BONE TUMORS AND TUMOR-LIKE CONDITIONS IN SKELETAL SYSTEM;CHOLESTEROL METABOLISM AND ATHEROSCLEROSIS;CLINICAL CHARACTERISTICS AND MANAGEMENT OF SARCOIDOSIS;CRISIS RESOLUTION AND HOME TREATMENT TEAMS IN MENTAL HEALTH;DIAGNOSIS AND MANAGEMENT OF GASTROINTESTINAL BLEEDING;DIAGNOSIS AND MANAGEMENT OF IGG4-RELATED DISEASE;DIAGNOSIS AND MANAGEMENT OF PITUITARY DISORDERS;DIAGNOSIS AND MANAGEMENT OF PLEURAL DISEASES;DIFFUSION MAGNETIC RESONANCE IMAGING;DISEASES RELATED TO BLOOD GROUP VARIANTS;EFFECTS OF BARIATRIC SURGERY ON OBESITY AND DIABETES;EPIDEMIOLOGY AND MANAGEMENT OF BIPOLAR DISORDER","9;7;3;3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","IMATINIB;IMATINIB MESYLATE;MEMORY T CELLS;NEUROMYELITIS OPTICA;NILOTINIB;AQUAPORIN 4;BREAKPOINT CLUSTER REGION;CHRONIC MYELOGENOUS LEUKEMIA;CLINICAL ENDPOINT;DISCONTINUATION;EMERGENCY TRACHEAL INTUBATION;ETIOLOGY;INTERNATIONAL MYELOMA WORKING GROUP;NERVE REGENERATION;PATHOGENESIS;PEDIATRIC INTUBATION;REFRACTORY (PLANETARY SCIENCE);REGULATORY T CELL;SALVAGE THERAPY;SOLITARY FIBROUS TUMOR","7;6;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CHRONIC MYELOID;MULTIPLE SCLEROSIS;MYELOID LEUKEMIA;CHRONIC PHASE;LEUKEMIA PATIENTS;FIBROUS TUMOR;IMATINIB-RESISTANT CHRONIC;MULTIPLE MYELOMA;NEUROMYELITIS OPTICA;PHASE CML-CP;SCLEROSIS PATIENTS;TRACHEAL RUPTURE;ACCELERATED PHASE;ACTING OCTREOTIDE;ACTIVATION-INDUCED CYTIDINE;ACUTE ABDOMEN;ACUTE LYMPHOBLASTIC;ACYCLOVIR LOADED;ADAPTER PROTEINS;ADRENAL INCIDENTALOMAS;ADULT SKELETAL;ADVANCED WELL-DIFFERENTIATED;AGED GT;ANAL SPHINCTER;ANALOGUE-NAIVE PATIENTS;ANTERIOR LUNG;ANTIACQUAPORIN ANTIBODIES;ANTIBODIES DETECTION;ANTIBODIES RECOGNIZING;ANTILEUKEMIA DRUGS","6;6;6;5;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","PUBMED SCOPUS;LUNG ULTRASOUND;CANCER PATIENTS;CERVICAL CORD;EMERGENCY DEPARTMENT;ACUTE RESPIRATORY;AVERAGE CORD;COLORECTAL CANCER;EMERG MED;MED -ABSTRACT;METASTATIC COLORECTAL;RESPIRATORY FAILURE;ACUTE DECOMPENSATED;BMS PATIENTS;DE NOVO;DECOMPENSATED HEART;SPMS PATIENTS;TRACHEAL RUPTURE;ALBEDSIDE ULTRASOUND;ANTERIOR CHEST;ATG MG;BLUE PROTOCOLCHEST;CHRONIC OBSTRUCTIVE;CIRCADIAN TIMING;CLINICAL PICTURE;COMPLAINING ACUTE;CORD FA;DT MRI;GA RELEVANCE;GH LEVELS","9;8;7;6;6;5;5;5;5;5;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3",6,0.09,8.02,5.75,0,1,0,0,7,0,0,5.75,0,1,0,0,8,0,0,0,0,0,0,171.75,171.75,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_GONZAGA",2010,51,10,3.07843137254902,0.32484076433121,0.549019607843137,0.352941176470588,0.274509803921569,0.431372549019608,1,28,5,3,8,0.55,0.1,0.06,0.16,67.14,1.48564666933712,0.176470588235294,0.784313725490196,NA,0.359558715452911,0.319444444444444,0.275914634146341,0.35,"GIUSEPPE SAGLIO;GIOVANNI VOLPICELLI;VALENTINA CONSIGLIO;ROBERTO MARIO SCARPA;LUCA OSTACOLI;FAUSTO CASTAGNETTI;MASSIMO BRECCIA;PIER MARIA FURLAN;FRANCESCA PALANDRI;GIANANTONIO ROSTI;ERICA SGUAZZOTTI;ANTONIO BERTOLOTTO;MARIA CHIARA DEAGOSTINI;MARIO BOCCADORO;MARIO TIRIBELLI;GABRIELE GUGLIOTTA;GIANLUCA GAÏDANO;MICHELE BACCARANI;GIORGINA BARBARA PICCOLI;ALFREDO BERRUTI","6;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3","GIUSEPPE SAGLIO;GIOVANNI VOLPICELLI;ROBERTO MARIO SCARPA;LUCIANO CARDINALE;VALENTINA CONSIGLIO;MARCO BUSSO;CESARE MARCO SCOFFONE;CECILIA MARIA CRACCO;MASSIMILIANO POGGIO;L. CARDINALE;FRANCESCO ARDISSONE;MARIA CHIARA DEAGOSTINI;GIORGINA BARBARA PICCOLI;ALDO CATALDI;MARINELLA CLERICO;LUCA DURELLI;MARCO CAPOBIANCO;LUCA OSTACOLI;PIER MARIA FURLAN;FEDERICA SOLITRO","1.24;0.99;0.84;0.59;0.57;0.5;0.5;0.5;0.5;0.5;0.47;0.46;0.4;0.39;0.39;0.39;0.38;0.36;0.36;0.34","GIUSEPPE SAGLIO;GIOVANNI VOLPICELLI;VALENTINA CONSIGLIO;ROBERTO MARIO SCARPA;LUCA OSTACOLI;PIER MARIA FURLAN;ERICA SGUAZZOTTI;ANTONIO BERTOLOTTO;MARIA CHIARA DEAGOSTINI;GIORGINA BARBARA PICCOLI;ALFREDO BERRUTI;MARINELLA CLERICO;LUCA DURELLI;MARCO CAPOBIANCO;ROCCO LUIGI PICCI;LUCIANO CARDINALE;TOMMASINA GUGLIELMELLI;GIUSEPPE POLI;ARIANNA SALA;ALESSANDRO MASSÈ","6;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2","GIUSEPPE SAGLIO;GIOVANNI VOLPICELLI;ROBERTO MARIO SCARPA;LUCIANO CARDINALE;VALENTINA CONSIGLIO;CESARE MARCO SCOFFONE;CECILIA MARIA CRACCO;MARIA CHIARA DEAGOSTINI;GIORGINA BARBARA PICCOLI;MARINELLA CLERICO;LUCA DURELLI;MARCO CAPOBIANCO;LUCA OSTACOLI;PIER MARIA FURLAN;F. PORPIGLIA;ALESSANDRO MASSÈ;GIUSEPPE POLI;FIORELLA BIASI;GABRIELLA LEONARDUZZI;CINZIA MASCIA","1.24;0.99;0.84;0.59;0.57;0.5;0.5;0.46;0.4;0.39;0.39;0.38;0.36;0.36;0.34;0.33;0.31;0.31;0.31;0.31","GIUSEPPE SAGLIO;ALBERT HOENEKOPP;ANDREAS HOCHHAUS;CLARISSE LOBO;DONG‐WOOK KIM;GABRIEL ÉTIENNE;HAGOP M. KANTARJIAN;MD ARIFUL HAQUE;MEI DONG;NEIL J. GALLAGHER;P. LE COUTRE;RICARDO PASQÜINI;RICHARD A. LARSON;RICHARD E. CLARK;SURAPOL ISSARAGRISIL;TIMOTHY P. HUGHES;ANTONIO PALUMBO;DAVIDE ROSSI;GIANLUCA GAÏDANO;GIULIA BENEVOLO","1625;1603;1603;1603;1603;1603;1603;1603;1603;1603;1603;1603;1603;1603;1603;1603;380;380;380;380","GIUSEPPE SAGLIO;TOMMASINA GUGLIELMELLI;GIORGINA BARBARA PICCOLI;VALENTINA CONSIGLIO;ALFREDO BERRUTI;FEDERICA D’AMICO;LUCA OSTACOLI;PIER MARIA FURLAN;ANTONIO BERTOLOTTO;C. GULOTTA;ERICA SGUAZZOTTI;ROCCO LUIGI PICCI;CARLO GULOTTA;ALESSIA DI SAPIO;ARIANNA SALA;FABIANA MARNETTO;FRANCESCA GILLI;FRANCESCA SPERLI;MARCO CAPOBIANCO;PAOLA VALENTINO","1625;380;225;225;210;191;143;143;116;106;102;102;91;83;83;83;83;83;83;83","GIUSEPPE SAGLIO;LUCA OSTACOLI;PIER MARIA FURLAN;GIORGINA BARBARA PICCOLI;GIOVANNI VOLPICELLI;VALENTINA CONSIGLIO;LUCA DURELLI;MARINELLA CLERICO;ALFREDO BERRUTI;ERICA SGUAZZOTTI;ROCCO LUIGI PICCI;MARIA CHIARA DEAGOSTINI;ALESSANDRO MASSÈ;ANTONIO BERTOLOTTO;F. PORPIGLIA;FIORELLA BIASI;GABRIELLA LEONARDUZZI;GIUSEPPE POLI;LUCIANO CARDINALE;MANUELA NEGRO","5;4;4;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;ECONOMICS;MATHEMATICS;GEOLOGY;MATERIALS SCIENCE;PSYCHOLOGY","47;17;7;3;2;2;1;1;1","INTERNAL MEDICINE;SURGERY;PATHOLOGY;GENETICS;IMMUNOLOGY;RADIOLOGY;BIOCHEMISTRY;ONCOLOGY;PSYCHIATRY;CARDIOLOGY;ENDOCRINOLOGY;CANCER RESEARCH;CELL BIOLOGY;INTENSIVE CARE MEDICINE;NURSING;PALEONTOLOGY;PEDIATRICS;UROLOGY;ANATOMY;CLINICAL PSYCHOLOGY;ENVIRONMENTAL HEALTH;FAMILY MEDICINE;GASTROENTEROLOGY;MEDICAL PHYSICS;NUCLEAR MEDICINE;OPTICS;PHYSICAL THERAPY","33;12;11;9;9;9;8;8;8;5;5;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2","GENE;CANCER;MULTIPLE SCLEROSIS;MYELOID LEUKEMIA;ADVERSE EFFECT;BIOPSY;CLINICAL TRIAL;HEART FAILURE;INFLAMMATION;KIDNEY;ANXIETY;HISTOLOGY;MAGNETIC RESONANCE IMAGING;NEUROLOGY;STEM CELL;ALTERNATIVE MEDICINE;ANTIBODY;CELL;CHEMOTHERAPY;COMPLICATION;COMPUTED TOMOGRAPHY;COPING (PSYCHOLOGY);CYTOLOGY;DISEASE;EMERGENCY DEPARTMENT;IMMUNOHISTOCHEMISTRY;IN VITRO;INCIDENCE (GEOMETRY);INTERFERON;INTERVENTIONAL RADIOLOGY;KIDNEY DISEASE;LEUKEMIA;LUNG;LUNG CANCER;MULTIPLE MYELOMA;PARENCHYMA;PATHOLOGICAL;POPULATION;POSITRON EMISSION TOMOGRAPHY;PREGNANCY;QUALITY OF LIFE (HEALTHCARE);RECEPTOR;STAGE (STRATIGRAPHY);ULTRASOUND","9;6;6;6;4;4;4;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","IMATINIB;CD34;CHROMOSOMAL TRANSLOCATION;CLINICAL ENDPOINT;CLINICAL ONCOLOGY;GENE EXPRESSION;LENALIDOMIDE;NEEDLE BIOPSY;ACTIVATOR (GENETICS);ACUTE DECOMPENSATED HEART FAILURE;ADJUVANT RADIOTHERAPY;ALLELE;AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE;AVASCULAR NECROSIS;BORTEZOMIB;CACO-2;CARDIAC FUNCTION CURVE;CARDIOPROTECTION;CD8;CHEMOKINE;CHEST TUBE;CHIROPRACTIC;CHRONIC MYELOGENOUS LEUKEMIA;DISTAL TIBIA;ELECTROLYTE DISORDER;EMERGENCY ULTRASOUND;ENTEROCYTE;EUTHYROID;FINE-NEEDLE ASPIRATION;FINGOLIMOD;FIXATION (POPULATION GENETICS);FLUID-ATTENUATED INVERSION RECOVERY;FUSION GENE;GENE SILENCING;GENOTYPE;GESTATION;HOSPITAL ANXIETY AND DEPRESSION SCALE;HUMAN GENETICS;HYPERNATREMIA;HYPOPHARYNGEAL CANCER;IMMUNOGLOBULIN E;INTERFERON BETA;LARYNGEAL NEOPLASM;LARYNGECTOMY;LIPID OXIDATION;LITHOTOMY POSITION;LUNG BIOPSY;LUNG CANCER SURGERY;LUNG ULTRASOUND;MAINTENANCE THERAPY;MASSAGE;MELPHALAN;MESENCHYMAL TUMOR;METASTASIS;METFORMIN;MITOTANE;MOOD DISORDERS;MULTIDETECTOR COMPUTED TOMOGRAPHY;MUTATION;MYELODYSPLASTIC SYNDROMES;NADPH OXIDASE;NATALIZUMAB;NEPHRECTOMY;NEPHROPATHY;NEURORADIOLOGY;NEUTRALIZING ANTIBODY;ONCOLOGY NURSING;ORAL CANCERS;OXYSTEROL;PERIPHERAL BLOOD MONONUCLEAR CELL;PERIPHERAL NERVOUS SYSTEM;PHARMACOVIGILANCE;PHASES OF CLINICAL RESEARCH;PHENOTYPE;PITUITARY GLAND;PNEUMONECTOMY;PREECLAMPSIA;PRIMARY HYPEROXALURIA;PROGRESSION-FREE SURVIVAL;PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY;PROINFLAMMATORY CYTOKINE;PROSTATE CANCER;PROTEIN KINASE B;PROTEINURIA;PULMONARY EDEMA;REAL-TIME POLYMERASE CHAIN REACTION;RELATIVE RISK;RENAL PELVIS;REPERFUSION INJURY;RESTLESS LEGS SYNDROME;RETROPERITONEAL FIBROSIS;RNA;SUBARACHNOID SPACE;T CELL;THYROID-STIMULATING HORMONE;TYPE 2 DIABETES;TYPE 2 DIABETES MELLITUS;TYROSINE-KINASE INHIBITOR;URETEROSCOPY;URINALYSIS;VASOPROTECTIVE;VIABILITY ASSAY","6;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","IMATINIB MESYLATE;NILOTINIB;PHILADELPHIA CHROMOSOME;SOLITARY FIBROUS TUMOR;AMINO ACID SUBSTITUTION;BONE METASTASIS;CARFILZOMIB;CD3;CHEMOKINE RECEPTOR;CXCL10;DASATINIB;FUSION TRANSCRIPT;HAPLOTYPE;INCRETIN;JURKAT CELLS;NOX1;OMALIZUMAB;OSTEOPROTEGERIN;POLYMORPHISM (COMPUTER SCIENCE);PRIMARY TUMOR;RANKL;REFLEXOLOGY;RNA INTERFERENCE;SINGLE-NUCLEOTIDE POLYMORPHISM;T-CELL RECEPTOR;TAQMAN;VILDAGLIPTIN","5;3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;FEMALE;MALE;ADULT;MIDDLE AGED;MULTIPLE SCLEROSIS;ITALY;AGED;ANTINEOPLASTIC AGENTS;LUNG NEOPLASMS;INTERFERON-BETA;NEOPLASMS;PYRIMIDINES;YOUNG ADULT;ADOLESCENT;BRONCHIAL DISEASES;FORCED EXPIRATORY VOLUME;PIPERAZINES;TRACHEAL DISEASES","30;20;19;18;15;14;14;12;11;10;8;6;6;6;6;5;5;5;5;5","EFFICACY AND RESISTANCE IN CML TREATMENT;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;PREVALENCE AND MANAGEMENT OF KIDNEY STONES;CLINICOPATHOLOGY OF FIBROUS TUMORS AND TREATMENT STRATEGIES;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;ROLE OF LUNG ULTRASOUND IN CRITICAL CARE;ACUTE MYELOID LEUKEMIA;ANTIMICROBIAL PEPTIDES IN HOST DEFENSE AND THERAPY;ASTHMA;BISPHOSPHONATES IN CANCER TREATMENT AND BONE HEALTH;BRAIN FLUID DYNAMICS AND WASTE CLEARANCE MECHANISMS;CANCER OF UNKNOWN PRIMARY SITE;CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY;CHOLESTEROL METABOLISM AND ATHEROSCLEROSIS;CILIOPATHIES: GENETIC DISORDERS INVOLVING PRIMARY CILIA;CLINICAL MANAGEMENT OF TRACHEAL AND AIRWAY DISORDERS;DIAGNOSIS AND MANAGEMENT OF HYPONATREMIA;DIAGNOSIS AND MANAGEMENT OF IGG4-RELATED DISEASE;DIAGNOSIS AND TREATMENT OF HEART FAILURE;DIAGNOSIS AND TREATMENT OF LUNG CANCER","6;3;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","IMATINIB;IMATINIB MESYLATE;TREATMENT;HISTOLOGY;NILOTINIB;CARDIAC ULTRASOUND;CLINICAL ENDPOINT;CLINICAL ONCOLOGY;IMMUNE RESPONSES;INFLAMMATION;INTERVENTIONAL RADIOLOGY;LUNG ULTRASOUND;NEEDLE BIOPSY;PARENCHYMA;PHILADELPHIA CHROMOSOME;SOLITARY FIBROUS TUMOR;ADAPTIVE IMMUNITY;ADJUVANT RADIOTHERAPY;ALTERNATIVE MEDICINE;AMINO ACID SUBSTITUTION","5;5;4;3;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1","MULTIPLE SCLEROSIS;CHRONIC MYELOID;MYELOID LEUKEMIA;GIMEMA CML;NEWLY DIAGNOSED;ORAL LENALIDOMIDE;SCLEROSIS PATIENTS;CHRONIC PHASE;CML TREATED;CML WP;EMISSION TOMOGRAPHY;LEUKEMIA CML;LUNG CANCER;MULTIPLE MYELOMA;MYELOMA PATIENTS;POSITRON EMISSION;SOLITARY FIBROUS;ACADEMIC CENTERS;ACTIVATE LUNG;ACUTE RENAL;AGXT DISEASE;AMYLOIDOSIS STUDIED;ANTERIOR CHEST;ANTINEOPLASTIC TREATMENTS;ANXIETY DEPRESSION;ASPIRATION BIOPSY;BCR-ABL FUSION;BENIGN SOLITARY;BIOLOGICAL ACTIVITY;BLAST VALUES","6;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","DISEASE ACTIVITY;MS PATIENTS;VEVCO SLOPE;BONE METASTASES;COPD PATIENTS;INFARCT SIZE;PRETERM DELIVERY;PULMONARY EDEMA;ANTERIOR CHEST;BLUE PROTOCOL;CESAREAN SECTION;CLINICAL FEATURES;COMPUTED TOMOGRAPHY;ED PATIENTS;EMERGENCY VISITS;EXPRESSION PROFILES;HEALTHY CONTROLS;INTENSIVE CARE;KIDNEY DISEASE;LUNG CANCER;MICROINVASIVE LESIONS;NODAL INVOLVEMENT;ACCURATE CLINICAL;AKT PHOSPHORYLATION;AMOXICILLIN CLAVULANATE;BONE METASTASIS;CARDIACBODY WEIGHT;CELL LINE;CELL VIABILITY;CENTRAL HYPOTHYROIDISM","5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2",8,0.16,5.25,2.5,0,2,0,0,1.75,0,1,2.75,0,1,1.5,0,0,0,1,1.5,1,0,0,93.5,93.75,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_GONZAGA",2011,72,11.4027777777778,3.23611111111111,0.309012875536481,0.388888888888889,0.402777777777778,0.222222222222222,0.472222222222222,0,31,19,11,6,0.43,0.26,0.15,0.08,33.79,0.794457109011584,0.236111111111111,0.847222222222222,NA,0.381405288594857,0.369454545454545,0.282608695652174,0.293333333333333,"DANIELE GENERALI;LUCA OSTACOLI;F. PORPIGLIA;ALFREDO BERRUTI;ANTONIO BERTOLOTTO;ALBERTO BOTTINI;MONICA PENTENERO;S GANDOLFO;LUIGI DOGLIOTTI;ANDREA VELTRI;MAURO F. FRASCISCO;UBALDO FAMILIARI;ALESSANDRA BERSIGA;GIOVANNI ALLEVI;GIORGINA BARBARA PICCOLI;MARIA PIA AMATO;GIOVANNINO CICCONE;WALTER GIARETTI;VITTORIO MONTEFUSCO;EMANUELA DI NALLO","7;6;6;5;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3","DANIELE GENERALI;DIANELLA SAVOIA;LUCA OSTACOLI;F. PORPIGLIA;ALFREDO BERRUTI;GIOVANNI VOLPICELLI;ALBERTO BOTTINI;MAURO F. FRASCISCO;ALESSANDRO MUSSA;MARIO ZUCCA;CLAUDIO CIACCO;PIERMARIA FURLAN;R.L. PICCI;ANDREA VELTRI;GIORGINA BARBARA PICCOLI;A. DE PASCALE;SABRINA CRIVELLARO;STEPHEN B. FOX;ADRIANO MASSIMILIANO PRIOLA;ANTONIO BERTOLOTTO","0.94;0.92;0.85;0.81;0.79;0.67;0.63;0.59;0.5;0.5;0.48;0.44;0.44;0.43;0.43;0.43;0.42;0.41;0.4;0.4","DANIELE GENERALI;LUCA OSTACOLI;F. PORPIGLIA;ALFREDO BERRUTI;ANTONIO BERTOLOTTO;ALBERTO BOTTINI;MONICA PENTENERO;S GANDOLFO;LUIGI DOGLIOTTI;ANDREA VELTRI;MAURO F. FRASCISCO;UBALDO FAMILIARI;ALESSANDRA BERSIGA;GIOVANNI ALLEVI;GIORGINA BARBARA PICCOLI;A. DE PASCALE;DIANELLA SAVOIA;STEPHEN B. FOX;CARMEN FAVA;ROCCO LUIGI PICCI","7;6;6;5;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3","DANIELE GENERALI;DIANELLA SAVOIA;LUCA OSTACOLI;F. PORPIGLIA;ALFREDO BERRUTI;GIOVANNI VOLPICELLI;ALBERTO BOTTINI;MAURO F. FRASCISCO;ALESSANDRO MUSSA;CLAUDIO CIACCO;PIERMARIA FURLAN;R.L. PICCI;ANDREA VELTRI;GIORGINA BARBARA PICCOLI;A. DE PASCALE;SABRINA CRIVELLARO;STEPHEN B. FOX;ADRIANO MASSIMILIANO PRIOLA;ANTONIO BERTOLOTTO;MONICA PENTENERO","0.94;0.92;0.85;0.81;0.79;0.67;0.63;0.59;0.5;0.48;0.44;0.44;0.43;0.43;0.43;0.42;0.41;0.4;0.4;0.39","FRANCO CAVALOT;GIOVANNI ANFOSSI;LEONARDO DI MARTINO;MARIELLA TROVATI;ANDREA PAGLIARINO;KATIA BONOMO;M. RODRIGUEZ‐DEL VALLE;PAOLA MASSUCCO;ALFREDO BERRUTI;ANTONIO BERTOLOTTO;F. PORPIGLIA;SILVIA DE FRANCIA;MARIA PIA AMATO;ADRIAAN A. VOORS;ALDO P. MAGGIONI;CRISTINA OPASICH;DIRK J. VAN VELDHUISEN;FRANCO COSMI;GIANNI TOGNONI;HANS L. HILLEGE","341;341;341;341;293;293;293;293;245;244;220;199;196;184;184;184;184;184;184;184","FRANCO CAVALOT;GIOVANNI ANFOSSI;LEONARDO DI MARTINO;MARIELLA TROVATI;ANDREA PAGLIARINO;KATIA BONOMO;M. RODRIGUEZ‐DEL VALLE;PAOLA MASSUCCO;ALFREDO BERRUTI;ANTONIO BERTOLOTTO;F. PORPIGLIA;SILVIA DE FRANCIA;LAURA MONTAGNA;LUCA OSTACOLI;CARMEN FAVA;MAURO PAPOTTI;MASSIMO TERZOLO;GIUSEPPE SAGLIO;ADRIANO MASSIMILIANO PRIOLA;ANNAMARIA FERRERO","341;341;341;341;293;293;293;293;245;244;220;199;184;171;166;142;136;132;127;127","ALFREDO BERRUTI;F. PORPIGLIA;ANTONIO BERTOLOTTO;LUCA OSTACOLI;DANIELE GENERALI;GIORGINA BARBARA PICCOLI;LUIGI DOGLIOTTI;GIOVANNI VOLPICELLI;ALBERTO BOTTINI;CARMEN FAVA;MAURO F. FRASCISCO;MAURO PAPOTTI;ROCCO LUIGI PICCI;UBALDO FAMILIARI;A. DE PASCALE;ALESSANDRO MUSSA;ANDREA ELIO SPRIO;ANDREA VELTRI;CHIARA GIORDANINO;CRISTIAN FIORI","8;6;5;5;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;PSYCHOLOGY;COMPUTER SCIENCE;ECONOMICS;PHILOSOPHY;GEOGRAPHY;MATHEMATICS;POLITICAL SCIENCE","67;28;11;5;5;3;3;2;1;1;1","INTERNAL MEDICINE;SURGERY;PATHOLOGY;GENETICS;ONCOLOGY;BIOCHEMISTRY;PSYCHIATRY;GASTROENTEROLOGY;IMMUNOLOGY;NURSING;RADIOLOGY;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;MOLECULAR BIOLOGY;PEDIATRICS;CANCER RESEARCH;CARDIOLOGY;PALEONTOLOGY;PHARMACOLOGY;UROLOGY","49;18;15;14;13;12;11;10;8;7;7;6;6;6;6;4;4;4;4;4","CANCER;GENE;DISEASE;CHEMOTHERAPY;CLINICAL TRIAL;CONFIDENCE INTERVAL;POPULATION;QUALITY OF LIFE (HEALTHCARE);ALTERNATIVE MEDICINE;DNA;MULTIPLE SCLEROSIS;MULTIVARIATE ANALYSIS;MYELOID LEUKEMIA;RENAL FUNCTION;TRANSPLANTATION;URINARY SYSTEM;ADVERSE EFFECT;ASTHMA;COMORBIDITY;DIFFERENTIAL DIAGNOSIS;KIDNEY;LOGISTIC REGRESSION;REFRACTORY (PLANETARY SCIENCE);SIGNAL TRANSDUCTION","18;10;9;6;5;5;5;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3","BREAST CANCER;CHROMOSOME;HAZARD RATIO;COLORECTAL CANCER;HEMATOPOIETIC STEM CELL TRANSPLANTATION;IMATINIB;NEUTROPENIA;PLOIDY;ADJUVANT THERAPY;ALCOHOL DEPENDENCE;ALEMTUZUMAB;AMYOTROPHIC LATERAL SCLEROSIS;BORTEZOMIB;CERVICAL CANCER;ENDOMETRIAL CANCER;FLUOROURACIL;GENOTYPE;GLYCEMIC;NATALIZUMAB;NEURORADIOLOGY;PERSONALITY DISORDERS;PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY;PROSTATE CANCER;REPERFUSION INJURY;RITUXIMAB;THALIDOMIDE;TYPE 2 DIABETES;UNIVARIATE ANALYSIS","6;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ANEUPLOIDY;DASATINIB;NEOADJUVANT THERAPY;ANTHRACYCLINE;COLONOSCOPY;COMPARATIVE GENOMIC HYBRIDIZATION;EPIRUBICIN;ESTROGEN RECEPTOR;MILLON CLINICAL MULTIAXIAL INVENTORY;SINGLE-NUCLEOTIDE POLYMORPHISM;SYSTEMIC THERAPY;TAMOXIFEN;ACTH SECRETION;ANDROGEN DEPRIVATION THERAPY;APNEA–HYPOPNEA INDEX;AXILLA;CHROMOSOME INSTABILITY;CONDITIONING REGIMEN;CYCLIN D1;DANDER;DNA MISMATCH REPAIR;E2F1;EFFECTIVE RENAL PLASMA FLOW;ESOPHAGEAL VARICES;FEBRILE NEUTROPENIA;FLUORESCENCE IN SITU HYBRIDIZATION;FRONTOTEMPORAL DEMENTIA;GENETICALLY MODIFIED MOUSE;HORMONAL THERAPY;IMATINIB MESYLATE;METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS;MICROCOCCACEAE;MIGRAINE WITH AURA;NILOTINIB;NUCLEOTIDE EXCISION REPAIR;OLIGOHYDRAMNIOS;OXALIPLATIN;PHILADELPHIA CHROMOSOME;PITTSBURGH SLEEP QUALITY INDEX;POMALIDOMIDE;PORTAL VENOUS PRESSURE;PROSTATECTOMY;RENAL ISCHEMIA;SENTINEL LYMPH NODE;SENTINEL NODE;STAPHYLOCOCCAL INFECTIONS;T-CELL RECEPTOR;TERIPARATIDE;THYMIDYLATE SYNTHASE","3;3;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;ANTINEOPLASTIC AGENTS;AGED;MIDDLE AGED;ADULT;BREAST NEOPLASMS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;MOUTH NEOPLASMS;;ITALY;LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE;PYRIMIDINES;YOUNG ADULT;BIOMARKERS, TUMOR;THIAZOLES;TREATMENT OUTCOME;AGED, 80 AND OVER;PROSTATIC NEOPLASMS","57;40;36;30;28;28;23;21;18;18;13;13;12;12;11;10;10;10;8;8","MOLECULAR RESEARCH ON BREAST CANCER;EFFICACY AND RESISTANCE IN CML TREATMENT;ORAL MUCOSAL DISORDERS AND MALIGNANT TRANSFORMATION RISK;ALLERGIC RHINITIS AND ITS IMPACT ON ASTHMA;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;BORDERLINE PERSONALITY DISORDER: PSYCHOPATHOLOGY AND TREATMENT;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;GYNECOLOGIC ONCOLOGY;POLYOMAVIRUS-ASSOCIATED CARCINOGENESIS AND CLINICAL MANIFESTATIONS;ANESTHESIA AND SEDATION MANAGEMENT;APELIN SIGNALING AND PHYSIOLOGY;ASSESSMENT OF DECISIONAL CAPACITY IN PSYCHIATRY;CANCER SURVIVORSHIP AND QUALITY OF LIFE;CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY;CHRONIC KIDNEY DISEASE AND ITS IMPLICATIONS;DIAGNOSIS AND MANAGEMENT OF BILIARY TRACT DISORDERS;DIAGNOSIS AND MANAGEMENT OF PITUITARY DISORDERS;DIAGNOSIS AND TREATMENT OF BLADDER CANCER","5;4;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","BREAST CANCER;TREATMENT;NEOADJUVANT THERAPY;REFRACTORY (PLANETARY SCIENCE);ADJUVANT THERAPY;ALCOHOL DEPENDENCE;ASTHMA;BREAST CANCER SCREENING;CARDIAC ULTRASOUND;CLINICAL PRACTICE GUIDELINES;COMPARATIVE GENOMIC HYBRIDIZATION;DIABETES;EPIRUBICIN;GYNECOLOGIC ONCOLOGY;IMATINIB;IMATINIB MESYLATE;IMMUNOSUPPRESSION;INTRATUMOR HETEROGENEITY;NATALIZUMAB;NEPHROLOGY","4;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","MULTIPLE SCLEROSIS;BREAST CANCER;CELL TRANSPLANTATION;STEM CELL;AMYOTROPHIC LATERAL;CANCER CENTERS;CHRONIC MYELOID;DETOXIFICATION TREATMENT;DNA FLOW;DNA REPAIR;ELDERLY PATIENTS;FLOW CYTOMETRY;FOLLOW-UP PRACTICE;GENDER DIFFERENCES;GYNECOLOGICAL ONCOLOGY;HAEMATOPOIETIC STEM;HUMAN INTERFERON;INTERFERON BETA;LATERAL SCLEROSIS;MULTIPLE MYELOMA;NETWORK STUDY;ONCOLOGY FOLLOW-UP;ONCOLOGY NETWORK;PATIENT CHARACTERISTICS;PERSONALITY DISORDERS;PIEDMONT REGIONAL;PRACTICE ATTRIBUTABLE;PRIMARY SYSTEMIC;REGIONAL ONCOLOGY;SCLEROSIS STUDY","6;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","PUBMED SCOPUS;CROSSREF PUBMED;RENAL TUBULAR;BREAST CANCER;TUBULAR ACIDOSIS;BLOOD GLUCOSE;DISTAL RENAL;SJÖGREN SYNDROME;URINARY TRACT;MYELOID LEUKEMIA;ADULT COMORBIDITY;CARDIOVASCULAR EVENTS;CHRONIC MYELOID;CLINICAL TRIALS;SEXUAL FUNCTION;SYSTEMIC THERAPY;COMORBIDITY EVALUATION-;DNA ANEUPLOID;GLOMERULAR FILTRATION;GLYCEMIC CONTROL;INT -CROSSREF;SEXUAL DYSFUNCTION;ADJUVANT THERAPY;ALL-CAUSE MORTALITY;ANEUPLOID SUBLINES;CHARLSON INDEX;DIABETIC PATIENTS;EVALUATION- SCORE;HAZARD RATIO;INFARCT SIZE","18;15;14;13;13;11;10;8;8;7;6;6;6;6;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4",15,0.21,7.9,10.5,1.5,1,0,0,5,0,1,10.5,0,1,8.5,1,0,1,2,7.25,1.25,0,0,102.5,102.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_GONZAGA",2012,107,12.1682242990654,2.57943925233645,0.38768115942029,0.411214953271028,0.308411214953271,0.467289719626168,0.327102803738318,6,70,17,7,10,0.65,0.16,0.07,0.09,33.65,0.805734912517204,0.280373831775701,0.831775700934579,7.36856368563687,0.457020114370268,0.46558197747184,0.481605351170569,0.30990990990991,"GIUSEPPE SAGLIO;DANIELA CILLONI;GIORGINA SPECCHIA;GIORGINA BARBARA PICCOLI;PELLEGRINO MUSTO;CARMEN FAVA;SIMONA SOVERINI;FABRIZIO PANE;GIOVANNI MARTINELLI;FABIO STAGNO;F. PORPIGLIA;MASSIMO BRECCIA;ALESSANDRA IURLO;ANTONIO BERTOLOTTO;ANGELO MICHELE CARELLA;GIUSEPPE VISANI;FAUSTO CASTAGNETTI;GABRIELE GUGLIOTTA;ENRICO BRACCO;MICHELE BACCARANI","20;10;8;7;7;7;6;6;6;6;6;6;5;5;5;5;5;5;5;5","GIORGINA BARBARA PICCOLI;GIUSEPPE SAGLIO;F. PORPIGLIA;ALESSANDRO APRATO;UMBERTO BARBERO;LUCIANO CARDINALE;CRISTIAN FIORI;FEDERICA GAMNA;ROBERTO TORCHIO;B PICCOLI;SANDRO MASSIMO PRIOLA;ADRIANO MASSIMILIANO PRIOLA;ANDREA VELTRI;DANIELA CILLONI;PAOLO NICOLI;GIOVANNI VOLPICELLI;RICCARDO BERTOLO;IVANO MORRA;STEFANO GEUNA;DARIO GNED","2.55;1.63;1.18;1.17;1.14;1.14;1.04;1;1;1;0.64;0.64;0.64;0.59;0.57;0.55;0.54;0.54;0.5;0.5","GIUSEPPE SAGLIO;DANIELA CILLONI;GIORGINA BARBARA PICCOLI;CARMEN FAVA;F. PORPIGLIA;ANTONIO BERTOLOTTO;ANDREA VELTRI;CRISTIAN FIORI;MARTINA FERRARESI;MARCO TAMPELLINI;TOMMASINA GUGLIELMELLI;SANDRO MASSIMO PRIOLA;M NANO;LUCA OSTACOLI;RICCARDO BERTOLO;MARIELLA TROVATI;SIMONA MALUCCHI;ALFREDO BERRUTI;GIOVANNI VOLPICELLI;GIOVANNA REGE‐CAMBRIN","20;10;7;7;6;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3","GIORGINA BARBARA PICCOLI;GIUSEPPE SAGLIO;F. PORPIGLIA;ALESSANDRO APRATO;UMBERTO BARBERO;LUCIANO CARDINALE;CRISTIAN FIORI;ROBERTO TORCHIO;B PICCOLI;SANDRO MASSIMO PRIOLA;ADRIANO MASSIMILIANO PRIOLA;ANDREA VELTRI;DANIELA CILLONI;PAOLO NICOLI;GIOVANNI VOLPICELLI;RICCARDO BERTOLO;IVANO MORRA;STEFANO GEUNA;DARIO GNED;CARMEN FAVA","2.55;1.63;1.18;1.17;1.14;1.14;1.04;1;1;0.64;0.64;0.64;0.59;0.57;0.55;0.54;0.54;0.5;0.5;0.45","PELLEGRINO MUSTO;GIUSEPPE VISANI;GIORGINA SPECCHIA;ALESSANDRA IURLO;ROBERTO LATAGLIATA;EMANUELE ANGELUCCI;MONIA LUNGHI;DANIELA CILLONI;ALESSIA TIEGHI;ANTONIO SPADEA;ARIANNA MASCIULLI;CATERINA MUSOLINO;DAVIDE RAPEZZI;ELENA MARIA ELLI;ELISA RUMI;FRANCESCA LUNGHI;GIOVANNI QUARTA;GUIDO FINAZZI;MARCO RUGGERI;MARIA LUIGIA RANDI","861;824;789;782;776;721;719;717;713;713;713;713;713;713;713;713;713;713;713;713","DANIELA CILLONI;GIORGINA BARBARA PICCOLI;MARTINA FERRARESI;CHIARA GIORDANINO;MARCO TINIVELLA;LUCA DURELLI;ANDREA CIVRA;DAVID LEMBO;MANUELA DONALISIO;A. BERTOLOTTO;BRUNO FERRERO;MARCO TAMPELLINI;GIUSEPPE SAGLIO;MARIELLA TROVATI;CARMEN FAVA;FRANCO CAVALOT;ANDREA VELTRI;ANTONIO BERTOLOTTO;T. ANGUSTI;VALERIO PODIO","717;356;253;250;183;181;175;175;175;154;154;146;135;134;125;120;110;104;102;102","GIUSEPPE SAGLIO;DANIELA CILLONI;CARMEN FAVA;GIORGINA BARBARA PICCOLI;ANTONIO BERTOLOTTO;ANDREA VELTRI;ADRIANO MASSIMILIANO PRIOLA;GIOVANNI VOLPICELLI;SANDRO MASSIMO PRIOLA;ALFREDO BERRUTI;F. PORPIGLIA;GIOVANNA REGE‐CAMBRIN;MARCO TAMPELLINI;MARIELLA TROVATI;MARTINA FERRARESI;SIMONA MALUCCHI;TOMMASINA GUGLIELMELLI;ALESSANDRO FALCONE;ALESSANDRO LAMORTE;ANDREA SAINI","19;10;7;7;5;4;3;3;3;3;3;3;3;3;3;3;3;2;2;2","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;ECONOMICS;PSYCHOLOGY;BUSINESS;ENGINEERING;MATHEMATICS;ART;MATERIALS SCIENCE;ENVIRONMENTAL SCIENCE;POLITICAL SCIENCE","100;34;11;9;6;6;6;3;3;3;2;2;1;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;GENETICS;IMMUNOLOGY;PATHOLOGY;GASTROENTEROLOGY;CANCER RESEARCH;ENDOCRINOLOGY;PSYCHIATRY;RADIOLOGY;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;PHARMACOLOGY;PHYSICAL THERAPY;CELL BIOLOGY;INTENSIVE CARE MEDICINE;CARDIOLOGY;MOLECULAR BIOLOGY;PEDIATRICS","79;30;26;18;16;16;15;13;11;11;11;10;7;7;7;6;6;5;5;5","CANCER;MYELOID LEUKEMIA;GENE;CHEMOTHERAPY;MULTIPLE SCLEROSIS;RECEPTOR;DISEASE;LEUKEMIA;COHORT;KIDNEY;LUNG;POPULATION;ADVERSE EFFECT;RETROSPECTIVE COHORT STUDY;ANXIETY;BONE MARROW;DEPRESSION (ECONOMICS);DISCONTINUATION;HEART FAILURE;INCIDENCE (GEOMETRY);LUNG CANCER;MULTIPLE MYELOMA;PREGNANCY;PROSPECTIVE COHORT STUDY;QUALITY OF LIFE (HEALTHCARE);SIGNAL TRANSDUCTION","24;18;11;9;8;8;7;7;6;6;6;6;5;5;4;4;4;4;4;4;4;4;4;4;4;4","IMATINIB;TYROSINE KINASE;COLORECTAL CANCER;TYROSINE-KINASE INHIBITOR;NEPHRECTOMY;PROSTATE CANCER;CHRONIC MYELOGENOUS LEUKEMIA;CUMULATIVE INCIDENCE;MUTATION;PERIPHERAL BLOOD MONONUCLEAR CELL;TOLERABILITY;BORTEZOMIB;CD34;CYCLOPHOSPHAMIDE;DEEP VEIN;DEMENTIA;DOCETAXEL;GENOTYPE;GROWTH FACTOR;GROWTH HORMONE;IMMUNOFLUORESCENCE;INTERLEUKIN;LENALIDOMIDE;METASTASIS;MYELODYSPLASTIC SYNDROMES;NEUTROPENIA;OSTEOARTHRITIS;PREECLAMPSIA;PROSTATE;PROTEINURIA;REAL-TIME POLYMERASE CHAIN REACTION","16;7;6;6;5;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","IMATINIB MESYLATE;NILOTINIB;DASATINIB;ABL;DISTANT METASTASIS;OXALIPLATIN;POMALIDOMIDE;ABDOMINAL OBESITY;ACROMEGALY;ACUTE LYMPHOCYTIC LEUKEMIA;ALTERNATIVE SPLICING;ANDROGEN DEPRIVATION THERAPY;BICUSPID VALVE;CABERGOLINE;CAPECITABINE;CETUXIMAB;COLONOSCOPY;COLORECTAL ADENOMA;DNA METHYLATION;DOPPLER IMAGING;EFFECTIVE RENAL PLASMA FLOW;ERYTHROPOIETIN-PRODUCING HEPATOCELLULAR (EPH) RECEPTOR;FOCAL SEGMENTAL GLOMERULOSCLEROSIS;FRONTOTEMPORAL DEMENTIA;GENOTYPING;GLOMERULOSCLEROSIS;GROWTH HORMONE DEFICIENCY;HERPESVIRIDAE;HIGH RESOLUTION MELT;IIF;INTERLEUKIN 22;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;JC VIRUS;MITOGEN-ACTIVATED PROTEIN KINASE KINASE;NUCLEAR EXPORT SIGNAL;ONCOGENE;PCA3;PEMETREXED;PITTSBURGH SLEEP QUALITY INDEX;PLACENTAL GROWTH FACTOR;PLATELET-DERIVED GROWTH FACTOR RECEPTOR;PNEUMOCOCCAL CONJUGATE VACCINE;PNEUMOCOCCAL DISEASE;PNEUMOCOCCAL VACCINE;PODOCYTE;PROSTATE BIOPSY;PROSTATE-SPECIFIC ANTIGEN;PROSTATIC ADENOCARCINOMA;PYELOPLASTY;RECTAL EXAMINATION;RIBAVIRIN;SINGLE-NUCLEOTIDE POLYMORPHISM;SOD1;SOLITARY FIBROUS TUMOR;THIOTEPA;TRANSFUSION-RELATED ACUTE LUNG INJURY;TRANSSPHENOIDAL SURGERY;VASCULAR DEMENTIA;WILD TYPE;WOMAC","13;12;8;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;MALE;FEMALE;MIDDLE AGED;ADULT;AGED;ITALY;COLORECTAL NEOPLASMS;AGED, 80 AND OVER;YOUNG ADULT;HYPERGLYCEMIA;MULTIPLE SCLEROSIS;TREATMENT OUTCOME;RENAL INSUFFICIENCY, CHRONIC;KIDNEY NEOPLASMS;LIVER NEOPLASMS;OBESITY;PROSPECTIVE STUDIES;PROSTATIC NEOPLASMS","56;49;44;41;33;29;26;17;15;14;11;10;10;10;9;8;8;8;8;8","EFFICACY AND RESISTANCE IN CML TREATMENT;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;PATHOPHYSIOLOGY AND MANAGEMENT OF PREECLAMPSIA;RENAL CELL CARCINOMA;ROLE OF LUNG ULTRASOUND IN CRITICAL CARE;ACUTE MYELOID LEUKEMIA;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;DIAGNOSIS AND MANAGEMENT OF ALZHEIMER'S DISEASE;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;STANDARDISATION AND MANAGEMENT OF COPD;14-3-3 PROTEINS: STRUCTURE, FUNCTION, AND REGULATION;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;ASTHMA;BREASTFEEDING: EPIDEMIOLOGY, MECHANISMS, AND HEALTH OUTCOMES;CANCER OF UNKNOWN PRIMARY SITE;CANCER SURVIVORSHIP AND QUALITY OF LIFE","16;6;4;3;3;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1","IMATINIB MESYLATE;IMATINIB;NILOTINIB;DEPRESSION (ECONOMICS);DISCONTINUATION;ECHOCARDIOGRAPHY;ABL;CHRONIC MYELOGENOUS LEUKEMIA;CUMULATIVE INCIDENCE;LUNG ULTRASOUND;METASTATIC COLORECTAL CANCER;MOLECULAR RESPONSE;POLYCYTHEMIA VERA;TOLERABILITY;BTK INHIBITORS;CANCER;CARDIAC ULTRASOUND;CARDIOTHORACIC SURGERY;DASATINIB;DIAGNOSIS","13;6;6;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2","MYELOID LEUKEMIA;CHRONIC MYELOID;CHRONIC PHASE;LEUKEMIA PATIENTS;MULTIPLE SCLEROSIS;NEWLY DIAGNOSED;PROSTATE CANCER;CANCER PATIENTS;COLORECTAL CANCER;PATIENTS TREATED;CML PATIENTS;GROWTH HORMONE;LUNG CANCER;MULTIPLE MYELOMA;PARTIAL NEPHRECTOMY;PHASE CML-CP;POLYCYTHEMIA VERA;RISK FACTORS;TYROSINE KINASE;ACUTE MYELOID;ANXIETY DEPRESSION;BCR-ABL TRANSCRIPT;CARDIOVASCULAR EVENTS;CELL LEVEL;CELL LUNG;CHRONIC KIDNEY;CML WP;CYTO-PV TRIAL;DIAGNOSED CHRONIC;FINAL RESULTS","12;11;6;6;6;6;5;4;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","PUBMED SCOPUS;CROSSREF PUBMED;KIDNEY DISEASE;SERUM LEVELS;CHRONIC KIDNEY;MED -CROSSREF;GROWTH FACTOR;CKD PATIENTS;OBSTET GYNECOL;CANCER PATIENTS;LUNG SLIDING;DIFFERENTIAL DIAGNOSIS;GLOMERULAR FILTRATION;END-STAGE RENAL;ENDOTHELIAL GROWTH;FILTRATION RATE;GROWTH HORMONE;NEPHROL -GOOGLE;SIGNIFICANTLY INCREASED;SOC NEPHROL;VASCULAR ENDOTHELIAL;ALAN AUTOMATED;AUTOMATED METHOD;CIRCADIAN DISRUPTION;DIAGNOSTIC ACCURACY;DISEASEN ENGL;GESTATIONAL AGE;GYNECOL -CROSSREF;IRGENS LM;LM LEIVESTAD","40;29;19;15;14;13;12;11;11;9;9;8;8;7;7;7;7;7;7;7;7;6;6;6;6;6;6;6;6;6",24,0.22,3.25,3,1,2.5,1,4,2.5,0,2,3,0,1,3,0,1,1.5,3,1,6,0,0,89,89.75,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_GONZAGA",2013,104,14.0769230769231,2.75,0.363636363636364,0.326923076923077,0.355769230769231,0.211538461538462,0.461538461538462,1,61,21,5,7,0.59,0.2,0.05,0.07,40.55,1.16208359238647,0.326923076923077,0.923076923076923,6.99555555555555,0.379092840852027,0.403100775193798,0.388250319284802,0.410931174089069,"GIUSEPPE SAGLIO;ANTONIO BERTOLOTTO;ANGELO GHEZZI;ANDREAS HOCHHAUS;SIMONA MALUCCHI;F. PORPIGLIA;ANDREA VELTRI;LUCA OSTACOLI;MICHELE BACCARANI;CARMEN FAVA;HAGOP M. KANTARJIAN;ROCCO LUIGI PICCI;PIER MARIA FURLAN;GIANANTONIO ROSTI;DANIELA CILLONI;MARCO ZUFFRANIERI;VALTER MARTINO;FAUSTO CASTAGNETTI;MASSIMO DEL SETTE;GABRIELE GUGLIOTTA","13;10;6;6;6;6;5;5;5;5;5;5;5;4;4;4;4;4;4;4","PICCOLI BARBARA;GIUSEPPE SAGLIO;ANTONIO BERTOLOTTO;ROCCO LUIGI PICCI;PIER MARIA FURLAN;SANDRO MASSIMO PRIOLA;ADRIANO MASSIMILIANO PRIOLA;F. PORPIGLIA;ANDREA VELTRI;SIMONA MALUCCHI;FRANCESCO OLIVA;GIOVANNI VOLPICELLI;LUCA OSTACOLI;ALESSANDRO LAMORTE;VALTER MARTINO;ANDREAS HOCHHAUS;ROBERTO TORCHIO;MARCO ZUFFRANIERI;R POZZI;CRISTIAN FIORI","1;0.92;0.9;0.77;0.77;0.77;0.64;0.6;0.59;0.59;0.58;0.54;0.54;0.49;0.49;0.44;0.43;0.42;0.4;0.4","GIUSEPPE SAGLIO;ANTONIO BERTOLOTTO;SIMONA MALUCCHI;F. PORPIGLIA;ANDREA VELTRI;LUCA OSTACOLI;CARMEN FAVA;ROCCO LUIGI PICCI;PIER MARIA FURLAN;DANIELA CILLONI;MARCO ZUFFRANIERI;VALTER MARTINO;GIOVANNI VOLPICELLI;ALESSANDRO LAMORTE;MARCO TAMPELLINI;ROBERTO TORCHIO;SILVIA NOVELLO;ALFREDO BERRUTI;MASSIMO TERZOLO;SANDRO MASSIMO PRIOLA","13;10;6;6;5;5;5;5;5;4;4;4;4;4;4;4;3;3;3;3","PICCOLI BARBARA;GIUSEPPE SAGLIO;ANTONIO BERTOLOTTO;ROCCO LUIGI PICCI;PIER MARIA FURLAN;SANDRO MASSIMO PRIOLA;ADRIANO MASSIMILIANO PRIOLA;F. PORPIGLIA;ANDREA VELTRI;SIMONA MALUCCHI;FRANCESCO OLIVA;GIOVANNI VOLPICELLI;LUCA OSTACOLI;ALESSANDRO LAMORTE;VALTER MARTINO;ROBERTO TORCHIO;MARCO ZUFFRANIERI;R POZZI;CRISTIAN FIORI;MARCO TAMPELLINI","1;0.92;0.9;0.77;0.77;0.77;0.64;0.6;0.59;0.59;0.58;0.54;0.54;0.49;0.49;0.43;0.42;0.4;0.4;0.38","GIUSEPPE SAGLIO;ANDREAS HOCHHAUS;HAGOP M. KANTARJIAN;DONG‐WOOK KIM;GIOVANNI VOLPICELLI;ALFREDO BERRUTI;ALESSANDRO LAMORTE;PEIMAN NAZERIAN;MICHELE BACCARANI;ANTONIO BERTOLOTTO;JUAN LUIS STEEGMANN;CAROLINA PAVLOVSKY;CHARLES CHUAH;CONCEPCIÓN BOQUÉ;ELIAS JABBOUR;HESHAM MOHAMED;JIŘÍ MAYER;JORGE E. CORTÉS;M. BRIGID BRADLEY‐GARELIK;MARK WILDGUST","758;740;534;526;492;480;476;466;437;405;390;382;382;382;382;382;382;382;382;382","GIUSEPPE SAGLIO;GIOVANNI VOLPICELLI;ALESSANDRO LAMORTE;ANTONIO BERTOLOTTO;MARCO VOLANTE;PAOLO MELLO TEGGIA;ALFREDO BERRUTI;ANDREA VELTRI;ARIANNA ARDITO;MASSIMO TERZOLO;MAURO PAPOTTI;ENRICO BOERO;MATTIA TULLIO;VALERIO STEFANONE;L. CARDINALE;MAURO F. FRASCISCO;R POZZI;SIMONA MALUCCHI;TOMMASINA GUGLIELMELLI;SILVIA DE FRANCIA","758;482;476;363;323;293;287;280;259;259;254;239;239;239;229;229;229;169;167;137","GIUSEPPE SAGLIO;ANTONIO BERTOLOTTO;SIMONA MALUCCHI;CARMEN FAVA;ALESSANDRO LAMORTE;ALFREDO BERRUTI;GIOVANNI VOLPICELLI;MARCO TAMPELLINI;ROBERTO TORCHIO;DANIELA CILLONI;F. PORPIGLIA;ALESSANDRO FALCONE;CARLO GULOTTA;GIORGINA BARBARA PICCOLI;JOSEPH VARGAS;LUCA DURELLI;LUCA OSTACOLI;LUISELLA RIGHI;MARCO GIBBIN;MARCO VOLANTE","13;9;6;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3","MEDICINE;BIOLOGY;CHEMISTRY;PSYCHOLOGY;ECONOMICS;ENGINEERING;PHYSICS;POLITICAL SCIENCE;COMPUTER SCIENCE;MATERIALS SCIENCE;MATHEMATICS;ART;BUSINESS;GEOGRAPHY;GEOLOGY;HISTORY;SOCIOLOGY","102;21;10;10;5;5;5;4;3;3;3;1;1;1;1;1;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;GASTROENTEROLOGY;PSYCHIATRY;IMMUNOLOGY;PATHOLOGY;BIOCHEMISTRY;RADIOLOGY;PALEONTOLOGY;CARDIOLOGY;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;PEDIATRICS;CLINICAL PSYCHOLOGY;GENETICS;UROLOGY;ANESTHESIA;GENERAL SURGERY;LAW;MACROECONOMICS;NUCLEAR MEDICINE;NURSING;PHARMACOLOGY","85;31;25;20;16;12;12;11;11;9;8;7;7;7;6;6;6;4;4;4;4;4;4;4","CANCER;MYELOID LEUKEMIA;CHEMOTHERAPY;MULTIPLE SCLEROSIS;RANDOMIZED CONTROLLED TRIAL;CONFIDENCE INTERVAL;ADVERSE EFFECT;DISCONTINUATION;OBSERVATIONAL STUDY;POPULATION;RETROSPECTIVE COHORT STUDY;ASTHMA;GENE;KIDNEY;LUNG;STAGE (STRATIGRAPHY);ANTIBODY;ANXIETY;BIOMARKER;BONE MARROW;COHORT;CONTEXT (ARCHAEOLOGY);DEPRESSION (ECONOMICS);DISEASE;EMERGENCY DEPARTMENT;LOGISTIC REGRESSION;LUNG CANCER;MULTIPLE MYELOMA;NEUROLOGY;PROSPECTIVE COHORT STUDY;QUALITY OF LIFE (HEALTHCARE);RENAL CELL CARCINOMA","18;13;12;11;9;8;7;7;7;6;6;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4","IMATINIB;CLINICAL ENDPOINT;HAZARD RATIO;COLORECTAL CANCER;MULTICENTER STUDY;NEURORADIOLOGY;LENALIDOMIDE;METASTASIS;NEPHRECTOMY;PROSTATE CANCER;RESPIRATORY DISEASE;ADENOCARCINOMA;AIRCRAFT NOISE;AIRWAY RESISTANCE;BREAST CANCER;BRONCHOCONSTRICTION;DOCETAXEL;EPIDERMAL GROWTH FACTOR RECEPTOR;FLUOROURACIL;INGUINAL HERNIA;KIDNEY CANCER;MITOTANE;MITOXANTRONE;MYELODYSPLASTIC SYNDROMES;NATALIZUMAB;NITRIC OXIDE SYNTHASE;PERFORMANCE STATUS;PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY;PULMONARY ANGIOGRAPHY;TOLERABILITY;TYROSINE-KINASE INHIBITOR;UNIVARIATE ANALYSIS","12;5;5;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","IMATINIB MESYLATE;NILOTINIB;OXALIPLATIN;METHACHOLINE;ANDROGEN DEPRIVATION THERAPY;ANDROGEN RECEPTOR;DASATINIB;ERLOTINIB;FOLINIC ACID;TAXANE;ACROMEGALY;ADENOSQUAMOUS CARCINOMA;ALPORT SYNDROME;ANAGRELIDE;BONE METASTASIS;CAPECITABINE;CETUXIMAB;CHRONIC MYELOMONOCYTIC LEUKEMIA;DIFFUSING CAPACITY;DNA METHYLATION;ENOS;FUNCTIONAL RESIDUAL CAPACITY;FUSION TRANSCRIPT;GENETIC HETEROGENEITY;HEAD AND NECK SQUAMOUS-CELL CARCINOMA;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;MILLON CLINICAL MULTIAXIAL INVENTORY;MODIFIED RANKIN SCALE;MONOCLONAL;MULTICENTER TRIAL;NON-SMALL CELL LUNG CANCER (NSCLC);PAPILLOMAVIRIDAE;PEROXYNITRITE;POMALIDOMIDE;PROSTATE-SPECIFIC ANTIGEN;RESIDUAL VOLUME;SADISTIC PERSONALITY DISORDER;SODIUM CHANNEL BLOCKER;SUGAMMADEX;TROCHANTER","11;7;4;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;MIDDLE AGED;AGED;;ADULT;AGED, 80 AND OVER;MULTIPLE SCLEROSIS;TREATMENT OUTCOME;ANTINEOPLASTIC AGENTS;BENZAMIDES;PIPERAZINES;PYRIMIDINES;ADENOCARCINOMA;ITALY;LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE;YOUNG ADULT;RETROSPECTIVE STUDIES;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS","66;52;45;42;39;35;35;24;24;21;20;19;19;19;17;17;17;16;15;14","EFFICACY AND RESISTANCE IN CML TREATMENT;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;RENAL CELL CARCINOMA;ROLE OF LUNG ULTRASOUND IN CRITICAL CARE;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ASTHMA;DIAGNOSIS AND MANAGEMENT OF CEREBRAL VEIN THROMBOSIS;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;ADVANCEMENTS IN LUNG CANCER RESEARCH;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION;EFFECTS OF NOISE POLLUTION ON HEALTH AND WELL-BEING;HERNIA REPAIR TECHNIQUES AND MATERIALS;PATHOPHYSIOLOGY OF MYOCARDIAL REPERFUSION INJURY;PATHOPHYSIOLOGY OF PARKINSON'S DISEASE;PHEOCHROMOCYTOMA AND PARAGANGLIOMA;POLYOMAVIRUS-ASSOCIATED CARCINOGENESIS AND CLINICAL MANIFESTATIONS;SCHIZOPHRENIA RESEARCH AND TREATMENT;SHOULDER PATHOLOGY AND TREATMENT OUTCOMES;ACUTE MYELOID LEUKEMIA","13;7;5;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;1","IMATINIB MESYLATE;DISCONTINUATION;IMATINIB;CLINICAL ENDPOINT;NILOTINIB;DEPRESSION (ECONOMICS);DIAGNOSTIC CRITERIA;NEURORADIOLOGY;TREATMENT;CARDIAC ULTRASOUND;CONCORDANCE;ECHOCARDIOGRAPHY;LUNG ULTRASOUND;METASTATIC COLORECTAL CANCER;METHACHOLINE;POINT-OF-CARE ULTRASONOGRAPHY;RESPIRATORY;STROKE (ENGINE);ABDOMINAL WALL RECONSTRUCTION;ADRENOCORTICAL CARCINOMA","12;7;7;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;2;2","CHRONIC MYELOID;MYELOID LEUKEMIA;MULTIPLE SCLEROSIS;CHRONIC PHASE;NEWLY DIAGNOSED;DIAGNOSED CHRONIC;OBSERVATIONAL STUDY;PHASE CML-CP;CELL LUNG;COLORECTAL CANCER;LIVER METASTASES;LUNG CANCER;MOLECULAR RESPONSE;MULTICENTER STUDY;NON-SMALL CELL;PATIENTS PTS;CANCER PROSE;CHEMOTHERAPY CT;CLINICAL OUTCOME;COSMO STUDY;ELDERLY PATIENTS;EMERGENCY DEPARTMENT;HEART DISEASE;HUMERAL FRACTURES;II STUDY;III STUDY;IMATINIB IM;INOPERABLE NON-SMALL;LEUKEMIA PATIENTS;LONG-TERM OUTCOMES","13;13;10;7;5;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","RANDOM GH;COGNITIVE IMPAIRMENT;BONE METASTASIS;COPD PATIENTS;AIR POLLUTION;AIRWAY OBSTRUCTION;HEART DISEASE;MULTIPLE SCLEROSIS;GH NADIR;MITOTANE CONCENTRATIONS;MS PATIENTS;URINARY TRACT;AIRCRAFT NOISE;CL MONTHS;CLINICAL DIAGNOSIS;CLINICAL PRACTICE;CONSECUTIVE PATIENTS;ELDERLY PATIENTS;FINAL CLINICAL;INSPIRATORY EFFORT;LEARNING CURVE;LEG VEINS;LPN ERA;MOOD DISORDER;MOOD DISORDERS;MULTIVARIATE ANALYSIS;NEUROLOGIC IMPROVEMENT;PERSONALITY TRAITS;ROAD TRAFFIC;TRAFFIC NOISE","9;8;7;7;6;6;6;6;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4",41,0.39,10.83,8,1.5,1,0,2.25,1.5,0,2,9,0,1,5,1,1,1,1,5,2,0,0,91,91,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_GONZAGA",2014,125,12.296,2.456,0.407166123778502,0.272,0.296,0.136,0.536,2,74,16,9,9,0.59,0.13,0.07,0.07,31.85,0.842724701332327,0.288,0.936,6.634765625,0.445255696862425,0.437590361445783,0.399872448979592,0.41304347826087,"F. PORPIGLIA;ANTONIO BERTOLOTTO;GIUSEPPE SAGLIO;CRISTIAN FIORI;SILVIA NOVELLO;RICCARDO BERTOLO;CARLO TERRONE;ANDREA MINERVINI;GIORGIO V. SCAGLIOTTI;GIUSEPPE MORGIA;SIMONA MALUCCHI;ALESSIA DI SAPIO;ALESSANDRO ANTONELLI;ANDREA MARI;MARCO CARINI;MASSIMO TERZOLO;FRANCESCA SPERLI;NICOLA LONGO;SERGIO SERNI;MARCO CAPOBIANCO","12;11;8;8;7;7;7;7;7;6;6;6;6;6;6;5;5;5;5;5","ANTONIO BERTOLOTTO;ALESSIA DI SAPIO;AOU SAN;ADRIANO MASSIMILIANO PRIOLA;MARTINA BORGHI;MARCO CAPOBIANCO;SANDRO MASSIMO PRIOLA;F. PORPIGLIA;GIORGINA BARBARA PICCOLI;SIMONA MALUCCHI;GIORGIO V. SCAGLIOTTI;FRANCESCA SPERLI;GIOVANNI SUCCO;ERIKA CROSETTI;GIOVANNI VOLPICELLI;MARIA MALENTACCHI;GIOVANNI VOLPICELLI;ANDREA VELTRI;W. TRONI;FEDERICA MELILLO","1.74;1;1;1;1;0.93;0.88;0.84;0.78;0.78;0.74;0.72;0.67;0.67;0.65;0.63;0.62;0.6;0.54;0.54","F. PORPIGLIA;ANTONIO BERTOLOTTO;GIUSEPPE SAGLIO;CRISTIAN FIORI;SILVIA NOVELLO;RICCARDO BERTOLO;CARLO TERRONE;GIORGIO V. SCAGLIOTTI;SIMONA MALUCCHI;ALESSIA DI SAPIO;MARCO CARINI;MASSIMO TERZOLO;FRANCESCA SPERLI;NICOLA LONGO;MARCO CAPOBIANCO;RICCARDO SCHIAVINA;ANDREA VELTRI;GIOVANNI SUCCO;DARIO GNED;ALESSANDRO MASSÈ","12;11;8;8;7;7;7;7;6;6;6;5;5;5;5;5;4;4;4;4","ANTONIO BERTOLOTTO;ALESSIA DI SAPIO;AOU SAN;ADRIANO MASSIMILIANO PRIOLA;MARTINA BORGHI;MARCO CAPOBIANCO;SANDRO MASSIMO PRIOLA;F. PORPIGLIA;GIORGINA BARBARA PICCOLI;SIMONA MALUCCHI;GIORGIO V. SCAGLIOTTI;FRANCESCA SPERLI;GIOVANNI SUCCO;GIOVANNI VOLPICELLI;MARIA MALENTACCHI;GIOVANNI VOLPICELLI;ANDREA VELTRI;W. TRONI;FEDERICA MELILLO;DARIO GNED","1.74;1;1;1;1;0.93;0.88;0.84;0.78;0.78;0.74;0.72;0.67;0.65;0.63;0.62;0.6;0.54;0.54;0.53","F. PORPIGLIA;ALESSANDRO VOLPE;CRISTIAN FIORI;GIOVANNI VOLPICELLI;ALESSANDRO ANTONELLI;ANDREA MINERVINI;CLAUDIO SIMEONE;SERGIO SERNI;CARLO TERRONE;MARCO CARINI;LUNA GARGANI;MARINELLA CLERICO;VALTER TORRI;M. ZACCHERO;STEFANIA DE MERCANTI;GIUSEPPE SAGLIO;MASSIMO TERZOLO;ANDREA SALONIA;ETTORE DI TRAPANI;F. REGIS","720;513;494;436;396;396;396;396;346;316;308;307;286;263;256;237;236;233;233;233","F. PORPIGLIA;CRISTIAN FIORI;GIOVANNI VOLPICELLI;MARINELLA CLERICO;STEFANIA DE MERCANTI;GIUSEPPE SAGLIO;ANDREA VELTRI;GIUSEPPE REIMONDO;MASSIMO TERZOLO;SILVIA NOVELLO;DARIO GNED;RICCARDO BERTOLO;MATTEO GIAJ LEVRA;GIORGIA MANDRILE;GIOVANNI SUCCO;MATTIA BERRONE;FRANCESCO ARDISSONE;F BOCCUZZI;LUCIANO CARDINALE;MARCO BUSSO","550;494;314;256;256;237;229;217;217;200;189;173;156;146;144;132;130;113;113;113","F. PORPIGLIA;ANTONIO BERTOLOTTO;CRISTIAN FIORI;GIUSEPPE SAGLIO;RICCARDO BERTOLO;SILVIA NOVELLO;GIORGIO V. SCAGLIOTTI;SIMONA MALUCCHI;ALESSIA DI SAPIO;ANDREA VELTRI;DARIO GNED;FRANCESCA SPERLI;MARCO CAPOBIANCO;MARIA MALENTACCHI;ENRICO BOLLITO;GIORGINA BARBARA PICCOLI;DANIELA GIACHINO;FRANCESCO ARDISSONE;MARCELLO TUCCI;MASSIMO TERZOLO","11;9;8;7;7;6;6;5;4;4;4;4;4;4;4;4;3;3;3;3","MEDICINE;BIOLOGY;CHEMISTRY;PSYCHOLOGY;PHYSICS;COMPUTER SCIENCE;POLITICAL SCIENCE;ECONOMICS;MATERIALS SCIENCE;MATHEMATICS;ENGINEERING;HISTORY;GEOGRAPHY","121;32;10;8;7;4;4;3;3;3;2;2;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;PATHOLOGY;GASTROENTEROLOGY;GENETICS;IMMUNOLOGY;RADIOLOGY;ENVIRONMENTAL HEALTH;BIOCHEMISTRY;PSYCHIATRY;UROLOGY;ANESTHESIA;ENDOCRINOLOGY;CANCER RESEARCH;GENERAL SURGERY;INTENSIVE CARE MEDICINE;CARDIOLOGY;CELL BIOLOGY;PALEONTOLOGY;PHYSICAL THERAPY","98;45;27;21;18;13;13;13;11;10;9;9;8;8;6;6;6;5;5;5;5","CANCER;CHEMOTHERAPY;DISEASE;GENE;POPULATION;LUNG;LUNG CANCER;MULTIPLE SCLEROSIS;KIDNEY;COHORT;MYELOID LEUKEMIA;CLINICAL TRIAL;DISCONTINUATION;MAGNETIC RESONANCE IMAGING;MULTIVARIATE ANALYSIS;ODDS RATIO;PERIOPERATIVE;RANDOMIZED CONTROLLED TRIAL;RETROSPECTIVE COHORT STUDY;STAGE (STRATIGRAPHY)","25;15;12;12;11;10;10;10;9;7;7;6;5;5;5;5;5;5;5;5","IMATINIB;NEPHRECTOMY;CISPLATIN;PROSTATE CANCER;CLINICAL ENDPOINT;NATALIZUMAB;UNIVARIATE ANALYSIS;AMYOTROPHIC LATERAL SCLEROSIS;COLORECTAL CANCER;EPIDERMAL GROWTH FACTOR RECEPTOR;FINGOLIMOD;GLATIRAMER ACETATE;HAZARD RATIO;LUNG FUNCTION;MUTATION;PHASES OF CLINICAL RESEARCH;RESPIRATORY DISEASE;A549 CELL;AIRWAY RESISTANCE;DNA SEQUENCING;DOCETAXEL;GENOME;HOME HEMODIALYSIS;INSULINOMA;LUNG ULTRASOUND;LUNG VOLUMES;MAJOR DEPRESSIVE DISORDER;MULTICENTER STUDY;NASOPHARYNGEAL CARCINOMA;PANCREATIC CANCER;POLYMERASE CHAIN REACTION;PROINFLAMMATORY CYTOKINE;PROSTATE;PULMONARY EDEMA;TOLERABILITY;TYPE 2 DIABETES MELLITUS","7;7;6;5;4;4;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","PEMETREXED;IMATINIB MESYLATE;NILOTINIB;DIFFUSING CAPACITY;AMPLICON;ANDROGEN DEPRIVATION THERAPY;ANDROGEN RECEPTOR;COPY-NUMBER VARIATION;DASATINIB;ERLOTINIB;INTRAEPITHELIAL NEOPLASIA;NON-SMALL CELL LUNG CANCER (NSCLC);PANCREATIC TUMOR;PCA3;PROSTATE BIOPSY;PROSTATE-SPECIFIC ANTIGEN;PROSTATITIS;RECTAL EXAMINATION;ABDUCENS NERVE;ANAPLASTIC LYMPHOMA KINASE;APOCYNIN;ARID1A;BRENTUXIMAB VEDOTIN;BRONCHIAL HYPERRESPONSIVENESS;BRONCHODILATOR AGENTS;CHELERYTHRINE;CHEMOKINE RECEPTOR;CHRONIC MYELOMONOCYTIC LEUKEMIA;COMPARATIVE GENOMIC HYBRIDIZATION;CYTOGENETICS;EXOME SEQUENCING;EXTRAPLEURAL PNEUMONECTOMY;GANCICLOVIR;GEFITINIB;GENEXPERT MTB/RIF;GESTATIONAL DIABETES;GLOMERULAR HYPERFILTRATION;GLUCAGONOMA;HUMAN BREAST;INEFFECTIVE ERYTHROPOIESIS;INTERLEUKIN 22;ION SEMICONDUCTOR SEQUENCING;IONOTROPIC EFFECT;IRON STATUS;KARYOTYPE;KRAS;MANIA;METASTASECTOMY;MISSENSE MUTATION;OSTEONECROSIS OF THE JAW;PIRFENIDONE;PLEURAL DISEASE;PRENATAL DIAGNOSIS;PROSTATECTOMY;PYELOPLASTY;SANGER SEQUENCING;SINGLE-NUCLEOTIDE POLYMORPHISM;TERIPARATIDE;TRPV1;UPPER MOTOR NEURON;URETEROPELVIC JUNCTION;WHIPPLE PROCEDURE","6;5;4;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;LUNG NEOPLASMS;AGED, 80 AND OVER;ITALY;KIDNEY NEOPLASMS;TREATMENT OUTCOME;CARCINOMA, NON-SMALL-CELL LUNG;LAPAROSCOPY;MULTIPLE SCLEROSIS, RELAPSING-REMITTING;RETROSPECTIVE STUDIES;BIOMARKERS, TUMOR;POSTOPERATIVE COMPLICATIONS;CARDIOVASCULAR DISEASES;PROSPECTIVE STUDIES","61;61;50;50;43;35;32;22;17;16;16;16;14;14;13;13;12;12;11;11","EFFICACY AND RESISTANCE IN CML TREATMENT;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;RENAL CELL CARCINOMA;ADVANCEMENTS IN LUNG CANCER RESEARCH;ROLE OF LUNG ULTRASOUND IN CRITICAL CARE;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;ASTHMA;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;MYASTHENIA GRAVIS AND THYMIC TUMORS RESEARCH;PHEOCHROMOCYTOMA AND PARAGANGLIOMA;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;CHRONIC KIDNEY DISEASE AND DIALYSIS TREATMENT;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;EPIDEMIOLOGY AND MANAGEMENT OF BIPOLAR DISORDER;GENOMIC REARRANGEMENTS AND COPY NUMBER VARIATIONS;MALIGNANT PLEURAL MESOTHELIOMA RESEARCH;OPERATIVE MANAGEMENT OF PELVIC FRACTURES;POLYOMAVIRUS-ASSOCIATED CARCINOGENESIS AND CLINICAL MANIFESTATIONS;PROSTATE CANCER RESEARCH AND TREATMENT","9;8;7;6;6;5;3;3;3;3;2;2;2;2;2;2;2;2;2;2","PEMETREXED;CARDIAC ULTRASOUND;DISCONTINUATION;IMATINIB MESYLATE;LUNG ULTRASOUND;CLINICAL ENDPOINT;INTERVENTIONAL RADIOLOGY;NATALIZUMAB;NEPHRON-SPARING SURGERY;NON-SMALL CELL LUNG CANCER;PANCREATIC NEUROENDOCRINE TUMORS;TREATMENT;UNIVARIATE ANALYSIS;DLCO;GLATIRAMER ACETATE;MALIGNANT PLEURAL MESOTHELIOMA;PNEUMOTHORAX DIAGNOSIS;POINT-OF-CARE ULTRASONOGRAPHY;PROGNOSTIC FACTORS;RADIOTHERAPY","6;5;5;5;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3","MULTIPLE SCLEROSIS;CHRONIC MYELOID;LUNG CANCER;MYELOID LEUKEMIA;ITALIAN SOCIETY;PATIENTS PTS;CANCER PATIENTS;PROSTATE CANCER;CELL LUNG;MULTICENTER STUDY;NON-SMALL CELL;PROSPECTIVE MULTICENTER;RECORD PROJECT;CELL CARCINOMA;CHRONIC KIDNEY;LUNG ULTRASOUND;NATALIZUMAB DISCONTINUATION;OBSERVATIONAL STUDY;PARTIAL NEPHRECTOMY;PERIOPERATIVE OUTCOMES;PHASE STUDY;PLEURAL MESOTHELIOMA;POSITIVE SURGICAL;PREDICTIVE FACTORS;SCLEROSIS PATIENTS;SURGICAL MARGINS;ADVANCED NONSQUAMOUS;AMYOTROPHIC LATERAL;CANCER GENE;CASTRATION-RESISTANT PROSTATE","9;7;7;7;6;6;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2","HOME HEMODIALYSIS;NS NSCLC;PROGNOSTIC FACTORS;SURGICAL TREATMENT;INTERFERON BETA;CLINICAL PRACTICE;MEDIAN AGE;HAZARD RATIO;SURVIVAL OS;BRENTUXIMAB VEDOTIN;ITALIAN SOCIETY;MEDIAN FOLLOW-UP;NSCLC PATIENTS;PATIENTS TREATED;ADVANCED NS;CANCER PATIENTS;CARDIOVASCULAR RISK;CHRONIC BRONCHITIS;CONFIDENCE INTERVAL;FIRST-LINE PEMCISPLATIN;HR PEM;LUNG CANCER;MULTIVARIABLE ANALYSIS;OS HR;PEM MAINTENANCE;POOLED RATIO;STEM CELL;TEST CLASSIFICATION;UA LEVELS;DOMINANT EMPHYSEMA","19;15;11;11;10;9;9;8;8;7;7;7;7;7;6;6;6;6;6;6;6;6;6;6;6;6;6;6;6;5",45,0.36,9.55,8,1,1,1.5,2,3,0,1,9,0,1,3,1,1,2,2,3.25,2,0,0,82,106,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_GONZAGA",2015,99,11.1010101010101,2.81818181818182,0.354838709677419,0.414141414141414,0.363636363636364,0.272727272727273,0.535353535353535,2,56,13,9,5,0.57,0.13,0.09,0.05,19.93,0.534753186845758,0.282828282828283,0.94949494949495,6.39928698752228,0.417019967381355,0.383445945945946,0.391854705558613,0.374666666666667,"F. PORPIGLIA;ANTONIO BERTOLOTTO;ANDREA VELTRI;PAOLA BERCHIALLA;GIUSEPPE SAGLIO;GIORGIO V. SCAGLIOTTI;CARMEN FAVA;GIUSEPPE MAINA;SILVIA NOVELLO;DARIO GNED;ALESSANDRO MOROTTI;GIORGINA BARBARA PICCOLI;MASSIMO AGLIETTA;GIOVANNI VOLPICELLI;MARCO CAPOBIANCO;ADRIANO MASSIMILIANO PRIOLA;ANGELO GUERRASIO;MARCELLO TUCCI;MATTEO MANFREDI;FILIPPO RUSSO","10;9;8;8;7;7;5;4;4;4;4;4;4;4;4;4;4;4;4;3","ANTONIO BERTOLOTTO;SILVIA DE FRANCIA;ANTONIO BERTOLOTTO;ANDREA VELTRI;F. PORPIGLIA;GIUSEPPE MAINA;ADRIANO MASSIMILIANO PRIOLA;SANDRO MASSIMO PRIOLA;PAOLA BERCHIALLA;GIORGIO V. SCAGLIOTTI;GIUSEPPE SAGLIO;ANDREA AGUGLIA;DARIO GNED;MATTEO MANFREDI;GIORGINA BARBARA PICCOLI;LUIGI SABATINI;FRANCESCO ATZORI;SILVIA TESTA;ROSALBA ROSATO;GIOVANNI SUCCO","1.23;1;1;0.98;0.98;0.97;0.95;0.82;0.77;0.7;0.65;0.62;0.58;0.52;0.5;0.5;0.5;0.49;0.49;0.48","F. PORPIGLIA;ANTONIO BERTOLOTTO;ANDREA VELTRI;GIUSEPPE SAGLIO;GIORGIO V. SCAGLIOTTI;CARMEN FAVA;GIUSEPPE MAINA;SILVIA NOVELLO;DARIO GNED;ALESSANDRO MOROTTI;GIORGINA BARBARA PICCOLI;GIOVANNI VOLPICELLI;MARCO CAPOBIANCO;ADRIANO MASSIMILIANO PRIOLA;ANGELO GUERRASIO;MARCELLO TUCCI;MATTEO MANFREDI;MASSIMO DI MAÏO;FEDERICA NEVE VIGOTTI;SANDRO MASSIMO PRIOLA","10;9;8;7;7;5;4;4;4;4;4;4;4;4;4;4;4;3;3;3","ANTONIO BERTOLOTTO;SILVIA DE FRANCIA;ANTONIO BERTOLOTTO;ANDREA VELTRI;F. PORPIGLIA;GIUSEPPE MAINA;ADRIANO MASSIMILIANO PRIOLA;SANDRO MASSIMO PRIOLA;GIORGIO V. SCAGLIOTTI;GIUSEPPE SAGLIO;ANDREA AGUGLIA;DARIO GNED;MATTEO MANFREDI;GIORGINA BARBARA PICCOLI;LUIGI SABATINI;FRANCESCO ATZORI;GIOVANNI SUCCO;ALESSANDRO MOROTTI;ANGELO GUERRASIO;G RADESCHI","1.23;1;1;0.98;0.98;0.97;0.95;0.82;0.7;0.65;0.62;0.58;0.52;0.5;0.5;0.5;0.48;0.48;0.48;0.45","F. PORPIGLIA;GIOVANNI VOLPICELLI;PAOLA BERCHIALLA;ANDREA VELTRI;PEIMAN NAZERIAN;CHIARA GIGLI;SIMONE VANNI;STEFANO GRIFONI;CRISTINA IANNELLO;FRANCESCA ROMANA ERMINI;LAURA BETTI;MAURIZIO BARTOLUCCI;MAURIZIO ZANOBETTI;CARLO ALBERA;ANTONIO BERTOLOTTO;GIACOMO NOVARA;CRISTIAN FIORI;MATTEO MANFREDI;FILIPPO RUSSO;ALBERTO MORMILE","303;248;226;218;206;205;205;205;184;184;184;184;184;165;154;130;122;121;119;117","F. PORPIGLIA;GIOVANNI VOLPICELLI;ANDREA VELTRI;CRISTINA IANNELLO;ANTONIO BERTOLOTTO;MATTEO MANFREDI;ALESSANDRO APRATO;CRISTIAN FIORI;RICCARDO BERTOLO;GIUSEPPE SAGLIO;ENRICO BOLLITO;G RADESCHI;GIUSEPPE MAINA;CARLO ALBERA;GIAN PIERO BANDELLI;ALESSANDRO MASSÈ;CATERINA ALLUTO;MARCO CAPOBIANCO;MARCO FAVUTO;PIERO LUIGI GIULIANO","287;248;207;184;154;114;113;106;106;97;83;76;75;72;72;70;70;70;70;62","ANTONIO BERTOLOTTO;F. PORPIGLIA;ANDREA VELTRI;GIORGIO V. SCAGLIOTTI;GIOVANNI VOLPICELLI;ALESSANDRO MOROTTI;ANGELO GUERRASIO;GIUSEPPE MAINA;GIUSEPPE SAGLIO;MARCELLO TUCCI;MARCO CAPOBIANCO;DARIO GNED;ENRICO BOLLITO;ADRIANO MASSIMILIANO PRIOLA;MARIA PIA BRIZZI;MATTEO MANFREDI;G RADESCHI;SILVIA NOVELLO;ALESSANDRA OGGERO;ALESSANDRO APRATO","9;9;6;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;2;2","MEDICINE;BIOLOGY;COMPUTER SCIENCE;CHEMISTRY;PSYCHOLOGY;MATHEMATICS;PHYSICS;ECONOMICS;POLITICAL SCIENCE;ART;ENGINEERING;BUSINESS;PHILOSOPHY;SOCIOLOGY","96;22;10;8;7;5;5;4;3;2;2;1;1;1","INTERNAL MEDICINE;RADIOLOGY;SURGERY;ONCOLOGY;PATHOLOGY;PSYCHIATRY;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;UROLOGY;IMMUNOLOGY;NUCLEAR MEDICINE;GENETICS;INTENSIVE CARE MEDICINE;PALEONTOLOGY;BIOCHEMISTRY;ENDOCRINOLOGY;NURSING;PROGRAMMING LANGUAGE;ANESTHESIA;MEDICAL PHYSICS","78;21;21;15;12;11;9;9;9;8;8;7;7;7;6;6;6;6;5;5","CANCER;LUNG;GENE;POPULATION;MAGNETIC RESONANCE IMAGING;MULTIPLE SCLEROSIS;ADVERSE EFFECT;ASYMPTOMATIC;BIOPSY;CHEMOTHERAPY;DISEASE;MYELOID LEUKEMIA;RECEPTOR;STAGE (STRATIGRAPHY);ULTRASOUND;COHORT;COMPUTED TOMOGRAPHY;CONFIDENCE INTERVAL;DISCONTINUATION;KIDNEY;LOGISTIC REGRESSION;PROSPECTIVE COHORT STUDY;PSYCHOLOGICAL INTERVENTION;QUALITY OF LIFE (HEALTHCARE);RADIATION THERAPY;RANDOMIZED CONTROLLED TRIAL","24;9;8;8;7;7;6;6;6;6;6;6;5;5;5;4;4;4;4;4;4;4;4;4;4;4","PROSTATE CANCER;IMATINIB;LUNG ULTRASOUND;NATALIZUMAB;BREAST CANCER;NEPHRECTOMY;PROSTATE;DYSGEUSIA;IDIOPATHIC PULMONARY FIBROSIS;PI3K/AKT/MTOR PATHWAY;PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY;RITUXIMAB;COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS;DEPRESSIVE SYMPTOMS;DIFFUSION MRI;DOCETAXEL;EPIDERMAL GROWTH FACTOR RECEPTOR;FINGOLIMOD;GENE EXPRESSION;GENOTYPE;GLATIRAMER ACETATE;HAZARD RATIO;LOCUS (GENETICS);LUNG FUNCTION;MULTICENTER STUDY;MUTATION;NEURORADIOLOGY;PERIPHERAL BLOOD MONONUCLEAR CELL;PHARMACODYNAMICS;PROGRESSION-FREE SURVIVAL;THYROID CANCER;TOLERABILITY","12;5;5;5;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ANDROGEN DEPRIVATION THERAPY;ANDROGEN RECEPTOR;IMATINIB MESYLATE;PROSTATECTOMY;DIFFUSING CAPACITY;NILOTINIB;PIRFENIDONE;PROSTATE BIOPSY;PROSTATE-SPECIFIC ANTIGEN;RECTAL EXAMINATION;SINGLE-NUCLEOTIDE POLYMORPHISM;ANTIRETROVIRAL THERAPY;CAVEOLIN;CAVEOLIN 3;CIRCULATING TUMOR CELL;COGNITIVE VULNERABILITY;CTGF;DASATINIB;DISCOVERY AND DEVELOPMENT OF MTOR INHIBITORS;ERLOTINIB;GEFITINIB;GENE EXPRESSION PROFILING;INTERNATIONAL PROGNOSTIC INDEX;INTRA ARTICULAR;INTRAEPITHELIAL NEOPLASIA;LY294002;MUCOADHESION;MULTIPARAMETRIC MRI;NUCLEOTIDE EXCISION REPAIR;PARS PLANA;PCA3;PNEUMOCOCCAL CONJUGATE VACCINE;PNEUMOCOCCAL DISEASE;PNEUMOCOCCAL VACCINE;POLOXAMER;POST-THROMBOTIC SYNDROME;POSTERIOR VITREOUS DETACHMENT;PROBAND;PROSTATITIS;PTEN;RADIOIODINE THERAPY;SABR VOLATILITY MODEL;SECONDARY HYPERPARATHYROIDISM;SHORT QT SYNDROME;STEROID BIOSYNTHESIS;TBARS;TERIFLUNOMIDE;THIOBARBITURIC ACID;THYMIDYLATE SYNTHASE;TRASTUZUMAB","3;3;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;MALE;FEMALE;MIDDLE AGED;AGED;ADULT;PROSTATIC NEOPLASMS;AGED, 80 AND OVER;YOUNG ADULT;ITALY;RETROSPECTIVE STUDIES;ADOLESCENT;ANTINEOPLASTIC AGENTS;ASTHMA;FOLLOW-UP STUDIES;IDIOPATHIC PULMONARY FIBROSIS;PROSPECTIVE STUDIES;KIDNEY NEOPLASMS;MAGNETIC RESONANCE IMAGING","49;49;42;38;31;27;24;15;11;11;10;9;8;8;8;8;8;8;7;7","EFFICACY AND RESISTANCE IN CML TREATMENT;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;PROSTATE CANCER RESEARCH AND TREATMENT;ROLE OF LUNG ULTRASOUND IN CRITICAL CARE;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;POLYOMAVIRUS-ASSOCIATED CARCINOGENESIS AND CLINICAL MANIFESTATIONS;IDIOPATHIC PULMONARY FIBROSIS: DIAGNOSIS AND MANAGEMENT;MYASTHENIA GRAVIS AND THYMIC TUMORS RESEARCH;RENAL CELL CARCINOMA;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;INTEGRATION OF PALLIATIVE CARE IN END-OF-LIFE;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;OBSESSIVE-COMPULSIVE DISORDER AND RELATED CONDITIONS;ADVANCEMENTS IN LUNG CANCER RESEARCH;ASTHMA;BOTULINUM TOXIN IN NEUROLOGY AND MEDICINE;CHALLENGES IN MEDICAL WASTE MANAGEMENT DURING COVID-19 PANDEMIC;CHEMOTHERAPY-INDUCED DERMATOLOGICAL TOXICITY;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT","6;5;5;5;4;4;3;3;3;2;2;2;2;2;1;1;1;1;1;1","CARDIAC ULTRASOUND;LUNG ULTRASOUND;MRI IMAGING;NATALIZUMAB;DISCONTINUATION;ABIRATERONE ACETATE;CONCOMITANT;CONCORDANCE;DIAGNOSIS;DIAGNOSTIC ACCURACY;DYSGEUSIA;IDIOPATHIC PULMONARY FIBROSIS;IMATINIB MESYLATE;MAGNETIC RESONANCE IMAGING;METASTATIC PROSTATE CANCER;PANCREATIC NEUROENDOCRINE TUMORS;PERFUSION IMAGING;PROSTATE CANCER;TREATMENT;ASTHMA EXACERBATIONS","5;5;5;5;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2","PROSTATE CANCER;MULTIPLE SCLEROSIS;LUNG ULTRASOUND;MAGNETIC RESONANCE;MYELOID LEUKEMIA;BREAST CANCER;CHRONIC MYELOID;COMPUTED TOMOGRAPHY;PROSPECTIVE STUDY;RESONANCE IMAGING;CANCER MCRPC;CASTRATION-RESISTANT PROSTATE;IDIOPATHIC PULMONARY;METASTATIC CASTRATION-RESISTANT;MULTIPARAMETRIC MAGNETIC;NATALIZUMAB DISCONTINUATION;PARTIAL NEPHRECTOMY;PATIENTS PTS;PULMONARY FIBROSIS;SCLEROSIS PATIENTS;ABIRATERONE ACETATE;ACETATE AA;ADJUVANT CHEMOTHERAPY;BIOSYNTHESIS PATHWAY;BONE SCINTIGRAPHY;BRONCHIAL MUCOSA;CANCER STAGING;CHEST COMPUTED;COMPARATIVE STUDY;DIFFUSION-WEIGHTED MRI","12;7;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2","PROSTATE CANCER;PUBMED SCOPUS;HIGH-VOLUME CENTERS;THYROID NODULES;URIC ACID;BLOOD LOSS;CROSSREF PUBMED;CYSTIC TUMOURS;FEMORAL HEAD;SIGNIFICANTLY LOWER;ADVERSE EFFECTS;CLINICAL PRACTICE;ESTIMATED BLOOD;HEAD FRACTURES;MAGNETIC RESONANCE;MP MRI;MS PATIENTS;MULTIPLE SCLEROSIS;RENAL TUMORS;THROMBOTIC RECURRENCES;TRIFECTA ACHIEVEMENT;ADJUVANT CHEMOTHERAPY;CARDIAC SURGERY;CLINICAL TRIALS;CSF CELLS;ESTIMATED GLOMERULAR;FILTRATION RATE;GENE EXPRESSION;GLEASON SCORE;GLOMERULAR FILTRATION","11;11;8;8;8;7;7;7;7;7;6;6;6;6;6;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5",38,0.38,5.83,7.75,2,1,1,1,1.5,0,1,8,1,1,6.75,1,1,1,2.5,5.25,2,0,0,78.5,78.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_GONZAGA",2016,178,12.2359550561798,3.06741573033708,0.326007326007326,0.370786516853933,0.337078651685393,0.264044943820225,0.573033707865168,0,115,10,18,13,0.65,0.06,0.1,0.07,40.24,1.23884987501174,0.303370786516854,0.887640449438202,6.3581081081081,0.454489590496416,0.488755622188905,0.427743086529884,0.476927570093458,"F. PORPIGLIA;GIUSEPPE SAGLIO;MASSIMO DI MAÏO;CRISTIAN FIORI;MARCELLO TUCCI;ANTONIO BERTOLOTTO;ANDREA VELTRI;VALTER MARTINO;MARCO CAPOBIANCO;ALESSIA FERRARESE;SILVIA NOVELLO;RICCARDO BERTOLO;SIMONA MALUCCHI;MARINELLA CLERICO;ORAZIO CAFFO;FAUSTO CASTAGNETTI;GIUSEPPE PROCOPIO;GIORGIO V. SCAGLIOTTI;ROBERTO PASSERA;ALESSIA DI SAPIO","15;13;12;12;12;11;10;9;9;9;8;8;8;8;7;7;7;7;7;6","MASSIMO DI MAÏO;F. PORPIGLIA;ANTONIO BERTOLOTTO;GIORGIO V. SCAGLIOTTI;CRISTIAN FIORI;ANDREA VELTRI;GIUSEPPE SAGLIO;VALTER MARTINO;ALESSIA FERRARESE;SIMONA MALUCCHI;MARCO CAPOBIANCO;PAOLO BIRONZO;RICCARDO BERTOLO;SARA CARLETTO;MARCELLO TUCCI;MARINELLA CLERICO;A. MITILLO;S ANGLESIO;ALESSIA DI SAPIO;MARTINA BORGHI","1.66;1.63;1.43;1.3;1.28;1.27;0.95;0.91;0.91;0.9;0.9;0.89;0.87;0.81;0.79;0.75;0.75;0.75;0.74;0.73","F. PORPIGLIA;GIUSEPPE SAGLIO;MASSIMO DI MAÏO;CRISTIAN FIORI;MARCELLO TUCCI;ANTONIO BERTOLOTTO;ANDREA VELTRI;VALTER MARTINO;MARCO CAPOBIANCO;ALESSIA FERRARESE;SILVIA NOVELLO;RICCARDO BERTOLO;SIMONA MALUCCHI;MARINELLA CLERICO;GIORGIO V. SCAGLIOTTI;ROBERTO PASSERA;ALESSIA DI SAPIO;ENRICO BOLLITO;MARCO TAMPELLINI;MARIO SOLEJ","15;13;12;12;12;11;10;9;9;9;8;8;8;8;7;7;6;6;6;6","MASSIMO DI MAÏO;F. PORPIGLIA;ANTONIO BERTOLOTTO;GIORGIO V. SCAGLIOTTI;CRISTIAN FIORI;ANDREA VELTRI;GIUSEPPE SAGLIO;VALTER MARTINO;ALESSIA FERRARESE;SIMONA MALUCCHI;MARCO CAPOBIANCO;PAOLO BIRONZO;RICCARDO BERTOLO;SARA CARLETTO;MARCELLO TUCCI;MARINELLA CLERICO;A. MITILLO;S ANGLESIO;ALESSIA DI SAPIO;MARTINA BORGHI","1.66;1.63;1.43;1.3;1.28;1.27;0.95;0.91;0.91;0.9;0.9;0.89;0.87;0.81;0.79;0.75;0.75;0.75;0.74;0.73","SILVIA NOVELLO;MARTIN RECK;FABRICE BARLÉSI;GONZÁLO VARELA;JOHAN VANSTEENKISTE;KEITH M. KERR;MATTEO GIAJ LEVRA;RAFFAELE CALIFANO;SANJAY POPAT;SIMON EKMAN;SOLANGE PETERS;SURESH SENAN;TANJA ČUFER;MARCO CAPOBIANCO;ALEXANDER SCHWARZ;ALEXANDER U. BRANDT;ALEXANDER WINKELMANN;BRIGITTE WILDEMANN;CORINNA TREBST;DIEGO FRANCIOTTA","2537;2515;2508;2508;2508;2508;2508;2508;2508;2508;2508;2508;2508;1292;1188;1188;1188;1188;1188;1188","SILVIA NOVELLO;MARCO CAPOBIANCO;F. PORPIGLIA;CRISTIAN FIORI;STEFANO DE LUCA;MATTEO MANFREDI;MARCELLO TUCCI;ANDREA VELTRI;ENRICO BOLLITO;F. MELE;MARCO COSSU;FAUSTO FANTÒ;RICCARDO BERTOLO;GIANLUCA ROSSO;GIUSEPPE SAGLIO;GIUSEPPE MAINA;ENRICO CHECCUCCI;MARINELLA CLERICO;ANTONIO BERTOLOTTO;STEFANIA DE MERCANTI","2537;1292;566;463;346;342;329;326;306;257;233;219;214;173;166;162;161;149;142;132","F. PORPIGLIA;CRISTIAN FIORI;GIUSEPPE SAGLIO;MARCELLO TUCCI;ANTONIO BERTOLOTTO;ANDREA VELTRI;ALESSIA FERRARESE;MARCO CAPOBIANCO;VALTER MARTINO;MASSIMO DI MAÏO;SILVIA NOVELLO;RICCARDO BERTOLO;GIORGIO V. SCAGLIOTTI;SIMONA MALUCCHI;STEFANO DE LUCA;ENRICO BOLLITO;MARCO TAMPELLINI;MARIO SOLEJ;STEFANO ENRICO;ALESSIA DI SAPIO","13;12;12;12;10;9;9;9;9;8;8;8;7;7;6;6;6;6;6;6","MEDICINE;BIOLOGY;PHYSICS;PSYCHOLOGY;CHEMISTRY;MATHEMATICS;COMPUTER SCIENCE;ECONOMICS;ENGINEERING;POLITICAL SCIENCE;PHILOSOPHY;ART;SOCIOLOGY;BUSINESS","173;29;20;16;13;12;9;9;6;6;4;2;2;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;PATHOLOGY;IMMUNOLOGY;GASTROENTEROLOGY;RADIOLOGY;UROLOGY;PSYCHIATRY;BIOCHEMISTRY;GENETICS;ENVIRONMENTAL HEALTH;GENERAL SURGERY;INTENSIVE CARE MEDICINE;PHARMACOLOGY;ENDOCRINOLOGY;MEDICAL PHYSICS;PEDIATRICS;PHYSICAL THERAPY;CANCER RESEARCH;CLINICAL PSYCHOLOGY;NEUROSCIENCE;NUCLEAR MEDICINE;NURSING;QUANTUM MECHANICS;STATISTICS","140;54;42;28;25;22;22;21;19;14;14;12;12;12;10;9;8;8;8;7;7;7;7;7;7;7","CANCER;ADVERSE EFFECT;MULTIPLE SCLEROSIS;CHEMOTHERAPY;CLINICAL TRIAL;RANDOMIZED CONTROLLED TRIAL;DISEASE;GENE;KIDNEY;POPULATION;MYELOID LEUKEMIA;LUNG;ULTRASOUND;DISCONTINUATION;MAGNETIC RESONANCE IMAGING;RECEPTOR;ALTERNATIVE MEDICINE;LUNG CANCER;ANTIBODY;COHORT;CONFIDENCE INTERVAL;LAPAROSCOPY;PERIOPERATIVE;PROPORTIONAL HAZARDS MODEL;QUALITY OF LIFE (HEALTHCARE);RADIATION THERAPY;RENAL FUNCTION;RETROSPECTIVE COHORT STUDY;TOXICITY;TRANSPLANTATION","52;20;19;18;15;15;12;12;12;12;11;10;10;8;8;8;7;7;6;6;6;6;6;6;6;6;6;6;6;6","PROSTATE CANCER;IMATINIB;NEPHRECTOMY;DOCETAXEL;PROSTATE;TOLERABILITY;CLINICAL ENDPOINT;COLORECTAL CANCER;HAZARD RATIO;BREAST CANCER;PROGRESSION-FREE SURVIVAL;ALEMTUZUMAB;CISPLATIN;LUNG ULTRASOUND;NATALIZUMAB;TYROSINE-KINASE INHIBITOR;CHRONIC LYMPHOCYTIC LEUKEMIA;GENOTYPE;METASTASIS;MUTATION;PLACEBO;TYROSINE KINASE;UNIVARIATE ANALYSIS","22;10;9;8;8;8;6;6;6;5;5;4;4;4;4;4;3;3;3;3;3;3;3","ANDROGEN DEPRIVATION THERAPY;ANDROGEN RECEPTOR;IMATINIB MESYLATE;NILOTINIB;PROSTATECTOMY;DASATINIB;OXALIPLATIN;PEMETREXED;PROSTATE BIOPSY;BONE METASTASIS;PROSTATE-SPECIFIC ANTIGEN;ABL;DISCOVERY AND DEVELOPMENT OF MTOR INHIBITORS;PCA3;PHILADELPHIA CHROMOSOME;VINORELBINE;AMPLICON;AXITINIB;BECK ANXIETY INVENTORY;BROCHURE;CHEMOIMMUNOTHERAPY;CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING;CLASSIFICATION OF MENTAL DISORDERS;COMPOUND HETEROZYGOSITY;CONCURRENT VALIDITY;CORONAVIRUS DISEASE 2019 (COVID-19);CXCL10;DIAGNOSTIC CLASSIFICATION OF MENTAL HEALTH AND DEVELOPMENTAL DISORDERS OF INFANCY AND EARLY CHILDHOOD;DIFFERENTIAL ITEM FUNCTIONING;DOPPLER IMAGING;EXTERNAL ANAL SPHINCTER;EXTERNAL BEAM RADIOTHERAPY;FUNCTIONAL RESIDUAL CAPACITY;GENOMIC SEQUENCING;GLOMERULOPATHY;GLOMERULOSCLEROSIS;GP41;HERPESVIRIDAE;HETEROZYGOTE ADVANTAGE;HISTAMINE H2 RECEPTOR;HISTIDINE DECARBOXYLASE;HUMAN METAPNEUMOVIRUS;IBRUTINIB;INSULIN-LIKE GROWTH FACTOR;INTERCLASS CORRELATION;INTERFERON BETA-1A;INTERFERON-STIMULATED GENE;INTERNAL ANAL SPHINCTER;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;INTRAVOXEL INCOHERENT MOTION;IRF7;ISG15;LNCAP;LYMPHEDEMA;MANNOSE RECEPTOR;MEMBER STATE;METASTATIC BREAST CANCER;MICROARRAY;MIRBASE;MIRTAZAPINE;MYELIN OLIGODENDROCYTE GLYCOPROTEIN;NEUROPSYCHOLOGICAL TEST;NINTEDANIB;NOD2;NON-SMALL CELL LUNG CANCER (NSCLC);PAIN LADDER;PALIPERIDONE;PALIPERIDONE PALMITATE;PAZOPANIB;PERITONEAL CARCINOMATOSIS;PLEURAL DISEASE;PYELOPLASTY;RECTAL EXAMINATION;RENAL SINUS;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;RIBAVIRIN;SINGLE-NUCLEOTIDE POLYMORPHISM;STEATOHEPATITIS;TAPENTADOL;TAXANE;THIOTEPA;UMBILICAL CORD BLOOD TRANSPLANTATION;VIRAL ENTRY","8;7;6;6;6;4;4;4;4;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;MALE;FEMALE;MIDDLE AGED;AGED;ADULT;PROSTATIC NEOPLASMS;KIDNEY NEOPLASMS;ITALY;NEPHRECTOMY;RETROSPECTIVE STUDIES;TREATMENT OUTCOME;LAPAROSCOPY;POSTOPERATIVE COMPLICATIONS;AGED, 80 AND OVER;BETA-THALASSEMIA;NEUROMYELITIS OPTICA;PROSPECTIVE STUDIES;YOUNG ADULT","94;82;63;53;49;41;39;29;22;19;19;18;17;16;16;14;13;13;13;13","DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;EFFICACY AND RESISTANCE IN CML TREATMENT;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;PROSTATE CANCER RESEARCH AND TREATMENT;RENAL CELL CARCINOMA;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;INNOVATIONS IN TRANSGASTRIC SURGICAL TECHNIQUES;POLYOMAVIRUS-ASSOCIATED CARCINOGENESIS AND CLINICAL MANIFESTATIONS;ROLE OF LUNG ULTRASOUND IN CRITICAL CARE;ADVANCEMENTS IN LUNG CANCER RESEARCH;BREAST MAGNETIC RESONANCE IMAGING IN ONCOLOGY;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;MALIGNANT PLEURAL MESOTHELIOMA RESEARCH;PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;BOTULINUM TOXIN IN NEUROLOGY AND MEDICINE;DIAGNOSIS AND TREATMENT OF VOICE DISORDERS;ECONOMIC BURDEN OF CANCER TREATMENT;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES","13;11;10;7;6;4;4;4;4;3;3;3;3;3;3;2;2;2;2;2","TREATMENT;DISCONTINUATION;TOLERABILITY;METASTATIC PROSTATE CANCER;CABAZITAXEL;CLINICAL ENDPOINT;ENZALUTAMIDE;IMATINIB MESYLATE;LUNG ULTRASOUND;ABIRATERONE ACETATE;DEPRESSION (ECONOMICS);PROGRESSION-FREE SURVIVAL;CARDIAC ULTRASOUND;DIAGNOSTIC ACCURACY;DIAGNOSTIC CRITERIA;NATALIZUMAB;NEPHROLOGY;PEMETREXED;PNEUMOTHORAX DIAGNOSIS;POINT-OF-CARE ULTRASONOGRAPHY","10;8;8;7;6;6;6;6;6;5;5;5;4;4;4;4;4;4;4;4","MULTIPLE SCLEROSIS;PROSTATE CANCER;MYELOID LEUKEMIA;CHRONIC MYELOID;CANCER MCRPC;CASTRATION-RESISTANT PROSTATE;METASTATIC CASTRATION-RESISTANT;MCRPC PATIENTS;AGENTS NAS;CLINICAL TRIAL;COLORECTAL CANCER;ITALIAN STUDY;MULTICENTER ITALIAN;PATIENTS PTS;RADICAL PROSTATECTOMY;LUNG CANCER;AUTOLOGOUS STEM;CLINICAL PRACTICE;CML PATIENTS;CONTROLLED TRIAL;FIRST-LINE TREATMENT;GENERIC OXALIPLATIN;HYPERSENSITIVITY REACTIONS;ITALIAN PATIENTS;LEUKEMIA PATIENTS;MAGNETIC RESONANCE;MULTICENTER STUDY;MULTIPLE MYELOMA;NEUROENDOCRINE TUMORS;OBSERVATIONAL STUDY","15;15;9;8;7;7;7;6;5;5;5;5;5;5;5;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3","LUNG CANCER;SAN RAFFAELE;MULTIPLE SCLEROSIS;RADICAL NEPHRECTOMY;CARATTERE SCIENTIFICO;DEGLI STUDI;DI RICOVERO;EUR UROL;EXPERIMENTAL ONCOLOGY;INSTITUTE DIVISION;INSTITUTE MILAN;ISTITUTO DI;MILAN ITALY;ONCOLOGY ISTITUTO;RAFFAELE SCIENTIFIC;RAFFAELE UNIVERSITY;RESEARCH INSTITUTE;SCIENTIFIC INSTITUTE;UNIVERSITY SAN;UNIVERSITÀ DEGLI;UROLOGICAL RESEARCH;UROLOGY VITA-SALUTE;VITA-SALUTE SAN;RENAL FUNCTION;UROL GOOGLE;ONCOL -GOOGLE;KIDNEY DISEASE;LEARNING CURVE;PROSTATE CANCER;ADVERSE EVENTS","53;32;28;23;16;16;16;16;16;16;16;16;16;16;16;16;16;16;16;16;16;16;16;15;15;14;13;13;13;12",70,0.39,10.45,8.75,2,1,1,4,2,0,1.25,10.5,0,1,8,1,2,3,3,6,4.25,0,0,94.5,94.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_GONZAGA",2017,164,13.8048780487805,3.07317073170732,0.325396825396825,0.365853658536585,0.310975609756098,0.23780487804878,0.597560975609756,1,91,43,14,7,0.55,0.26,0.09,0.04,24.76,0.840107628694024,0.390243902439024,0.920731707317073,5.92668621700879,0.502770705425435,0.432789048325911,0.398701298701299,0.413411078717201,"ENRICO CERRATO;MARCELLO TUCCI;ANTONIO BERTOLOTTO;SILVIA NOVELLO;MASSIMO DI MAÏO;MARCO VOLANTE;ORAZIO CAFFO;CRISTIAN FIORI;FIORENZO GAÏTA;RICCARDO BERTOLO;F. PORPIGLIA;MASSIMO TERZOLO;ANDREA VELTRI;GIUSEPPE SAGLIO;EMILIO BRIA;FRANCESCO PORPIGLIA;CHIARA BARATELLI;DANIELE AMPARORE;GIUSEPPE PROCOPIO;ISABELLA SPERDUTI","12;12;11;10;9;9;8;8;7;7;7;6;6;6;6;6;6;6;6;6","SILVIA NOVELLO;ENRICO CERRATO;ANTONIO BERTOLOTTO;RICCARDO BERTOLO;FRANCESCO PORPIGLIA;CRISTIAN FIORI;FERDINANDO VARBELLA;GIUSEPPE MAINA;DANIELE AMPARORE;ANDREA VELTRI;MARCO VOLANTE;ANDREA AGUGLIA;MARCELLO TUCCI;GIOVANNI VOLPICELLI;F. PORPIGLIA;CELESTE CAGNAZZO;FRANCESCA ARIZIO;MARCO CAPOBIANCO;MASSIMO DI MAÏO;MATTEO MANFREDI","1.86;1.64;1.46;1.38;1.21;1.16;1.05;1.02;0.95;0.88;0.85;0.83;0.82;0.79;0.77;0.68;0.68;0.68;0.65;0.61","ENRICO CERRATO;MARCELLO TUCCI;ANTONIO BERTOLOTTO;SILVIA NOVELLO;MARCO VOLANTE;CRISTIAN FIORI;RICCARDO BERTOLO;F. PORPIGLIA;MASSIMO TERZOLO;ANDREA VELTRI;GIUSEPPE SAGLIO;FRANCESCO PORPIGLIA;CHIARA BARATELLI;DANIELE AMPARORE;GIORGIO V. SCAGLIOTTI;FERDINANDO VARBELLA;GIUSEPPE MAINA;ELISA PIRRO;MARCO CAPOBIANCO;CELESTE CAGNAZZO","12;12;11;10;9;8;7;7;6;6;6;6;6;6;6;6;5;5;5;5","SILVIA NOVELLO;ENRICO CERRATO;ANTONIO BERTOLOTTO;RICCARDO BERTOLO;FRANCESCO PORPIGLIA;CRISTIAN FIORI;FERDINANDO VARBELLA;GIUSEPPE MAINA;DANIELE AMPARORE;ANDREA VELTRI;MARCO VOLANTE;ANDREA AGUGLIA;MARCELLO TUCCI;GIOVANNI VOLPICELLI;F. PORPIGLIA;CELESTE CAGNAZZO;FRANCESCA ARIZIO;MARCO CAPOBIANCO;MATTEO MANFREDI;UMBERTO ALBERT","1.86;1.64;1.46;1.38;1.21;1.16;1.05;1.02;0.95;0.88;0.85;0.83;0.82;0.79;0.77;0.68;0.68;0.68;0.61;0.59","CRISTIAN FIORI;F. PORPIGLIA;GIORGIO V. SCAGLIOTTI;SERGIO LEONARDI;CORA N. STERNBERG;ANDREA NECCHI;ARISTOTELIS BAMIAS;AUDE FLÉCHON;AVIVIT PEER;FREDRIK LAESTADIUS;GIAMPAOLO TORTORA;LAJOS GÉCZI;NOBUAKI MATSUBARA;MARCO VOLANTE;BERNARDO CORTESE;CARLO BRIGUORI;DIK HEG;ENRICO FRIGOLI;GIUSEPPE ANDÒ;MARCO VALGIMIGLI","460;384;353;328;324;320;320;320;320;320;320;320;320;298;280;276;276;276;276;276","CRISTIAN FIORI;F. PORPIGLIA;DANIELE AMPARORE;MARCO VOLANTE;SILVIA NOVELLO;RICCARDO BERTOLO;MARCELLO TUCCI;GIOVANNI VOLPICELLI;ANTONIO BERTOLOTTO;ENRICO CHECCUCCI;FRANCESCO PORPIGLIA;MARIA PIA BRIZZI;ANDREA VELTRI;MASSIMO TERZOLO;GIORGIO V. SCAGLIOTTI;G. GATTI;GIUSEPPE REIMONDO;ENRICO CERRATO;FABIO FERRARI;FABIO MANGIACAPRA","460;384;273;263;240;235;230;224;197;196;181;174;169;169;165;164;148;142;138;138","ENRICO CERRATO;MARCELLO TUCCI;ANTONIO BERTOLOTTO;SILVIA NOVELLO;CRISTIAN FIORI;F. PORPIGLIA;RICCARDO BERTOLO;MARCO VOLANTE;FRANCESCO PORPIGLIA;FERDINANDO VARBELLA;DANIELE AMPARORE;GIUSEPPE SAGLIO;MATTEO MANFREDI;ANDREA VELTRI;ELISA PIRRO;FRANCESCA ARIZIO;GIOVANNI VOLPICELLI;MARCO CAPOBIANCO;MASSIMO TERZOLO;SILVIA DE FRANCIA","12;12;11;10;8;7;7;7;6;6;6;6;5;5;5;5;5;5;5;5","MEDICINE;BIOLOGY;PHYSICS;PSYCHOLOGY;CHEMISTRY;MATHEMATICS;COMPUTER SCIENCE;ECONOMICS;ENGINEERING;POLITICAL SCIENCE;BUSINESS;HISTORY;SOCIOLOGY;MATERIALS SCIENCE;PHILOSOPHY;GEOGRAPHY;GEOLOGY","159;35;16;11;10;10;7;6;4;4;3;3;3;2;2;1;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;PATHOLOGY;CARDIOLOGY;RADIOLOGY;GENETICS;PSYCHIATRY;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;IMMUNOLOGY;UROLOGY;INTENSIVE CARE MEDICINE;BIOCHEMISTRY;CANCER RESEARCH;ENDOCRINOLOGY;OPTICS;NUCLEAR MEDICINE;PHARMACOLOGY;CLINICAL PSYCHOLOGY;PEDIATRICS;STATISTICS","129;38;33;28;20;20;17;16;15;14;13;12;11;10;10;9;9;8;8;6;6;6","CANCER;CLINICAL TRIAL;GENE;MULTIPLE SCLEROSIS;POPULATION;CONFIDENCE INTERVAL;MYOCARDIAL INFARCTION;ADVERSE EFFECT;DISEASE;LUNG;LUNG CANCER;RANDOMIZED CONTROLLED TRIAL;ALTERNATIVE MEDICINE;ANTIBODY;CHEMOTHERAPY;IMMUNOHISTOCHEMISTRY;DISCONTINUATION;INCIDENCE (GEOMETRY);KIDNEY;OBSERVATIONAL STUDY;OVERALL SURVIVAL;RENAL FUNCTION","40;15;14;14;13;12;11;9;9;9;9;8;7;7;7;7;6;6;6;6;6;6","PROSTATE CANCER;CLINICAL ENDPOINT;DOCETAXEL;COLORECTAL CANCER;PERCUTANEOUS CORONARY INTERVENTION;PROGRESSION-FREE SURVIVAL;EPIDERMAL GROWTH FACTOR RECEPTOR;NEPHRECTOMY;HAZARD RATIO;PROSTATE;ACUTE CORONARY SYNDROME;CISPLATIN;CORONARY ANGIOGRAPHY;MUTATION;PREDICTIVE MARKER;TOLERABILITY;UNIVARIATE ANALYSIS;ALEMTUZUMAB;ALLELE;DIFFUSION MRI;IMATINIB;METASTASIS;MITOTANE;MONOCLONAL ANTIBODY;OSTEOARTHRITIS;PI3K/AKT/MTOR PATHWAY;THERAPEUTIC DRUG MONITORING","14;11;9;8;7;7;6;6;5;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3","ANDROGEN DEPRIVATION THERAPY;ANDROGEN RECEPTOR;BONE METASTASIS;GEFITINIB;MICROSATELLITE;PROSTATECTOMY;ACROMEGALY;ARTERY DISSECTION;BIORESORBABLE SCAFFOLD;EPITHELIAL–MESENCHYMAL TRANSITION;ERLOTINIB;MISSENSE MUTATION;MONOCLONAL;PEMETREXED;ROS1;THYMIDYLATE SYNTHASE;AMPK;ANAPLASTIC LYMPHOMA KINASE;ANDROSTENEDIONE;ANTIRETROVIRAL THERAPY;ARTHROPATHY;BECK ANXIETY INVENTORY;BONE MORPHOGENETIC PROTEIN 7;CD4 T CELL;CD52;CHROMOPHOBE CELL;COMPARATIVE GENOMIC HYBRIDIZATION;COPY-NUMBER VARIATION;CRIZOTINIB;DEHYDROEPIANDROSTERONE;DRUG-ELUTING STENT;DUAL ENERGY;EGFR INHIBITORS;ERYTHROBLAST;FRACTIONAL ANISOTROPY;FRACTIONAL FLOW RESERVE;GAS6;GENOMICS;GERMLINE MUTATION;GREY MATTER;HAMP;HERPESVIRIDAE;HYPOPHOSPHATASIA;IL-2 RECEPTOR;IMATINIB MESYLATE;IMIPENEM;INEFFECTIVE ERYTHROPOIESIS;INTERFERON BETA-1A;INTRAEPITHELIAL NEOPLASIA;ISCHEMIC CARDIOMYOPATHY;JAK-STAT SIGNALING PATHWAY;KRAS;LDL RECEPTOR;LIPOTOXICITY;LOWER URINARY TRACT SYMPTOMS;MACE;MANIA;MEAN ARTERIAL PRESSURE;MECHANICAL INDEX;MEMBER STATE;MTORC1;NILOTINIB;NINTEDANIB;NON-SMALL CELL LUNG CANCER (NSCLC);NONALCOHOLIC FATTY LIVER DISEASE;OTOTOXICITY;PHARMACOGENETICS;POSACONAZOLE;PRIMARY TUMOR;PROBAND;PROSTATE BIOPSY;PROSTATE CARCINOMA;PROSTATIC DISEASES;PROSTATITIS;PTEN;PYELOPLASTY;QUANTITATIVE COMPUTED TOMOGRAPHY;RENAL TUMOR;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;RIBAVIRIN;SDHA;SHORT QT SYNDROME;SINGLE-NUCLEOTIDE POLYMORPHISM;SJÖGREN SYNDROME;SMALL HAIRPIN RNA;SOMATOSTATIN RECEPTOR 2;STEATOHEPATITIS;SUICIDE ATTEMPT;THERAPEUTIC ABORTION;TUMOR M2-PK;UROTHELIAL CARCINOMA;VENETOCLAX;WOMAC","8;7;4;3;3;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;;MIDDLE AGED;AGED;ADULT;LUNG NEOPLASMS;ITALY;KIDNEY NEOPLASMS;TREATMENT OUTCOME;MULTIPLE SCLEROSIS;PROSPECTIVE STUDIES;ROBOTIC SURGICAL PROCEDURES;AGED, 80 AND OVER;RETROSPECTIVE STUDIES;YOUNG ADULT;NEPHRECTOMY;PERCUTANEOUS CORONARY INTERVENTION;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS","92;72;71;67;57;47;41;26;21;20;20;19;17;17;15;15;15;14;14;13","DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;RENAL CELL CARCINOMA;ADVANCEMENTS IN LUNG CANCER RESEARCH;PHEOCHROMOCYTOMA AND PARAGANGLIOMA;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;ROLE OF LUNG ULTRASOUND IN CRITICAL CARE;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;EFFICACY AND RESISTANCE IN CML TREATMENT;OBSESSIVE-COMPULSIVE DISORDER AND RELATED CONDITIONS;POSITRON EMISSION TOMOGRAPHY IMAGING IN ONCOLOGY;ATRIAL FIBRILLATION;BREAST MAGNETIC RESONANCE IMAGING IN ONCOLOGY;CHOLESTEROL-LOWERING TREATMENT;DIAGNOSIS AND MANAGEMENT OF PITUITARY DISORDERS;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;DIAGNOSIS AND TREATMENT OF LUNG CANCER;ETHICAL CONSIDERATIONS IN MEDICAL RESEARCH PARTICIPATION","12;9;7;7;6;5;4;4;4;3;3;3;3;2;2;2;2;2;2;2","CLINICAL ENDPOINT;ABIRATERONE ACETATE;EGFR MUTATIONS;ENZALUTAMIDE;METASTATIC COLORECTAL CANCER;METASTATIC PROSTATE CANCER;PROGRESSION-FREE SURVIVAL;DISCONTINUATION;TREATMENT;CABAZITAXEL;KRAS MUTATIONS;ADRENOCORTICAL CARCINOMA;ALPHA PARTICLE THERAPY;BRAF MUTATIONS;CONCOMITANT;DIAGNOSTIC CRITERIA;ECHOCARDIOGRAPHY;LUNG ULTRASOUND;PREDICTIVE MARKER;TOLERABILITY","11;7;7;7;7;7;7;6;6;5;5;4;4;4;4;4;4;4;4;4","MULTIPLE SCLEROSIS;PROSTATE CANCER;CASTRATION-RESISTANT PROSTATE;METASTATIC CASTRATION-RESISTANT;SCLEROSIS PATIENTS;COLORECTAL CANCER;CANCER MCRPC;LUNG CANCER;METASTATIC COLORECTAL;PARTIAL NEPHRECTOMY;CLINICAL TRIAL;CORONARY ARTERY;CANCER MCRC;CANCER PATIENTS;DISSECTING PRIMARY;PATIENTS TREATED;PRIMARY RESISTANCE;PROGNOSTIC FACTORS;WT METASTATIC;ACCESS PROGRAM;BRAF WT;CASE-CONTROL STUDY;CHRONIC MYELOID;CLINICAL OUTCOMES;ITALIAN STUDY;MULTICENTER ITALIAN;MYELOID LEUKEMIA;OBSERVATIONAL STUDY;PROGRAM EAP;RADICAL PROSTATECTOMY","14;10;9;9;9;7;6;6;6;6;5;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3","PARTIAL NEPHRECTOMY;LUNG CANCER;RENAL FUNCTION;MULTIPLE SCLEROSIS;TUMOR INFILTRATE;UROLOGY UNIVERSITY;CLINICAL PRACTICE;CONFIDENCE INTERVAL;CORONARY ARTERY;EUR UROL;NSCLC PATIENTS;UROL GOOGLE;TUMOR CELLS;ADVERSE EVENTS;HR CI;INDEPENDENT PREDICTORS;PATIENTS UNDERWENT;PROSTATE CANCER;TYROSINE KINASE;VERTEBRAL DEFORMITIES;BONE METASTASES;CLINICAL TRIAL;CLINICAL TRIALS;HAZARD RATIO;LONG-ACTING PASIREOTIDE;PRIMARY ENDPOINT;PRIMARY MALIGNANCIES;PTS TREATED;BASELINE CHARACTERISTICS;CLINICAL RESEARCH","26;15;14;13;12;12;11;11;11;11;11;11;10;9;9;9;9;9;9;9;8;8;8;8;8;8;8;8;7;7",71,0.43,9.53,8.5,2,1,1,10,11.5,0,1,9,1,1,8.75,0,2,3,8,6,5.25,0,0,73.5,73.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_GONZAGA",2018,136,16.6544117647059,2.875,0.347826086956522,0.323529411764706,0.308823529411765,0.272058823529412,0.61764705882353,0,86,17,10,11,0.63,0.12,0.07,0.08,59.13,1.93824112009759,0.411764705882353,0.933823529411765,6.53351573187415,0.469045687876457,0.48294930875576,0.472976680384088,0.531333333333333,"ENRICO CERRATO;ANTONIO BERTOLOTTO;FERDINANDO VARBELLA;GIORGIO QUADRI;FABRIZIO D’ASCENZO;FRANCESCO PORPIGLIA;CRISTIAN FIORI;FRANCESCO TOMASSINI;RICCARDO BERTOLO;SILVIA NOVELLO;CHRISTIAN TEMPLIN;ANDREA VELTRI;ANDREA ROGNONI;ALESSANDRO DURANTE;IOANNA XANTHOPOULOU;ALBERT ARIZA‐SOLÉ;ENRICO CHECCUCCI;PIETRO CAIRONI;ALFONSO IELASI;DANIELE AMPARORE","20;14;13;12;12;11;10;8;8;7;7;7;6;6;6;6;6;6;6;6","ANTONIO BERTOLOTTO;CRISTIAN FIORI;ENRICO CERRATO;FRANCESCO PORPIGLIA;ANDREA VELTRI;RICCARDO AUTORINO;DARIO GNED;FERDINANDO VARBELLA;GIORGIO QUADRI;RICCARDO BERTOLO;DANIELE AMPARORE;ENRICO CHECCUCCI;ADRIANO MASSIMILIANO PRIOLA;PIETRO CAIRONI;BARBARA MESSORE;RAFFAELE NUZZI;F TRIDICO;FRANCO CAVALOT;CARLOTTA BIGLIA;MARCO CAPOBIANCO","1.86;1.41;1.31;1.08;1.06;0.87;0.84;0.84;0.81;0.8;0.71;0.69;0.62;0.59;0.58;0.58;0.58;0.56;0.54;0.54","ENRICO CERRATO;ANTONIO BERTOLOTTO;FERDINANDO VARBELLA;GIORGIO QUADRI;FRANCESCO PORPIGLIA;CRISTIAN FIORI;FRANCESCO TOMASSINI;RICCARDO BERTOLO;SILVIA NOVELLO;ANDREA VELTRI;ENRICO CHECCUCCI;PIETRO CAIRONI;DANIELE AMPARORE;BARBARA MESSORE;MARCO CAPOBIANCO;DARIO GNED;CARLOTTA BIGLIA;RICCARDO AUTORINO;FRANCO CAVALOT;CRISTINA ROLFO","20;14;13;12;11;10;8;8;7;7;6;6;6;6;6;5;5;5;5;5","ANTONIO BERTOLOTTO;CRISTIAN FIORI;ENRICO CERRATO;FRANCESCO PORPIGLIA;ANDREA VELTRI;RICCARDO AUTORINO;DARIO GNED;FERDINANDO VARBELLA;GIORGIO QUADRI;RICCARDO BERTOLO;DANIELE AMPARORE;ENRICO CHECCUCCI;ADRIANO MASSIMILIANO PRIOLA;PIETRO CAIRONI;BARBARA MESSORE;RAFFAELE NUZZI;F TRIDICO;FRANCO CAVALOT;CARLOTTA BIGLIA;MARCO CAPOBIANCO","1.86;1.41;1.31;1.08;1.06;0.87;0.84;0.84;0.81;0.8;0.71;0.69;0.62;0.59;0.58;0.58;0.58;0.56;0.54;0.54","SILVIA NOVELLO;EDWARD B. GARON;FRANCESCO GROSSI;BELÉN RUBIO‐VIQUEIRA;DELVYS RODRÍGUEZ‐ABREU;EMILIO ESTEBAN;ENRIQUETA FELIP;FLÁVIA DE ANGELIS;HARRY RAFTOPOULOS;HELGE BISCHOFF;JHANELLE E. GRAY;JING YANG;JOHN VIDA;LEENA GANDHI;M. CATHERINE PIETANZA;MANUEL DÓMINE;MARINA CHIARA GARASSINO;MARTIN RECK;MAXIMILIAN J. HOCHMAIR;MICHAEL BOYER","5444;5332;5281;5280;5280;5280;5280;5280;5280;5280;5280;5280;5280;5280;5280;5280;5280;5280;5280;5280","SILVIA NOVELLO;CRISTIAN FIORI;FRANCESCO PORPIGLIA;RICCARDO BERTOLO;DANIELE AMPARORE;ENRICO CHECCUCCI;F. PORPIGLIA;ENRICO CERRATO;ANDREA VELTRI;PIETRO CAIRONI;ENRICO BOLLITO;ANNE CLAIRE TOFFART;MATTEO GIAJ LEVRA;FRANCO CAVALOT;MARIA PIA BRIZZI;ANTONIO BERTOLOTTO;MANUELA MATTA;ALBERTO PIANA;ANDREA BELLIN;FEDERICA MASSA","5439;635;603;465;353;340;288;205;190;142;113;107;107;105;100;96;79;78;78;78","ENRICO CERRATO;ANTONIO BERTOLOTTO;CRISTIAN FIORI;FRANCESCO PORPIGLIA;GIORGIO QUADRI;FERDINANDO VARBELLA;ANDREA VELTRI;RICCARDO BERTOLO;DANIELE AMPARORE;FRANCESCO TOMASSINI;SILVIA NOVELLO;BARBARA MESSORE;ENRICO CHECCUCCI;PIETRO CAIRONI;CRISTINA ROLFO;MARCO CAPOBIANCO;FRANCO CAVALOT;CARLOTTA BIGLIA;DARIO GNED;ELISA CLIVATI","20;13;11;11;9;7;7;7;6;6;6;6;6;6;5;5;5;4;4;4","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;PSYCHOLOGY;SOCIOLOGY;MATERIALS SCIENCE;MATHEMATICS;ECONOMICS;ENGINEERING;BUSINESS;ENVIRONMENTAL SCIENCE;PHILOSOPHY;POLITICAL SCIENCE","131;33;15;11;10;8;6;5;5;4;4;2;2;2;2","INTERNAL MEDICINE;SURGERY;ONCOLOGY;CARDIOLOGY;RADIOLOGY;IMMUNOLOGY;PATHOLOGY;UROLOGY;PSYCHIATRY;ENDOCRINOLOGY;GENETICS;BIOCHEMISTRY;GASTROENTEROLOGY;PEDIATRICS;ENVIRONMENTAL HEALTH;ANESTHESIA;OPTICS;PALEONTOLOGY;CANCER RESEARCH;CLINICAL PSYCHOLOGY;ECOLOGY;PHYSICAL THERAPY","112;36;23;19;18;16;16;14;13;12;12;11;11;9;7;6;6;6;5;5;5;5","CANCER;MYOCARDIAL INFARCTION;MULTIPLE SCLEROSIS;CONFIDENCE INTERVAL;GENE;RANDOMIZED CONTROLLED TRIAL;CHEMOTHERAPY;IN VITRO;KIDNEY;MAGNETIC RESONANCE IMAGING;ADVERSE EFFECT;DISEASE;COHORT;CYSTIC FIBROSIS;DIABETES MELLITUS;INCIDENCE (GEOMETRY);OBSERVATIONAL STUDY;POPULATION;PROPORTIONAL HAZARDS MODEL;RETROSPECTIVE COHORT STUDY;TRANSPLANTATION","28;18;15;10;9;9;8;8;8;8;7;7;6;6;6;6;6;6;6;6;6","PROSTATE CANCER;PERCUTANEOUS CORONARY INTERVENTION;ACUTE CORONARY SYNDROME;HAZARD RATIO;CLINICAL ENDPOINT;NEPHRECTOMY;DOCETAXEL;PROSTATE;FINGOLIMOD;SEPTIC SHOCK;ALEMTUZUMAB;COLORECTAL CANCER;CONVENTIONAL PCI;MULTICENTER STUDY;NATALIZUMAB;PROGRESSION-FREE SURVIVAL;PSEUDOMONAS AERUGINOSA;TOLERABILITY;BREAST CANCER;CORONARY ANGIOGRAPHY;EXPANDED DISABILITY STATUS SCALE;KIDNEY CANCER;METFORMIN;PHENOTYPE;TYPE 2 DIABETES","11;9;8;8;7;7;6;6;5;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3","PROSTATECTOMY;TICAGRELOR;BIORESORBABLE SCAFFOLD;PRASUGREL;ANDROGEN DEPRIVATION THERAPY;ANDROGEN RECEPTOR;ARTERY DISSECTION;MACE;MANIA;OXALIPLATIN;SEVERE SEPSIS;TOBRAMYCIN;ACROMEGALY;ADENOSINE DIPHOSPHATE;ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS;ANIMAL-ASSISTED THERAPY;AUTOIMMUNE THYROIDITIS;BONE METASTASIS;CAPSULORHEXIS;CARBOPLATIN;CETUXIMAB;CLINICAL GLOBAL IMPRESSION;CORONAVIRUS DISEASE 2019 (COVID-19);DIABETES MANAGEMENT;DRUG-ELUTING STENT;ERLOTINIB;FRACTIONAL FLOW RESERVE;GEFITINIB;GENE EXPRESSION PROFILING;HEMATOPOIETIC STEM CELL;INDUCED PLURIPOTENT STEM CELL;INEFFECTIVE ERYTHROPOIESIS;INSULIN GLARGINE;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;KOUNIS SYNDROME;KRAS;KYNURENIC ACID;LEISHMANIA INFANTUM;LONG NON-CODING RNA;MEGAKARYOCYTE;MICROARRAY;MICROARRAY ANALYSIS TECHNIQUES;MISSENSE MUTATION;MOOD STABILIZER;MULTIPARAMETRIC MRI;NEOADJUVANT THERAPY;NINTEDANIB;OMALIZUMAB;ONCOGENE;OSTEOPROTEGERIN;P-SELECTIN;PEMBROLIZUMAB;PENETRANCE;PERCUTANEOUS ETHANOL INJECTION;PIPERACILLIN;RANKL;RIGHT CORONARY ARTERY;RUXOLITINIB;SCLEROSTIN;SEROPREVALENCE;STAPHYLOCOCCUS;TAKOTSUBO SYNDROME;TAMOXIFEN;TERIFLUNOMIDE;VECTOR (MOLECULAR BIOLOGY);VINCRISTINE;VIRAL VECTOR","6;6;5;5;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;;MIDDLE AGED;AGED;ADULT;RETROSPECTIVE STUDIES;ACUTE CORONARY SYNDROME;KIDNEY NEOPLASMS;TREATMENT OUTCOME;PERCUTANEOUS CORONARY INTERVENTION;ITALY;MULTIPLE SCLEROSIS;PROSTATIC NEOPLASMS;AGED, 80 AND OVER;NEPHRECTOMY;ROBOTIC SURGICAL PROCEDURES;PRASUGREL HYDROCHLORIDE;SHOCK, SEPTIC","78;59;59;56;52;46;29;25;24;24;24;21;20;19;19;17;16;16;14;14","DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;RENAL CELL CARCINOMA;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;CANCER IMMUNOTHERAPY;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;PROSTATE CANCER RESEARCH AND TREATMENT;THERAPEUTIC ADVANCES IN CYSTIC FIBROSIS RESEARCH;ADVANCEMENTS IN LUNG CANCER RESEARCH;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;EPIDEMIOLOGY AND MANAGEMENT OF SEPSIS AND SEPTIC SHOCK;MANAGEMENT OF CARDIOVASCULAR DISEASES DURING PREGNANCY;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ASTHMA;CATARACT SURGERY TECHNIQUES AND COMPLICATIONS;COLORECTAL CANCER RESEARCH AND TREATMENT;EPIDEMIOLOGY AND MANAGEMENT OF BIPOLAR DISORDER;HEPATOCELLULAR CARCINOMA;MOLECULAR MECHANISMS OF HEME BIOSYNTHESIS AND RELATED DISORDERS;SHOULDER PATHOLOGY AND TREATMENT OUTCOMES","10;8;7;5;5;5;5;3;3;3;3;3;2;2;2;2;2;2;2;2","TREATMENT;CLINICAL ENDPOINT;BIORESORBABLE SCAFFOLD;CORONARY STENTS;MRI IMAGING;NATALIZUMAB;PROGRESSION-FREE SURVIVAL;TOLERABILITY;CYSTIC FIBROSIS;DIAGNOSTIC CRITERIA;DRUG-ELUTING STENTS;KIDNEY CANCER;MULTIPLE SCLEROSIS;NEOADJUVANT THERAPY;PANCREATIC NEUROENDOCRINE TUMORS;RENAL TRANSPLANTATION;SEPTIC SHOCK;ABIRATERONE ACETATE;ALPHA PARTICLE THERAPY;ARTERY DISSECTION","8;7;5;5;5;4;4;4;3;3;3;3;3;3;3;3;3;2;2;2","MULTIPLE SCLEROSIS;CYSTIC FIBROSIS;PARTIAL NEPHRECTOMY;PROSTATE CANCER;CORONARY ARTERY;FIBROSIS PATIENTS;ACUTE CORONARY;BIORESORBABLE SCAFFOLD;CANCER PATIENTS;PATIENTS TREATED;RADICAL PROSTATECTOMY;SCAFFOLD IMPLANTATION;ADULT CYSTIC;CORONARY SYNDROME;ITALIAN MULTICENTER;LUNG CANCER;MULTICENTER STUDY;NEUROENDOCRINE TUMORS;OBSERVATIONAL STUDY;PATIENTS PTS;PRELIMINARY RESULTS;PROSPECTIVE STUDY;REAL WORLD;REAL-WORLD STUDY;RENAL FUNCTION;RENAL TUMORS;ROBOT-ASSISTED PARTIAL;TYPE DIABETES;ADVANCED NSCLC;ARTERY DISEASE","10;6;6;6;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2","MERCK SHARP;SHARP DOHME;BRISTOL-MYERS SQUIBB;SEPTIC SHOCK;RESEARCH FUNDING;BOEHRINGER INGELHEIM;MULTIPLE SCLEROSIS;PATIENTS TREATED;DAY MORTALITY;HAZARD RATIO;CANCER PATIENTS;ELI LILLY;RENAL FUNCTION;STANDARD DEVIATION;ASTRAZENECA ROCHE;BTP EPISODES;CONFIDENCE INTERVAL;DOHME CORP;MEDIAN PFS;PRIMARY ENDPOINT;SKIN PREPARATION;SOMATOSTATIN ANALOGUES;SPEAKERS BUREAU;ADVERSE CARDIOVASCULAR;CARDIOVASCULAR EVENTS;CLINICAL TRIAL;INDEPENDENT PREDICTORS;KENILWORTH NJ;LUNG CANCER;MAGNETIC RESONANCE","23;23;17;16;13;12;12;12;11;11;10;10;10;9;8;8;8;8;8;8;8;8;8;7;7;7;7;7;7;7",69,0.51,6,6,2.25,1,2.25,19,16,0,4,7,1,1,5.5,2,2,3,4,4,3,0,0,69,69,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_GONZAGA",2019,192,16.1666666666667,2.83333333333333,0.352941176470588,0.296875,0.302083333333333,0.197916666666667,0.625,1,107,28,15,13,0.56,0.15,0.08,0.07,18.6,0.764857694863271,0.390625,0.963541666666667,6.59169550173011,0.474499852839307,0.452929771650151,0.471778306698402,0.484905660377359,"SILVIA NOVELLO;ENRICO CERRATO;GIORGIO QUADRI;FERDINANDO VARBELLA;GIUSEPPE MAINA;FRANCESCO PORPIGLIA;FABRIZIO D’ASCENZO;CRISTIAN FIORI;GIORGIO V. SCAGLIOTTI;GIACOMO BOCCUZZI;ANDREA ROGNONI;ANTONIO BERTOLOTTO;UMBERTO MORBIDUCCI;DIEGO GALLO;ANDREA MONTABONE;CRISTINA ROLFO;SEBASTIANO GILI;MASSIMO TERZOLO;MICHELE AUTELLI;MAURO RINALDI","20;20;15;15;12;12;12;12;12;11;10;9;9;9;9;9;9;8;8;8","GIORGIO V. SCAGLIOTTI;GIUSEPPE MAINA;ANTONIO BERTOLOTTO;SILVIA NOVELLO;LEONARDO MURATORI;FRANCESCO PORPIGLIA;ENRICO CERRATO;ANTONIO PIGA;FILOMENA LONGO;CRISTIAN FIORI;MASSIMO TERZOLO;PAOLA SPERONE;PAOLO BIRONZO;GIOVANNI CAVALLO;F. PORPIGLIA;ANDREA FAGIOLINI;ANGELO GUERRASIO;MARCELLO TUCCI;MATTEO BIANCO;SORAYA PUGLISI","2.26;1.56;1.54;1.4;0.99;0.99;0.95;0.93;0.93;0.89;0.85;0.82;0.75;0.73;0.66;0.63;0.63;0.6;0.6;0.6","SILVIA NOVELLO;ENRICO CERRATO;GIORGIO QUADRI;FERDINANDO VARBELLA;GIUSEPPE MAINA;FRANCESCO PORPIGLIA;CRISTIAN FIORI;GIORGIO V. SCAGLIOTTI;ANTONIO BERTOLOTTO;CRISTINA ROLFO;MASSIMO TERZOLO;MATTEO BIANCO;F. PORPIGLIA;DANIELE AMPARORE;FRANCESCO TOMASSINI;LUISELLA RIGHI;ANGELA PECORARO;CARMEN FAVA;MARCELLO TUCCI;MATTEO MANFREDI","20;20;15;15;12;12;12;12;9;9;8;8;8;7;6;6;6;6;6;6","GIORGIO V. SCAGLIOTTI;GIUSEPPE MAINA;ANTONIO BERTOLOTTO;SILVIA NOVELLO;LEONARDO MURATORI;FRANCESCO PORPIGLIA;ENRICO CERRATO;ANTONIO PIGA;FILOMENA LONGO;CRISTIAN FIORI;MASSIMO TERZOLO;PAOLA SPERONE;PAOLO BIRONZO;GIOVANNI CAVALLO;F. PORPIGLIA;ANGELO GUERRASIO;MARCELLO TUCCI;MATTEO BIANCO;SORAYA PUGLISI;GIUSEPPE REIMONDO","2.26;1.56;1.54;1.4;0.99;0.99;0.95;0.93;0.93;0.89;0.85;0.82;0.75;0.73;0.66;0.63;0.6;0.6;0.6;0.6","TORU KUMAGAI;SILVIA NOVELLO;KAZUHIKO NAKAGAWA;MARTIN RECK;DENIS MORO‐SIBILOT;FUMIO IMAMURA;KEISUKE AOE;KEUNCHIL PARK;KIYOTAKA YOH;MAKOTO NISHIO;TAKASHI SETO;CRISTIAN FIORI;FRANCESCO PORPIGLIA;EDWARD B. GARON;TAKAYASU KURATA;HELGE BISCHOFF;DOMENICO GALETTA;ALESSANDRO DEL CONTE;VANESA GREGORC;ERNEST NADAL","1437;1100;1010;987;958;958;958;958;958;958;958;591;514;511;508;505;497;495;486;484","SILVIA NOVELLO;CRISTIAN FIORI;FRANCESCO PORPIGLIA;ENRICO CERRATO;DANIELE AMPARORE;GIUSEPPE MAINA;MATTEO MANFREDI;F. PORPIGLIA;ENRICO CHECCUCCI;FERDINANDO VARBELLA;ANGELA PECORARO;GIORGIO QUADRI;DIEGO MANFRIN;ENRICO BOLLITO;ALBERTO PIANA;DANIELE TOTA;FEDERICA MASSA;GIOVANNI VOLPICELLI;PIETRO PIAZZOLLA;GIANLUCA ROSSO","1061;591;514;363;331;326;214;205;186;182;168;143;134;131;100;100;100;100;100;95","ENRICO CERRATO;SILVIA NOVELLO;GIUSEPPE MAINA;CRISTIAN FIORI;FRANCESCO PORPIGLIA;GIORGIO QUADRI;FERDINANDO VARBELLA;GIORGIO V. SCAGLIOTTI;ANTONIO BERTOLOTTO;CRISTINA ROLFO;F. PORPIGLIA;MATTEO BIANCO;DANIELE AMPARORE;MASSIMO TERZOLO;ANGELA PECORARO;MATTEO MANFREDI;LEONARDO MURATORI;LUISELLA RIGHI;ANNA LA SALVIA;ENRICO BOLLITO","19;16;12;12;12;12;12;11;9;8;8;8;7;6;6;6;5;5;4;4","MEDICINE;BIOLOGY;PSYCHOLOGY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;SOCIOLOGY;ENGINEERING;ECONOMICS;MATHEMATICS;POLITICAL SCIENCE;HISTORY;MATERIALS SCIENCE;PHILOSOPHY;BUSINESS","189;37;16;15;14;14;9;7;6;4;4;2;2;2;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;CARDIOLOGY;PSYCHIATRY;RADIOLOGY;ENVIRONMENTAL HEALTH;PATHOLOGY;BIOCHEMISTRY;UROLOGY;IMMUNOLOGY;GASTROENTEROLOGY;GENETICS;ENDOCRINOLOGY;INTENSIVE CARE MEDICINE;PALEONTOLOGY;PEDIATRICS;CANCER RESEARCH;CLINICAL PSYCHOLOGY;FAMILY MEDICINE;OPTICS;PHARMACOLOGY","164;54;50;31;23;23;22;22;16;15;14;13;13;12;12;11;11;9;7;7;7;7","CANCER;MYOCARDIAL INFARCTION;POPULATION;CHEMOTHERAPY;LUNG CANCER;RANDOMIZED CONTROLLED TRIAL;DISEASE;GENE;CONFIDENCE INTERVAL;LOGISTIC REGRESSION;KIDNEY;MULTIPLE SCLEROSIS;ADVERSE EFFECT;CLINICAL TRIAL;COHORT;RETROSPECTIVE COHORT STUDY;STENT;INCIDENCE (GEOMETRY);LUNG;ALTERNATIVE MEDICINE;MAGNETIC RESONANCE IMAGING;MYELOID LEUKEMIA;OBSERVATIONAL STUDY;REGIMEN;TRANSPLANTATION","55;21;21;20;20;16;14;13;12;12;11;11;10;10;10;10;9;8;8;7;7;7;7;7;7","CLINICAL ENDPOINT;PERCUTANEOUS CORONARY INTERVENTION;PROSTATE CANCER;ACUTE CORONARY SYNDROME;CONVENTIONAL PCI;IMMUNOTHERAPY;NEPHRECTOMY;PROSTATE;CISPLATIN;COLORECTAL CANCER;REVASCULARIZATION;HAZARD RATIO;BIPOLAR DISORDER;CLOPIDOGREL;PROGRESSION-FREE SURVIVAL;ALEMTUZUMAB;BLADDER CANCER;PHASES OF CLINICAL RESEARCH;TOLERABILITY;BREAST CANCER;CORONARY ANGIOGRAPHY;EPIDERMAL GROWTH FACTOR RECEPTOR;IDIOPATHIC PULMONARY FIBROSIS;IMATINIB;PLACEBO","19;16;13;11;11;10;9;9;8;8;8;7;6;6;6;5;5;5;5;4;4;4;4;4;4","PROSTATECTOMY;MACE;PEMETREXED;PRASUGREL;TICAGRELOR;CARBOPLATIN;PEMBROLIZUMAB;ERLOTINIB;OXALIPLATIN;ARTERY DISSECTION;KRAS;NIVOLUMAB;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;ANDROGEN DEPRIVATION THERAPY;ANDROGEN RECEPTOR;CAPECITABINE;DIGITAL POLYMERASE CHAIN REACTION;GEFITINIB;IMATINIB MESYLATE;MANIA;METASTASECTOMY;NINTEDANIB;SYSTEMIC THERAPY;TARGET LESION;UROTHELIAL CARCINOMA;VINORELBINE","10;7;6;6;6;5;5;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;;MALE;FEMALE;MIDDLE AGED;AGED;ADULT;ITALY;PROSTATIC NEOPLASMS;CORONARY ARTERY DISEASE;PERCUTANEOUS CORONARY INTERVENTION;RETROSPECTIVE STUDIES;LUNG NEOPLASMS;TREATMENT OUTCOME;AGED, 80 AND OVER;PLATELET AGGREGATION INHIBITORS;KIDNEY NEOPLASMS;ACUTE CORONARY SYNDROME;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;POSTOPERATIVE COMPLICATIONS","97;94;82;75;62;55;41;32;31;29;29;29;28;28;25;23;21;19;19;19","RENAL CELL CARCINOMA;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;ADVANCEMENTS IN LUNG CANCER RESEARCH;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;PROSTATE CANCER RESEARCH AND TREATMENT;CANCER IMMUNOTHERAPY;EPIDEMIOLOGY AND MANAGEMENT OF BIPOLAR DISORDER;PHEOCHROMOCYTOMA AND PARAGANGLIOMA;EFFICACY AND RESISTANCE IN CML TREATMENT;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;DIAGNOSIS AND TREATMENT OF LUNG CANCER;LYMPHOID NEOPLASMS;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;MANAGEMENT OF CARDIOVASCULAR DISEASES DURING PREGNANCY;PATHOGENESIS AND TREATMENT OF SYSTEMIC SCLEROSIS;ALLERGIC RHINITIS AND ITS IMPACT ON ASTHMA;CHRONIC RHINOSINUSITIS AND NASAL POLYPS","11;9;9;7;7;7;6;6;6;5;4;4;4;3;3;3;3;3;2;2","CLINICAL ENDPOINT;PROSTATE CANCER;TREATMENT;MACE;REGIMEN;DISCONTINUATION;INTERQUARTILE RANGE;PEMETREXED;CORONARY STENTS;DRUG-ELUTING STENTS;EGFR MUTATIONS;METASTATIC PROSTATE CANCER;NON-SMALL CELL LUNG CANCER;PROGRESSION-FREE SURVIVAL;TOLERABILITY;BIPOLAR DISORDER;CARBOPLATIN;CARDIAC IMAGING;CARDIOVASCULAR RISK ASSESSMENT;LUNG ULTRASOUND","18;8;8;7;7;6;6;6;5;5;5;5;5;5;5;4;4;4;4;4","PATIENTS TREATED;LUNG CANCER;MULTIPLE SCLEROSIS;PROSTATE CANCER;RADICAL PROSTATECTOMY;LEFT MAIN;PARTIAL NEPHRECTOMY;ADRENOCORTICAL CARCINOMA;BIPOLAR DISORDER;MAGNETIC RESONANCE;NSCLC PATIENTS;OBSERVATIONAL STUDY;ANTIPLATELET THERAPY;BRAIN METASTASES;CELL CARCINOMA;CELL LUNG;CORONARY ARTERY;DUAL ANTIPLATELET;NON-SMALL CELL;PATIENTS PTS;ACUTE CORONARY;ARTERY DISSECTION;CANCER NSCLC;CHRONIC MYELOID;COHORT STUDY;CORONARY SYNDROME;CRITICALLY ILL;ILL PATIENTS;METASTATIC NONSQUAMOUS;MYOCARDIAL INFARCTION","13;12;9;9;7;6;6;5;5;5;5;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3","ADVISORY CONSULTANCY;PRIMARY HYPEROXALURIA;CROSSREF PUBMED;PUBMED SCOPUS;HYPEROXALURIA TYPE;LUNG CANCER;PATIENTS TREATED;GRHPR GENE;HR CI;RESEARCH FUNDING;STUDY EXON;MYOCARDIAL INFARCTION;SCHOLAR EXON;ACCOMMODATION EXPENSES;ADVERSE EVENTS;PLEURAL MESOTHELIOMA;TRAVEL ACCOMMODATION;ADVISORY COMMITTEES;ENTITYS BOARD;INTERQUARTILE RANGE;LOGISTIC REGRESSION;MALIGNANT PLEURAL;NON- IRA;CONFIDENCE INTERVAL;CONSULTANCY PFIZER;GLYOXYLATE REDUCTASE;PUBMED GOOGLE;SIGNIFICANT DIFFERENCES;WILLIAMS EL;BOEHRINGER INGELHEIM","72;48;44;43;42;28;21;20;19;16;15;14;14;13;13;13;13;12;12;12;12;12;12;11;11;11;11;11;11;10",89,0.46,10.55,12,1,1,0,1.75,1.75,1,1,13,1,1,12,1,0,2.5,6,9,4,0,0,52,52,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_GONZAGA",2020,214,17.2196261682243,2.42056074766355,0.413127413127413,0.228971962616822,0.219626168224299,0.196261682242991,0.644859813084112,0,117,44,7,11,0.55,0.21,0.03,0.05,38.58,1.53101721831545,0.476635514018692,0.97196261682243,7.94831013916503,0.480765776243194,0.454798534798535,0.376330353341848,0.422605965463108,"ENRICO CERRATO;ALESSANDRO ANTONELLI;FRANCESCO PORPIGLIA;CRISTIAN FIORI;DANIELE AMPARORE;CLAUDIO SIMEONE;IVÁN J. NÚÑEZ‐GIL;FRED SAAD;SILVIA NOVELLO;ALBERTO BRIGANTI;FABRIZIO D’ASCENZO;MASSIMO TERZOLO;ZHE TIAN;ANGELA PECORARO;SHAHROKH F. SHARIAT;F. PORPIGLIA;FERDINANDO VARBELLA;GIUSEPPE MAINA;CARLOTTA PALUMBO;ANTONIO BERTOLOTTO","20;16;15;14;13;13;12;12;11;11;11;10;10;10;10;10;10;9;9;9","GIOVANNI VOLPICELLI;GIUSEPPE MAINA;FRANCESCO PORPIGLIA;CRISTIAN FIORI;MASSIMO TERZOLO;ENRICO CERRATO;DANIELE AMPARORE;GIANLUCA ROSSO;ALESSANDRO ANTONELLI;FRED SAAD;MARCO CALANDRI;ANTONIO BERTOLOTTO;CLAUDIO SIMEONE;SILVIA NOVELLO;ALBERTO BRIGANTI;ZHE TIAN;ANGELA PECORARO;SHAHROKH F. SHARIAT;VITINA CARRIERO;FABIO LUIGI MASSIMO RICCIARDOLO","1.72;1.35;1.14;1.1;1.07;1.02;0.97;0.94;0.92;0.9;0.88;0.87;0.8;0.78;0.77;0.73;0.73;0.73;0.73;0.73","ENRICO CERRATO;FRANCESCO PORPIGLIA;CRISTIAN FIORI;DANIELE AMPARORE;FRED SAAD;SILVIA NOVELLO;MASSIMO TERZOLO;ANGELA PECORARO;F. PORPIGLIA;FERDINANDO VARBELLA;GIUSEPPE MAINA;ANTONIO BERTOLOTTO;CONSUELO BUTTIGLIERO;GIORGIO QUADRI;MARCO VOLANTE;MARCO CALANDRI;SORAYA PUGLISI;FRANCESCO MONTORSI;GIOVANNI VOLPICELLI;ANDREA VELTRI","20;15;14;13;12;11;10;10;10;10;9;9;9;7;7;7;7;7;7;6","GIOVANNI VOLPICELLI;GIUSEPPE MAINA;FRANCESCO PORPIGLIA;CRISTIAN FIORI;MASSIMO TERZOLO;ENRICO CERRATO;DANIELE AMPARORE;GIANLUCA ROSSO;FRED SAAD;MARCO CALANDRI;ANTONIO BERTOLOTTO;SILVIA NOVELLO;ANGELA PECORARO;VITINA CARRIERO;FABIO LUIGI MASSIMO RICCIARDOLO;ANDREA ELIO SPRIO;FRANCESCA BERTOLINI;SORAYA PUGLISI;MARCO VOLANTE;F. PORPIGLIA","1.72;1.35;1.14;1.1;1.07;1.02;0.97;0.94;0.9;0.88;0.87;0.78;0.73;0.73;0.73;0.73;0.73;0.66;0.66;0.63","PIETRO CAIRONI;FEDERICA ROMITTI;LUCIANO GATTINONI;MATTIA BUSANA;DAVIDE CHIUMELLO;LUCA BRAZZI;LUIGI CAMPOROTA;SILVIA NOVELLO;EDWARD B. GARON;FRANCESCO GROSSI;MARINA CHIARA GARASSINO;BELÉN RUBIO‐VIQUEIRA;DELVYS RODRÍGUEZ‐ABREU;EMILIO ESTEBAN;ENRIQUETA FELIP;GIOVANNA SPERANZA;HELGE BISCHOFF;JHANELLE E. GRAY;JING YANG;M. CATHERINE PIETANZA","1805;1733;1733;1733;1727;1727;1727;1389;1085;1014;867;861;861;861;861;861;861;861;861;861","PIETRO CAIRONI;SILVIA NOVELLO;ENRICO CERRATO;GIOVANNI VOLPICELLI;FRANCESCO PORPIGLIA;F. PORPIGLIA;DANIELE AMPARORE;CRISTIAN FIORI;MARCO CALANDRI;MARCO CAPOBIANCO;ENRICO CHECCUCCI;MASSIMO TERZOLO;GIUSEPPE MAINA;SORAYA PUGLISI;MARCO TAMPELLINI;FRANCESCO PASSIGLIA;ALBERTO PERBONI;FEDERICA GAMNA;STEFANO BRAMANTE;SYLVIA RIGARDETTO","1786;1386;592;590;533;517;474;410;255;249;244;218;198;193;192;178;174;157;152;152","ENRICO CERRATO;FRANCESCO PORPIGLIA;CRISTIAN FIORI;DANIELE AMPARORE;SILVIA NOVELLO;ANGELA PECORARO;F. PORPIGLIA;CONSUELO BUTTIGLIERO;GIOVANNI VOLPICELLI;ANTONIO BERTOLOTTO;FERDINANDO VARBELLA;GIUSEPPE MAINA;SORAYA PUGLISI;MASSIMO TERZOLO;ENRICO CHECCUCCI;ADRIANA BOCCUZZI;GIANLUCA ROSSO;MARCO CALANDRI;MARCO CAPOBIANCO;PAOLO BIRONZO","19;15;14;13;10;10;10;9;9;9;8;8;7;7;6;5;5;5;5;5","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;ECONOMICS;COMPUTER SCIENCE;MATHEMATICS;SOCIOLOGY;PSYCHOLOGY;ENGINEERING;PHILOSOPHY;POLITICAL SCIENCE;BUSINESS;MATERIALS SCIENCE","207;49;13;10;10;9;9;9;8;6;5;5;3;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;GASTROENTEROLOGY;RADIOLOGY;PSYCHIATRY;PATHOLOGY;UROLOGY;CARDIOLOGY;INTENSIVE CARE MEDICINE;ENVIRONMENTAL HEALTH;IMMUNOLOGY;PALEONTOLOGY;PEDIATRICS;GENETICS;BIOCHEMISTRY;CANCER RESEARCH;FAMILY MEDICINE;VIROLOGY;EMERGENCY MEDICINE;OPTICS","184;55;44;31;27;26;25;25;24;23;22;19;19;19;18;15;12;12;12;10;10","CANCER;DISEASE;CHEMOTHERAPY;POPULATION;RETROSPECTIVE COHORT STUDY;GENE;CONFIDENCE INTERVAL;COHORT;KIDNEY;MYOCARDIAL INFARCTION;MULTIPLE SCLEROSIS;CLINICAL TRIAL;LUNG CANCER;OUTBREAK;RENAL CELL CARCINOMA;STAGE (STRATIGRAPHY);INCIDENCE (GEOMETRY);PROPORTIONAL HAZARDS MODEL;LOGISTIC REGRESSION;PERIOPERATIVE;RANDOMIZED CONTROLLED TRIAL","52;40;22;22;22;19;18;17;17;17;15;13;13;13;12;11;10;10;9;9;9","INFECTIOUS DISEASE (MEDICAL SPECIALTY);CLINICAL ENDPOINT;NEPHRECTOMY;IMMUNOTHERAPY;HAZARD RATIO;CONVENTIONAL PCI;2019-20 CORONAVIRUS OUTBREAK;CISPLATIN;PROSTATE CANCER;PERCUTANEOUS CORONARY INTERVENTION;LUNG ULTRASOUND;PROGRESSION-FREE SURVIVAL;PROSTATE;DOCETAXEL;PHASES OF CLINICAL RESEARCH;REVASCULARIZATION;BLADDER CANCER;COLORECTAL CANCER;KIDNEY CANCER;MUTATION;NEURORADIOLOGY","23;15;15;14;13;11;10;10;10;9;7;7;7;6;6;6;5;5;5;5;5","CORONAVIRUS DISEASE 2019 (COVID-19);PEMBROLIZUMAB;CARBOPLATIN;PROSTATECTOMY;ANDROGEN DEPRIVATION THERAPY;LOWER URINARY TRACT SYMPTOMS;NIVOLUMAB;ANDROGEN RECEPTOR;CYSTECTOMY;EXOME SEQUENCING;MACE;PEMETREXED;BONE METASTASIS;CHROMOPHOBE CELL;DASATINIB;IMATINIB MESYLATE;IVACAFTOR;KRAS;MANIA;NILOTINIB;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS;TARGET LESION;TAXANE;TRANSCRIPTOME;TREATMENT-RESISTANT DEPRESSION","23;8;6;5;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2",";HUMANS;MALE;FEMALE;MIDDLE AGED;AGED;ITALY;KIDNEY NEOPLASMS;TREATMENT OUTCOME;ADULT;NEPHRECTOMY;RETROSPECTIVE STUDIES;CORONARY ARTERY DISEASE;LUNG NEOPLASMS;CARCINOMA, NON-SMALL-CELL LUNG;POSTOPERATIVE COMPLICATIONS;COVID-19;CARCINOMA, RENAL CELL;PNEUMONIA, VIRAL;PROSPECTIVE STUDIES","117;96;64;54;50;40;32;29;27;25;25;25;24;24;23;22;21;19;16;16","RENAL CELL CARCINOMA;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;ROLE OF LUNG ULTRASOUND IN CRITICAL CARE;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;PHEOCHROMOCYTOMA AND PARAGANGLIOMA;CANCER IMMUNOTHERAPY;CORONAVIRUS DISEASE 2019;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;POLY(ADP-RIBOSE) POLYMERASE INHIBITION IN CANCER THERAPY;APPLICATIONS OF DEEP LEARNING IN MEDICAL IMAGING;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;EFFICACY AND RESISTANCE IN CML TREATMENT;STANDARDISATION OF LOWER URINARY TRACT FUNCTION;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;ASTHMA;CHRONIC RHINOSINUSITIS AND NASAL POLYPS;EPIDEMIOLOGY AND MANAGEMENT OF BIPOLAR DISORDER;MOLECULAR MECHANISMS OF CARDIAC ARRHYTHMIAS;PROSTATE CANCER RESEARCH AND TREATMENT","18;11;9;8;8;6;6;6;6;5;4;4;4;4;3;3;3;3;3;3","CLINICAL ENDPOINT;PANDEMIC;2019-20 CORONAVIRUS OUTBREAK;LUNG ULTRASOUND;RENAL CELL CARCINOMA;CARDIAC ULTRASOUND;PROGRESSION-FREE SURVIVAL;CARBOPLATIN;ADRENOCORTICAL CARCINOMA;CARDIOVASCULAR RISK ASSESSMENT;DEPRESSION (ECONOMICS);DIAGNOSTIC CRITERIA;KIDNEY CANCER;METASTATIC PROSTATE CANCER;NEUROENDOCRINE TUMORS;TREATMENT;ADRENAL INCIDENTALOMA;CHEST X-RAY;CONCOMITANT;DISCONTINUATION","16;13;9;8;8;7;7;6;5;5;5;5;5;5;5;5;4;4;4;4","MULTIPLE SCLEROSIS;RENAL CELL;CELL CARCINOMA;LUNG CANCER;PARTIAL NEPHRECTOMY;PROSTATE CANCER;PHASE II;CANCER PATIENTS;LUNG ULTRASOUND;CASTRATION-RESISTANT PROSTATE;CORONAVIRUS DISEASE;II STUDY;METASTATIC CASTRATION-RESISTANT;MYELOID LEUKEMIA;SCLEROSIS PATIENTS;ADRENOCORTICAL CARCINOMA;CHEST X-RAY;CHRONIC MYELOID;COLORECTAL CANCER;LEFT MAIN;MULTICENTER STUDY;PATIENTS AFFECTED;PD-L EXPRESSION;RELAPSING-REMITTING MULTIPLE;ABIRATERONE ACETATE;ADVANCED NSCLC;BIPOLAR DISORDER;CANCER MCRPC;CELL LUNG;CLINICAL EXOME","14;10;9;9;9;9;8;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3","PUBMED SCOPUS;CROSSREF PUBMED;HR CI;CLINICAL PRACTICE;LUNG CANCER;ADRENOCORTICAL CARCINOMA;SPEAKERS BUREAU;ADVISORY COMMITTEES;ENTITYS BOARD;PATIENTS TREATED;CONSULTANCY HONORARIA;LUNG ULTRASOUND;CORONAVIRUS DISEASE;DISEASE PROGRESSION;INDEPENDENT PREDICTORS;RESEARCH FUNDING;ADVERSE EVENTS;MEDIAN AGE;MULTIPLE SCLEROSIS;PROGRESSION-FREE SURVIVAL;SURVIVAL OS;PD-L EXPRESSION;RETROSPECTIVE STUDY;ADRENAL INCIDENTALOMAS;F-FDG PETCT;PRIMARY ENDPOINT;THYROID AES;COMPUTED TOMOGRAPHY;RESPONSE RATE;SCLEROSIS MS","55;38;21;20;20;19;19;18;18;18;17;17;15;15;15;15;14;14;14;14;14;13;12;11;11;11;11;10;10;10",117,0.55,13.6,15,1,1,0,7.25,1,1,1.5,20,1,1,13,2,1,2,5.5,9,4.5,0,0,66,63,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_GONZAGA",2021,262,18.6832061068702,2.7175572519084,0.367977528089888,0.229007633587786,0.286259541984733,0.16030534351145,0.66412213740458,1,148,37,22,17,0.56,0.14,0.08,0.06,14.51,0.941036372868723,0.442748091603053,0.961832061068702,8.42294520547946,0.498501981842433,0.440651260504202,0.467426400759734,0.424501424501424,"ENRICO CERRATO;SILVIA NOVELLO;IVÁN J. NÚÑEZ‐GIL;SERGIO RAPOSEIRAS‐ROUBÍN;CRISTIAN FIORI;GIORGIO V. SCAGLIOTTI;DANIELE AMPARORE;VÍCTOR MANUEL BECERRA‐MUÑOZ;VICENTE ESTRADA;RODOLFO ROMERO;GIUSEPPE MAINA;FABRIZIO D’ASCENZO;ENRICO CHECCUCCI;FRANCESCO PORPIGLIA;MATTEO BIANCO;AITOR URIBARRI;PAOLO BIRONZO;MARTINO PEPE;İBRAHIM AKIN;ANTONIO FERNÁNDEZ-ORTÍZ","29;26;19;16;16;16;15;15;14;14;13;13;12;12;12;12;11;11;11;11","GIUSEPPE MAINA;SILVIA NOVELLO;ENRICO CERRATO;CRISTIAN FIORI;DANIELE AMPARORE;GIORGIO V. SCAGLIOTTI;FRANCESCO PORPIGLIA;LUISELLA RIGHI;ENRICO CHECCUCCI;MARCO VOLANTE;DANIELA BERARDINELLI;MARINELLA CLERICO;F. PORPIGLIA;FRANCESCO LEO;GIANLUCA ROSSO;MATTEO MANFREDI;IVÁN J. NÚÑEZ‐GIL;STEFANIA FEDERICA DE MERCANTI;MASSIMO TERZOLO;ENRICO BOLLITO","2.04;1.9;1.85;1.45;1.43;1.12;1.12;1.09;1.07;1.04;1;0.94;0.87;0.87;0.78;0.77;0.77;0.76;0.73;0.72","ENRICO CERRATO;SILVIA NOVELLO;CRISTIAN FIORI;GIORGIO V. SCAGLIOTTI;DANIELE AMPARORE;GIUSEPPE MAINA;ENRICO CHECCUCCI;FRANCESCO PORPIGLIA;MATTEO BIANCO;PAOLO BIRONZO;MATTEO MANFREDI;LUISELLA RIGHI;MARIA LUCIA REALE;MASSIMO TERZOLO;CONSUELO BUTTIGLIERO;MARINELLA CLERICO;MARCO CAPOBIANCO;F. PORPIGLIA;ANTONIO BERTOLOTTO;PIETRO CAIRONI","29;26;16;16;15;13;12;12;12;11;11;10;10;9;9;9;9;9;8;8","GIUSEPPE MAINA;SILVIA NOVELLO;ENRICO CERRATO;CRISTIAN FIORI;DANIELE AMPARORE;GIORGIO V. SCAGLIOTTI;FRANCESCO PORPIGLIA;LUISELLA RIGHI;ENRICO CHECCUCCI;MARCO VOLANTE;DANIELA BERARDINELLI;MARINELLA CLERICO;F. PORPIGLIA;FRANCESCO LEO;GIANLUCA ROSSO;MATTEO MANFREDI;STEFANIA FEDERICA DE MERCANTI;MASSIMO TERZOLO;ENRICO BOLLITO;PAOLO BIRONZO","2.04;1.9;1.85;1.45;1.43;1.12;1.12;1.09;1.07;1.04;1;0.94;0.87;0.87;0.78;0.77;0.76;0.73;0.72;0.71","NICOLA DE ROSSI;MARCO CAPOBIANCO;CINZIA CORDIOLI;MARIA PIA SORMANI;GIANCARLO COMI;FRANCESCO PATTI;MARCO SALVETTI;GIOACCHINO TEDESCHI;IRENE SCHIAVETTI;LUCA CARMISCIANO;MARIA TROJANO;MARIO ALBERTO BATTAGLIA;MARTA RADAELLI;PAOLO IMMOVILLI;LUCIA MOIOLA;PAOLA ZARATIN;ENRICO CERRATO;IVÁN J. NÚÑEZ‐GIL;VÍCTOR MANUEL BECERRA‐MUÑOZ;CONSUELO BUTTIGLIERO","601;588;582;582;562;557;557;546;546;546;546;546;546;546;532;429;392;330;316;300","MARCO CAPOBIANCO;ENRICO CERRATO;CONSUELO BUTTIGLIERO;MATTEO BIANCO;CRISTIAN FIORI;GIORGIO V. SCAGLIOTTI;FEDERICO ITRI;GIOVANNI VOLPICELLI;DANIELE AMPARORE;FRANCESCO PORPIGLIA;ENRICO CHECCUCCI;MATTEO MANFREDI;SILVIA NOVELLO;GIOVANNI CAPPA;FRANCESCO PASSIGLIA;LAURA MONTAGNA;GIORGIO QUADRI;PIETRO CAIRONI;SABRINA DE CILLIS;FERDINANDO VARBELLA","588;381;300;285;248;248;247;247;229;215;196;189;173;150;148;148;141;131;127;113","ENRICO CERRATO;SILVIA NOVELLO;CRISTIAN FIORI;DANIELE AMPARORE;GIORGIO V. SCAGLIOTTI;FRANCESCO PORPIGLIA;MATTEO BIANCO;ENRICO CHECCUCCI;MATTEO MANFREDI;GIUSEPPE MAINA;CONSUELO BUTTIGLIERO;F. PORPIGLIA;MARCO CAPOBIANCO;MARIA LUCIA REALE;ANTONIO BERTOLOTTO;MASSIMO TERZOLO;GIOVANNI VOLPICELLI;LUISELLA RIGHI;MARCO CALANDRI;SIMONA CARNIO","28;23;16;15;14;12;12;11;11;10;9;9;9;9;8;8;7;7;7;7","MEDICINE;BIOLOGY;PSYCHOLOGY;COMPUTER SCIENCE;PHYSICS;CHEMISTRY;ECONOMICS;MATHEMATICS;SOCIOLOGY;ENGINEERING;BUSINESS;PHILOSOPHY;POLITICAL SCIENCE;GEOGRAPHY;MATERIALS SCIENCE;ART;ENVIRONMENTAL SCIENCE;HISTORY","256;49;24;18;18;12;11;10;9;8;3;3;3;2;2;1;1;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;PATHOLOGY;PSYCHIATRY;CARDIOLOGY;RADIOLOGY;IMMUNOLOGY;INTENSIVE CARE MEDICINE;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;UROLOGY;PEDIATRICS;VIROLOGY;GENETICS;PALEONTOLOGY;EMERGENCY MEDICINE;NURSING;BIOCHEMISTRY;CLINICAL PSYCHOLOGY","222;68;44;40;35;29;29;28;27;26;22;21;20;19;18;17;16;13;11;11","CANCER;DISEASE;COHORT;LUNG CANCER;OUTBREAK;POPULATION;CHEMOTHERAPY;CONFIDENCE INTERVAL;GENE;CLINICAL TRIAL;MULTIPLE SCLEROSIS;ADVERSE EFFECT;MYOCARDIAL INFARCTION;RETROSPECTIVE COHORT STUDY;MULTIVARIATE ANALYSIS;PROPORTIONAL HAZARDS MODEL;RANDOMIZED CONTROLLED TRIAL;KIDNEY;LUNG;PNEUMONIA;PROSPECTIVE COHORT STUDY","76;58;26;23;23;23;21;21;19;18;17;16;16;16;12;12;12;11;11;11;11","INFECTIOUS DISEASE (MEDICAL SPECIALTY);2019-20 CORONAVIRUS OUTBREAK;CLINICAL ENDPOINT;PROSTATE CANCER;IMMUNOTHERAPY;HAZARD RATIO;PERCUTANEOUS CORONARY INTERVENTION;CONVENTIONAL PCI;PROSTATE;ACUTE CORONARY SYNDROME;NEPHRECTOMY;DOCETAXEL;BREAST CANCER;CABOZANTINIB;EJECTION FRACTION;METASTASIS;TYROSINE-KINASE INHIBITOR;ANTIPSYCHOTIC;BLADDER CANCER;CARDIOMYOPATHY;COLORECTAL CANCER;MUTATION;NEURORADIOLOGY;PRIMARY HYPEROXALURIA;TYROSINE KINASE","41;22;19;19;13;12;11;9;9;8;8;7;6;5;5;5;5;4;4;4;4;4;4;4;4","CORONAVIRUS DISEASE 2019 (COVID-19);PEMBROLIZUMAB;MACE;PROSTATE BIOPSY;NIVOLUMAB;PROSTATE-SPECIFIC ANTIGEN;TICAGRELOR;ANDROGEN RECEPTOR;NON-SMALL CELL LUNG CANCER (NSCLC);POLY ADP RIBOSE POLYMERASE;PROSTATECTOMY;TAKOTSUBO SYNDROME;ADJUVANT CHEMOTHERAPY;AXITINIB;BONE METASTASIS;BRAIN METASTASIS;CHA2DS2–VASC SCORE;DASATINIB;DIGITAL POLYMERASE CHAIN REACTION;ERLOTINIB;FRACTIONAL FLOW RESERVE;KRAS;METASTASECTOMY;NILOTINIB;OCRELIZUMAB;ONCOGENE;PROSTATE CARCINOMA;RECTAL EXAMINATION;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;TAXANE","41;7;6;5;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2",";HUMANS;COVID-19;MALE;FEMALE;AGED;MIDDLE AGED;ITALY;RETROSPECTIVE STUDIES;SARS-COV-2;MULTIPLE SCLEROSIS;KIDNEY NEOPLASMS;TREATMENT OUTCOME;ADULT;AGED, 80 AND OVER;REGISTRIES;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;HEART FAILURE;LUNG","149;112;74;55;49;40;37;35;31;26;21;20;19;17;17;17;16;16;14;13","RENAL CELL CARCINOMA;CORONAVIRUS DISEASE 2019;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;CANCER IMMUNOTHERAPY;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;ADVANCEMENTS IN LUNG CANCER RESEARCH;ROLE OF LUNG ULTRASOUND IN CRITICAL CARE;EFFICACY AND RESISTANCE IN CML TREATMENT;PHEOCHROMOCYTOMA AND PARAGANGLIOMA;POLY(ADP-RIBOSE) POLYMERASE INHIBITION IN CANCER THERAPY;PROSTATE CANCER RESEARCH AND TREATMENT;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;EPIDEMIOLOGY AND MANAGEMENT OF SEPSIS AND SEPTIC SHOCK;SCHIZOPHRENIA RESEARCH AND TREATMENT;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;CORONAVIRUS DISEASE 2019 RESEARCH;DIAGNOSIS AND TREATMENT OF LUNG CANCER;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;THERAPEUTIC ADVANCES IN CYSTIC FIBROSIS RESEARCH","14;12;11;10;10;8;7;6;6;6;6;5;5;5;4;4;4;4;4;4","CLINICAL ENDPOINT;2019-20 CORONAVIRUS OUTBREAK;PANDEMIC;METASTATIC PROSTATE CANCER;CLINICAL CHARACTERISTICS;LUNG ULTRASOUND;TREATMENT;BIOMARKERS FOR IMMUNOTHERAPY;CONCOMITANT;DISCONTINUATION;MACE;RENAL CELL CARCINOMA;ADRENOCORTICAL CARCINOMA;CABOZANTINIB;CARDIAC ULTRASOUND;CYSTIC FIBROSIS;EGFR MUTATIONS;INTERQUARTILE RANGE;PROSTATE BIOPSY;PROSTATE CANCER","20;17;13;11;7;7;7;6;6;6;6;6;5;5;5;5;5;5;5;5","LUNG CANCER;MULTIPLE SCLEROSIS;PROSTATE CANCER;CASTRATION-RESISTANT PROSTATE;CELL LUNG;CANCER PATIENTS;NON-SMALL CELL;PATIENTS TREATED;METASTATIC CASTRATION-RESISTANT;ACUTE CORONARY;CORONARY ARTERY;CORONARY SYNDROME;CYSTIC FIBROSIS;LUNG ULTRASOUND;ADRENOCORTICAL CARCINOMA;CANCER MCRPC;CELL CARCINOMA;CHRONIC MYELOID;HEART FAILURE;HOPE COVID-;NSCLC PATIENTS;PATIENTS PTS;PHASE II;RENAL CELL;TALAZOPARIB TALA;CANCER NSCLC;COVID- REGISTRY;DNA DAMAGE;GASTRIC CANCER;HEALTH OUTCOME","19;17;16;10;10;9;9;8;7;6;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5;4;4;4;4;4","HR CI;ADVISORY COMMITTEES;ENTITYS BOARD;LUNG CANCER;PERSONAL FEES;CLINICAL TRIAL;COVID- PANDEMIC;CORONAVIRUS DISEASE;COVID- PATIENTS;STAGE II-IIIA;ALL-CAUSE DEATH;SPEAKERS BUREAU;PATIENTS TREATED;PRIMARY ENDPOINT;HONORARIA MEMBERSHIP;PB- PB-;ACUTE RESPIRATORY;BMI KGM;BRISTOL MYERS;CLINICAL TRIALS;DISEASE COVID-;INTENSIVE CARE;CANCER PATIENTS;CONSULTANCY HONORARIA;INCREASED RISK;MYERS SQUIBB;NSCLC PATIENTS;ADVERSE EVENTS;II-IIIA NSCLC;MORTALITY RATE","47;35;35;35;30;24;23;21;21;21;19;19;18;17;16;15;14;14;14;14;14;14;13;13;13;13;13;12;12;12",126,0.48,9.14,9.75,1,1,0,2,1,0,1,11.75,0,0,10.5,1,1,1,3,6,5,0,0,37.75,37.75,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_GONZAGA",2022,213,20.5774647887324,2.72769953051643,0.366609294320138,0.248826291079812,0.253521126760563,0.178403755868545,0.71830985915493,0,106,29,13,13,0.5,0.14,0.06,0.06,7.28,0.815710359326608,0.535211267605634,0.981220657276995,7.71383147853735,0.529010074006458,0.490683229813665,0.536470588235294,0.481851851851852,"FRANCESCO PORPIGLIA;CRISTIAN FIORI;DANIELE AMPARORE;ENRICO CERRATO;ENRICO CHECCUCCI;SABRINA DE CILLIS;GIORGIO V. SCAGLIOTTI;MATTEO MANFREDI;FEDERICO PIRAMIDE;PAOLO VERRI;ALBERTO PIANA;ANGELA PECORARO;SILVIA NOVELLO;CONSUELO BUTTIGLIERO;FEDERICO ITRI;MARCO CAPOBIANCO;FRANCESCO PASSIGLIA;MASSIMO DI MAÏO;DANIELA CILLONI;MARCO VOLANTE","24;22;19;16;15;15;15;14;13;10;10;9;8;8;8;8;7;7;7;7","DANIELE AMPARORE;FRANCESCO PORPIGLIA;CRISTIAN FIORI;SABRINA DE CILLIS;ENRICO CHECCUCCI;FEDERICO PIRAMIDE;MATTEO MANFREDI;ANGELA PECORARO;GIORGIO V. SCAGLIOTTI;PAOLO VERRI;THOMAS FRACCALINI;ALBERTO PIANA;ENRICO CERRATO;SARAH ALLEGRA;SILVIA DE FRANCIA;CONSUELO BUTTIGLIERO;FRANCESCO CHIARA;FRANCESCO PASSIGLIA;GIUSEPPE MAINA;FABIO TURCO","2.13;1.76;1.69;1.43;1.39;1.29;1.28;1.21;1;0.87;0.87;0.86;0.85;0.81;0.81;0.78;0.73;0.7;0.65;0.59","FRANCESCO PORPIGLIA;CRISTIAN FIORI;DANIELE AMPARORE;ENRICO CERRATO;ENRICO CHECCUCCI;SABRINA DE CILLIS;GIORGIO V. SCAGLIOTTI;MATTEO MANFREDI;FEDERICO PIRAMIDE;PAOLO VERRI;ALBERTO PIANA;ANGELA PECORARO;SILVIA NOVELLO;CONSUELO BUTTIGLIERO;FEDERICO ITRI;MARCO CAPOBIANCO;FRANCESCO PASSIGLIA;DANIELA CILLONI;MARCO VOLANTE;PAOLO BIRONZO","24;22;19;16;15;15;15;14;13;10;10;9;8;8;8;8;7;7;7;7","DANIELE AMPARORE;FRANCESCO PORPIGLIA;CRISTIAN FIORI;SABRINA DE CILLIS;ENRICO CHECCUCCI;FEDERICO PIRAMIDE;MATTEO MANFREDI;ANGELA PECORARO;GIORGIO V. SCAGLIOTTI;PAOLO VERRI;THOMAS FRACCALINI;ALBERTO PIANA;ENRICO CERRATO;SARAH ALLEGRA;SILVIA DE FRANCIA;CONSUELO BUTTIGLIERO;FRANCESCO CHIARA;FRANCESCO PASSIGLIA;GIUSEPPE MAINA;FABIO TURCO","2.13;1.76;1.69;1.43;1.39;1.29;1.28;1.21;1;0.87;0.87;0.86;0.85;0.81;0.81;0.78;0.73;0.7;0.65;0.59","FRANCESCO PORPIGLIA;CRISTIAN FIORI;DANIELE AMPARORE;MARCO CAPOBIANCO;ENRICO CHECCUCCI;MATTEO MANFREDI;SABRINA DE CILLIS;ALBERTO PIANA;ACHIM BERTHELE;AMANDA EISELE;AXEL REGENITER;BERNHARD NEUMANN;BRIGITTE WILDEMANN;CATHARINA C. GROß;CHRISTOPH KLEINSCHNITZ;DIEGO FRANCIOTTA;E. KELLER;FEDERICO PIRAMIDE;FLORENCE PACHE;FRIEDEMANN PAUL","239;184;172;161;147;136;126;118;117;117;117;117;117;117;117;117;117;117;117;117","FRANCESCO PORPIGLIA;CRISTIAN FIORI;DANIELE AMPARORE;MARCO CAPOBIANCO;MATTEO MANFREDI;SABRINA DE CILLIS;ALBERTO PIANA;FEDERICO PIRAMIDE;PAOLO VERRI;SILVIA NOVELLO;FEDERICO ITRI;ANGELA PECORARO;GIORGIO V. SCAGLIOTTI;MARIA PIA BRIZZI;GIOVANNI VOLPICELLI;ENRICO CERRATO;ENRICO CHECCUCCI;F. PORPIGLIA;IRENE PERSANO;GIOVANNA REGE‐CAMBRIN","239;184;172;161;136;126;118;117;115;96;86;79;78;77;76;67;51;51;50;42","FRANCESCO PORPIGLIA;CRISTIAN FIORI;DANIELE AMPARORE;ENRICO CERRATO;SABRINA DE CILLIS;GIORGIO V. SCAGLIOTTI;MATTEO MANFREDI;FEDERICO PIRAMIDE;ALBERTO PIANA;PAOLO VERRI;SILVIA NOVELLO;ANGELA PECORARO;ENRICO CHECCUCCI;CONSUELO BUTTIGLIERO;DANIELA CILLONI;MARCO CAPOBIANCO;FRANCESCO PASSIGLIA;F. PORPIGLIA;FEDERICO ITRI;PAOLO BIRONZO","24;22;19;16;15;14;14;13;10;10;10;9;9;8;8;8;7;6;6;6","MEDICINE;BIOLOGY;COMPUTER SCIENCE;PHYSICS;PSYCHOLOGY;CHEMISTRY;ECONOMICS;MATHEMATICS;SOCIOLOGY;ENGINEERING;POLITICAL SCIENCE;HISTORY;PHILOSOPHY;GEOLOGY;MATERIALS SCIENCE;BUSINESS;ENVIRONMENTAL SCIENCE;GEOGRAPHY","213;36;18;14;10;8;8;7;7;6;6;3;3;2;2;1;1;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;PATHOLOGY;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;CARDIOLOGY;PSYCHIATRY;UROLOGY;IMMUNOLOGY;RADIOLOGY;GENETICS;EMERGENCY MEDICINE;PEDIATRICS;CANCER RESEARCH;INTENSIVE CARE MEDICINE;BIOCHEMISTRY;OPTICS;ARTIFICIAL INTELLIGENCE;PALEONTOLOGY","188;57;55;32;27;27;25;22;22;21;21;19;13;13;12;11;10;10;9;9","CANCER;DISEASE;COHORT;POPULATION;CLINICAL TRIAL;LUNG CANCER;ADVERSE EFFECT;GENE;KIDNEY;CHEMOTHERAPY;MYOCARDIAL INFARCTION;RETROSPECTIVE COHORT STUDY;CONFIDENCE INTERVAL;PROPORTIONAL HAZARDS MODEL;INCIDENCE (GEOMETRY);LOGISTIC REGRESSION;OBSERVATIONAL STUDY;OUTBREAK;PERIOPERATIVE;PROPENSITY SCORE MATCHING","63;40;28;25;23;22;20;19;19;16;16;15;12;12;10;10;10;10;10;10","INFECTIOUS DISEASE (MEDICAL SPECIALTY);CLINICAL ENDPOINT;NEPHRECTOMY;PROSTATE CANCER;IMMUNOTHERAPY;2019-20 CORONAVIRUS OUTBREAK;PERCUTANEOUS CORONARY INTERVENTION;EJECTION FRACTION;HAZARD RATIO;PROSTATE;TOLERABILITY;ADENOCARCINOMA;COLORECTAL CANCER;CONVENTIONAL PCI;MYELOFIBROSIS;UNIVARIATE ANALYSIS;BLADDER CANCER;BREAST CANCER;CISPLATIN;MALIGNANT PLEURAL EFFUSION","26;18;18;13;11;9;8;7;7;7;7;6;6;6;6;6;5;5;5;5","CORONAVIRUS DISEASE 2019 (COVID-19);PEMBROLIZUMAB;PROSTATECTOMY;CRIZOTINIB;NIVOLUMAB;PEMETREXED;ANAPLASTIC LYMPHOMA KINASE;HORMONAL THERAPY;KRAS;NILOTINIB;POLY ADP RIBOSE POLYMERASE;RUXOLITINIB;SUICIDAL IDEATION;TAXANE;CETUXIMAB;DASATINIB;DIGITAL POLYMERASE CHAIN REACTION;FRACTIONAL FLOW RESERVE;GERMLINE MUTATION;IBRUTINIB;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;MYELOPROLIFERATIVE NEOPLASM;POSACONAZOLE;PRIMARY TUMOR;RIVAROXABAN;THYMIDYLATE SYNTHASE;TICAGRELOR;TIMI;UROTHELIAL CANCER;UROTHELIAL CARCINOMA","26;7;6;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;;MALE;RETROSPECTIVE STUDIES;COVID-19;LUNG NEOPLASMS;FEMALE;KIDNEY NEOPLASMS;NEPHRECTOMY;ROBOTIC SURGICAL PROCEDURES;NEUROENDOCRINE TUMORS;CARCINOMA, NON-SMALL-CELL LUNG;PERCUTANEOUS CORONARY INTERVENTION;PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;TREATMENT OUTCOME;MIDDLE AGED;PROSTATIC NEOPLASMS;AGED;MULTIPLE SCLEROSIS;ADULT","108;103;33;30;29;27;25;22;20;17;16;15;15;15;15;14;13;12;12;11","RENAL CELL CARCINOMA;ADVANCEMENTS IN LUNG CANCER RESEARCH;CORONAVIRUS DISEASE 2019;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;CANCER IMMUNOTHERAPY;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;EFFICACY AND RESISTANCE IN CML TREATMENT;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;POLY(ADP-RIBOSE) POLYMERASE INHIBITION IN CANCER THERAPY;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION;PROSTATE CANCER RESEARCH AND TREATMENT;STANDARDISATION OF LOWER URINARY TRACT FUNCTION;ACUTE MYELOID LEUKEMIA;CHRONIC RHINOSINUSITIS AND NASAL POLYPS;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS","21;12;9;7;6;5;5;5;5;5;4;4;4;4;4;4;4;3;3;3","CLINICAL ENDPOINT;2019-20 CORONAVIRUS OUTBREAK;NEPHROLOGY;PANDEMIC;METASTATIC PROSTATE CANCER;TOLERABILITY;UNIVARIATE ANALYSIS;DEPRESSION (ECONOMICS);NEUROENDOCRINE TUMORS;REGIMEN;RENAL CELL CARCINOMA;ATEZOLIZUMAB;CARDIAC IMAGING;CLINICAL CHARACTERISTICS;DISCONTINUATION;HEART FAILURE;INTERQUARTILE RANGE;MYELOFIBROSIS;NON-SMALL CELL LUNG CANCER;PEMETREXED","18;8;8;8;7;7;6;5;5;5;5;4;4;4;4;4;4;4;4;4","LUNG CANCER;PARTIAL NEPHRECTOMY;PROSTATE CANCER;ROBOT-ASSISTED PARTIAL;CASTRATION-RESISTANT PROSTATE;CELL LUNG;DAMAGE RESPONSE;DNA DAMAGE;MULTIPLE SCLEROSIS;OBSERVATIONAL STUDY;CANCER PATIENTS;CORONARY ARTERY;METASTATIC CASTRATION-RESISTANT;NON-SMALL CELL;PATIENTS TREATED;RESPONSE ALTERATIONS;COVID- PANDEMIC;COVID- PATIENTS;HEART FAILURE;LONG-TERM OUTCOMES;MINIMALLY INVASIVE;MULTICENTER STUDY;MYOCARDIAL INFARCTION;NEUROENDOCRINE TUMORS;NSCLC PATIENTS;SARS-COV- INFECTION;SICKLE CELL;ACUTE CORONARY;ADVANCED NON-SMALL;ARTERY DISEASE","14;14;11;8;6;6;6;6;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;3;3;3","HR CI;PARTIAL NEPHRECTOMY;LUNG CANCER;ADVERSE EVENTS;CORONARY ARTERY;MEDIAN AGE;PROGRESSION-FREE SURVIVAL;RENAL FUNCTION;PATIENTS TREATED;RISK FACTORS;LOGISTIC REGRESSION;RENAL MASSES;SIGNIFICANT DIFFERENCES;NON-SMALL CELL;STAGE III;ADULT PATIENTS;CELL LUNG;CLINICAL PRACTICE;MEDIAN FOLLOW-UP;PROSTATE CANCER;COVID- PANDEMIC;PATIENTS UNDERGOING;PRIMARY ENDPOINT;AHR CI;CML PATIENTS;CONFIDENCE INTERVAL;ROBOT-ASSISTED PARTIAL;STATISTICALLY SIGNIFICANT;SUICIDAL IDEATION;SURVIVAL PFS","28;23;22;20;17;17;17;17;15;15;14;14;14;13;13;12;12;12;12;12;11;11;11;10;10;10;10;10;10;10",111,0.52,8.4,8.5,1,1,0,2,2,1,1,9.5,1,0,9,1,1,1,4,6,3,0,0,20,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_GONZAGA",2023,267,20.5393258426966,2.97378277153558,0.336272040302267,0.243445692883895,0.250936329588015,0.157303370786517,0.651685393258427,0,130,34,14,15,0.49,0.13,0.05,0.06,6.74,1.53808703655231,0.449438202247191,0.970037453183521,6.77653213751868,0.559606271501878,0.532589694497628,0.451386071670047,0.508525956801819,"DANIELE AMPARORE;CRISTIAN FIORI;FRANCESCO PORPIGLIA;ENRICO CHECCUCCI;SABRINA DE CILLIS;SILVIA NOVELLO;FEDERICO PIRAMIDE;G. VOLPI;ENRICO CERRATO;GIUSEPPE MAINA;ALBERTO PIANA;FABIO LUIGI MASSIMO RICCIARDOLO;MATTEO BIANCO;F. PORPIGLIA;MATTEO MANFREDI;PAOLO VERRI;VITINA CARRIERO;FRANCESCO MARCHESI;PAOLO BIRONZO;FRANCESCA FARINA","33;28;25;23;23;21;18;15;14;13;13;12;12;11;11;10;10;10;10;10","DANIELE AMPARORE;GIUSEPPE MAINA;SABRINA DE CILLIS;CRISTIAN FIORI;FRANCESCO PORPIGLIA;ENRICO CHECCUCCI;FABIO LUIGI MASSIMO RICCIARDOLO;FEDERICO PIRAMIDE;SILVIA NOVELLO;VALERIO RICCI;PAOLO GERETTO;VITINA CARRIERO;FRANCESCA BERTOLINI;GIUSEPPE GUIDA;V. PHÉ;ENRICO CERRATO;G. VOLPI;SILVIA DE FRANCIA;GIANLUCA ROSSO;THOMAS FRACCALINI","2.77;2.36;2.26;2.21;1.75;1.65;1.41;1.29;1.28;1.17;1.06;1.04;1.04;1;0.97;0.94;0.94;0.88;0.86;0.86","DANIELE AMPARORE;CRISTIAN FIORI;FRANCESCO PORPIGLIA;ENRICO CHECCUCCI;SABRINA DE CILLIS;SILVIA NOVELLO;FEDERICO PIRAMIDE;G. VOLPI;ENRICO CERRATO;GIUSEPPE MAINA;ALBERTO PIANA;FABIO LUIGI MASSIMO RICCIARDOLO;MATTEO BIANCO;F. PORPIGLIA;MATTEO MANFREDI;PAOLO VERRI;VITINA CARRIERO;PAOLO BIRONZO;FRANCESCA BERTOLINI;FEDERICO ITRI","33;28;25;23;23;21;18;15;14;13;13;12;12;11;11;10;10;10;10;10","DANIELE AMPARORE;GIUSEPPE MAINA;SABRINA DE CILLIS;CRISTIAN FIORI;FRANCESCO PORPIGLIA;ENRICO CHECCUCCI;FABIO LUIGI MASSIMO RICCIARDOLO;FEDERICO PIRAMIDE;SILVIA NOVELLO;VALERIO RICCI;PAOLO GERETTO;VITINA CARRIERO;FRANCESCA BERTOLINI;GIUSEPPE GUIDA;ENRICO CERRATO;G. VOLPI;SILVIA DE FRANCIA;GIANLUCA ROSSO;THOMAS FRACCALINI;GABRIELE DI SALVO","2.77;2.36;2.26;2.21;1.75;1.65;1.41;1.29;1.28;1.17;1.06;1.04;1.04;1;0.94;0.94;0.88;0.86;0.86;0.83","SILVIA NOVELLO;CHRISTOPHE DOOMS;HEATHER A. WAKELEE;AYMAN SAMKARI;DELVYS RODRÍGUEZ‐ABREU;E. EIGENDORFF;GASTÓN L. MARTINENGO;JAMIE E. CHAFT;MARGARITA MAJEM;MOÏSHE LIBERMAN;O. BYLICKI;SHUGENG GAO;TERUFUMI KATO;JING YANG;JONATHAN SPICER;KE‐NENG CHEN;MASAHIRO TSUBOI;SE‐HOON LEE;STEVEN M. KELLER;ADRIANUS J. DE LANGEN","841;684;446;442;442;442;442;442;442;442;442;442;442;399;399;399;399;399;399;327","SILVIA NOVELLO;DANIELE AMPARORE;CRISTIAN FIORI;SABRINA DE CILLIS;FRANCESCO PORPIGLIA;FEDERICO PIRAMIDE;ALBERTO PIANA;PAOLO VERRI;FEDERICO ITRI;F. PORPIGLIA;GIAN LUCA FADDA;ENRICO CHECCUCCI;MICHELE SICA;ENRICO CERRATO;FRANCESCO PASSIGLIA;S. NOVELLO;GIOVANNI VOLPICELLI;GIOVANNI BUSACCA;GIUSEPPE MAINA;STEFANO DE LUCA","841;176;139;123;118;100;69;66;54;53;52;49;44;43;43;43;41;37;34;30","DANIELE AMPARORE;CRISTIAN FIORI;SABRINA DE CILLIS;FRANCESCO PORPIGLIA;SILVIA NOVELLO;FEDERICO PIRAMIDE;ENRICO CERRATO;GIUSEPPE MAINA;ALBERTO PIANA;MATTEO MANFREDI;F. PORPIGLIA;MATTEO BIANCO;PAOLO VERRI;PAOLO BIRONZO;FABIO LUIGI MASSIMO RICCIARDOLO;GIOVANNI BUSACCA;GIUSEPPE GUIDA;ALESSANDRA CHINAGLIA;FEDERICO ITRI;MICHELE SICA","33;27;23;22;20;18;14;12;11;11;11;11;10;10;10;9;9;9;9;9","MEDICINE;BIOLOGY;COMPUTER SCIENCE;CHEMISTRY;PHYSICS;PSYCHOLOGY;ENGINEERING;ECONOMICS;MATHEMATICS;SOCIOLOGY;BUSINESS;POLITICAL SCIENCE;MATERIALS SCIENCE;HISTORY;PHILOSOPHY","259;42;29;19;19;18;16;10;8;8;6;6;4;3;3","INTERNAL MEDICINE;SURGERY;ONCOLOGY;PATHOLOGY;GASTROENTEROLOGY;PSYCHIATRY;IMMUNOLOGY;CARDIOLOGY;ENVIRONMENTAL HEALTH;RADIOLOGY;UROLOGY;BIOCHEMISTRY;PEDIATRICS;INTENSIVE CARE MEDICINE;GENETICS;PALEONTOLOGY;ENDOCRINOLOGY;CLINICAL PSYCHOLOGY;CANCER RESEARCH;ARTIFICIAL INTELLIGENCE;EMERGENCY MEDICINE;MECHANICAL ENGINEERING","226;71;61;42;32;31;30;29;29;27;24;23;21;17;16;16;13;12;11;10;10;10","CANCER;DISEASE;COHORT;LUNG CANCER;POPULATION;CLINICAL TRIAL;CHEMOTHERAPY;GENE;KIDNEY;LUNG;RETROSPECTIVE COHORT STUDY;MYOCARDIAL INFARCTION;ADVERSE EFFECT;RANDOMIZED CONTROLLED TRIAL;LOGISTIC REGRESSION;COHORT STUDY;CONFIDENCE INTERVAL;MULTIPLE SCLEROSIS;MYELOID LEUKEMIA;ALTERNATIVE MEDICINE;ASTHMA;STAGE (STRATIGRAPHY)","72;34;31;27;26;24;19;17;17;17;17;16;15;15;12;11;11;11;11;10;10;10","PROSTATE CANCER;NEPHRECTOMY;IMMUNOTHERAPY;INFECTIOUS DISEASE (MEDICAL SPECIALTY);CLINICAL ENDPOINT;PROSTATE;ACUTE CORONARY SYNDROME;TOLERABILITY;ADENOCARCINOMA;COLORECTAL CANCER;HAZARD RATIO;PERCUTANEOUS CORONARY INTERVENTION;DOCETAXEL;EJECTION FRACTION;BREAST CANCER;IMATINIB;SUICIDE PREVENTION;2019-20 CORONAVIRUS OUTBREAK;CONVENTIONAL PCI;INTERIM ANALYSIS","23;15;14;14;12;11;10;10;9;9;9;9;7;7;6;6;6;5;5;5","CORONAVIRUS DISEASE 2019 (COVID-19);PEMBROLIZUMAB;PROSTATECTOMY;KRAS;NIVOLUMAB;CYSTECTOMY;NILOTINIB;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;ANTIRETROVIRAL THERAPY;DASATINIB;GLUTAMATE CARBOXYPEPTIDASE II;LOWER URINARY TRACT SYMPTOMS;SUICIDAL IDEATION;SUICIDE ATTEMPT;ACROMEGALY;ADJUVANT CHEMOTHERAPY;ANDROGEN DEPRIVATION THERAPY;CARBOPLATIN;DIFFUSING CAPACITY;DISEASE MANAGEMENT;DNA MISMATCH REPAIR;ERLOTINIB;GERMLINE MUTATION;IMATINIB MESYLATE;LEFT ATRIAL APPENDAGE OCCLUSION;MACE;MEPOLIZUMAB;NEUROENDOCRINE DIFFERENTIATION;OMALIZUMAB;PEMETREXED;PROSTATE BIOPSY;PROSTATE-SPECIFIC ANTIGEN;SEROTONERGIC;SINGLE-NUCLEOTIDE POLYMORPHISM;TIMI;TRASTUZUMAB","14;9;8;6;5;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2",";HUMANS;MALE;LUNG NEOPLASMS;ADULT;KIDNEY NEOPLASMS;RETROSPECTIVE STUDIES;FEMALE;PROSTATIC NEOPLASMS;CARCINOMA, NON-SMALL-CELL LUNG;AGED;COVID-19;TREATMENT OUTCOME;MIDDLE AGED;MULTIPLE SCLEROSIS;PERCUTANEOUS CORONARY INTERVENTION;ACUTE CORONARY SYNDROME;DIABETES MELLITUS, TYPE 1;PROSPECTIVE STUDIES;NEPHRECTOMY","143;122;39;30;27;25;25;23;23;22;20;20;19;17;17;14;13;12;12;11","ADVANCEMENTS IN LUNG CANCER RESEARCH;RENAL CELL CARCINOMA;PROSTATE CANCER RESEARCH AND TREATMENT;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;EFFICACY AND RESISTANCE IN CML TREATMENT;ASTHMA;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;CANCER IMMUNOTHERAPY;SURGICAL SIMULATION AND TRAINING TECHNIQUES;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;CORONAVIRUS DISEASE 2019 RESEARCH;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;PREVALENCE AND MANAGEMENT OF KIDNEY STONES;THERAPEUTIC ADVANCES IN CYSTIC FIBROSIS RESEARCH;ATRIAL FIBRILLATION;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION","14;14;12;9;9;7;6;6;6;5;5;5;4;4;4;4;4;4;3;3","CLINICAL ENDPOINT;TOLERABILITY;METASTATIC PROSTATE CANCER;TREATMENT;DISCONTINUATION;MRI IMAGING;PROSTATE CANCER;2019-20 CORONAVIRUS OUTBREAK;ASTHMA;PANDEMIC;STROKE (ENGINE);VIRTUAL REALITY TRAINING;BIOMARKERS FOR IMMUNOTHERAPY;CONCOMITANT;INTERIM ANALYSIS;REGIMEN;ADRENOCORTICAL CARCINOMA;ATEZOLIZUMAB;ECHOCARDIOGRAPHY;EGFR MUTATIONS","13;10;9;9;8;8;7;6;6;6;6;6;5;5;5;5;4;4;4;4","LUNG CANCER;PARTIAL NEPHRECTOMY;PROSTATE CANCER;MULTIPLE SCLEROSIS;ACUTE CORONARY;CANCER PATIENTS;CELL LUNG;EPICOVIDEHA REGISTRY;HEART FAILURE;PATIENTS PTS;RADICAL PROSTATECTOMY;ROBOT-ASSISTED PARTIAL;TYPE DIABETES;CELL CARCINOMA;CHRONIC MYELOID;CORONARY SYNDROME;NON-SMALL-CELL LUNG;PHASE II;RENAL CELL;RETROSPECTIVE STUDY;ROBOT-ASSISTED RADICAL;SEVERE ASTHMA;CANCER NSCLC;CARDIOVASCULAR DISEASE;COHORT STUDY;CORONARY ARTERY;CYSTIC FIBROSIS;ITALIAN MULTICENTER;MYELOID LEUKEMIA;NON-SMALL CELL","15;13;13;11;7;6;6;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4","HR CI;SELECTIVE CLAMPING;ADVERSE EVENTS;LUNG CANCER;MEDIAN AGE;MEDIAN FOLLOW-UP;COHORT STUDY;MOLECULAR RESPONSE;PATIENTS RECEIVING;PROGRESSION-FREE SURVIVAL;RETROSPECTIVE STUDY;ACTIVE SURVEILLANCE;HAEMATOLOGICAL MALIGNANCY;MYELOID LEUKEMIA;PATIENTS TREATED;SURVIVAL OS;PROSTATE CANCER;RESPONSE RATE;CHRONIC MYELOID;CLINICAL OUTCOMES;PRIMARY ENDPOINT;RISK FACTORS;TYROSINE KINASE;ACUTE CORONARY;CLINICAL PRACTICE;CORONARY SYNDROME;COVID- INFECTION;HEPATIC STEATOSIS;INCREASED RISK;MORTALITY RATE","34;23;21;19;19;16;15;15;15;14;14;13;13;13;13;13;12;12;11;11;11;11;11;10;10;10;10;10;10;10",100,0.37,9.67,14,2,1.5,0,14,0,0,1,15,2,1,14,1,1,2,3.25,9,5,0,0,9.25,9.25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_GONZAGA",2024,169,20.7455621301775,2.85207100591716,0.350622406639004,0.21301775147929,0.260355029585799,0.183431952662722,0.538461538461538,0,95,18,10,5,0.56,0.11,0.06,0.03,0.84,0.879180395403132,0.461538461538462,0.976331360946746,5.4720588235294,0.477270363342359,0.474622770919067,0.44,0.462854349951124,"DANIELE AMPARORE;SABRINA DE CILLIS;ENRICO CERRATO;FEDERICO PIRAMIDE;CRISTIAN FIORI;FRANCESCO PORPIGLIA;RICCARDO CAMPI;ALBERTO PIANA;MATTEO BIANCO;F. PORPIGLIA;SILVIA NOVELLO;ENRICO CHECCUCCI;GIUSEPPE MAINA;ALESSANDRA CHINAGLIA;SORAYA PUGLISI;CONSUELO BUTTIGLIERO;ALESSANDRO ANTONELLI;JAVIER ESCANED;MATTEO MANFREDI;MARTINA MANDALETTI","18;15;14;13;13;12;11;10;10;10;9;9;8;8;8;8;8;8;8;7","GIUSEPPE MAINA;MATTEO BIANCO;VALERIO RICCI;ENRICO CERRATO;DANIELE AMPARORE;SABRINA DE CILLIS;ALESSANDRA CHINAGLIA;FEDERICO PIRAMIDE;GIOVANNI MARTINOTTI;CRISTIAN FIORI;RICCARDO CAMPI;THOMAS FRACCALINI;ALBERTO PIANA;CARLOALBERTO BIOLÈ;FRANCESCO PORPIGLIA;CAROLA GRIFFITH BROOKLES;ENRICO CHECCUCCI;STEFANO PIZZIMENTI;MARTINA MANDALETTI;F. PORPIGLIA","1.52;1.25;1.14;1.13;1.11;1.01;0.98;0.77;0.75;0.73;0.73;0.72;0.71;0.65;0.63;0.58;0.56;0.54;0.53;0.52","DANIELE AMPARORE;SABRINA DE CILLIS;ENRICO CERRATO;FEDERICO PIRAMIDE;CRISTIAN FIORI;FRANCESCO PORPIGLIA;ALBERTO PIANA;MATTEO BIANCO;F. PORPIGLIA;SILVIA NOVELLO;GIUSEPPE MAINA;ALESSANDRA CHINAGLIA;SORAYA PUGLISI;CONSUELO BUTTIGLIERO;MATTEO MANFREDI;MARTINA MANDALETTI;MICHELE SICA;PAOLO VERRI;VALERIO RICCI;FERDINANDO VARBELLA","18;15;14;13;13;12;10;10;10;9;8;8;8;8;8;7;7;6;6;6","GIUSEPPE MAINA;MATTEO BIANCO;VALERIO RICCI;ENRICO CERRATO;DANIELE AMPARORE;SABRINA DE CILLIS;ALESSANDRA CHINAGLIA;FEDERICO PIRAMIDE;CRISTIAN FIORI;THOMAS FRACCALINI;ALBERTO PIANA;CARLOALBERTO BIOLÈ;FRANCESCO PORPIGLIA;CAROLA GRIFFITH BROOKLES;STEFANO PIZZIMENTI;MARTINA MANDALETTI;F. PORPIGLIA;MATTEO MANFREDI;VINCENZO RUSSOTTO;PAOLO BIRONZO","1.52;1.25;1.14;1.13;1.11;1.01;0.98;0.77;0.73;0.72;0.71;0.65;0.63;0.58;0.54;0.53;0.52;0.51;0.5;0.49","SILVIA NOVELLO;JAVIER ESCANED;ENRICO CERRATO;GIANLUCA CAMPO;IGNACIO J. AMAT‐SANTOS;GIANNI CASELLA;RAÚL MORENO;ROBERTO SCARSINI;SIMONE BISCAGLIA;VINCENZO GUIDUCCI;EMANUELE BARBATO;GIORGIO SACCHETTA;IGINIO COLAIORI;JOSÉ LUIS DÍEZ GIL;ANDREA MARRONE;MARINELLA CLERICO;ALESSIA DI SAPIO;ANGEL QIN;ANNA MINCHOM;ANTONIO PASSARO","23;22;21;20;20;19;19;19;19;19;17;17;17;17;15;15;14;14;14;14","ENRICO CERRATO;SILVIA NOVELLO;ALESSIA DI SAPIO;DANIELE AMPARORE;FEDERICO PIRAMIDE;FERDINANDO VARBELLA;CRISTIAN FIORI;FRANCESCO PORPIGLIA;GIUSEPPE MAINA;SABRINA DE CILLIS;ANNA CALABRESE;GIANLUCA ROSSO;SORAYA PUGLISI;F. PORPIGLIA;FRANCESCO PASSIGLIA;MATTEO BIANCO;ALESSANDRA CHINAGLIA;ANDREA VELTRI;ELENA MELCHIONDA;FEDERICO ITRI","20;16;14;12;12;11;10;9;9;9;6;6;6;5;5;5;4;4;4;4","DANIELE AMPARORE;CRISTIAN FIORI;ENRICO CERRATO;SABRINA DE CILLIS;FEDERICO PIRAMIDE;FRANCESCO PORPIGLIA;MATTEO BIANCO;ALESSANDRA CHINAGLIA;F. PORPIGLIA;ALBERTO PIANA;SILVIA NOVELLO;CONSUELO BUTTIGLIERO;MATTEO MANFREDI;SORAYA PUGLISI;MARTINA MANDALETTI;GIUSEPPE MAINA;MARCELLO DELLA CORTE;PAOLO VERRI;VALERIO RICCI;CARLOALBERTO BIOLÈ","18;16;14;14;13;10;10;9;9;9;9;8;8;7;7;7;6;6;6;5","MEDICINE;BIOLOGY;PSYCHOLOGY;COMPUTER SCIENCE;ECONOMICS;ENGINEERING;PHYSICS;SOCIOLOGY;CHEMISTRY;MATHEMATICS;PHILOSOPHY;POLITICAL SCIENCE;ART;HISTORY;BUSINESS;GEOGRAPHY","167;24;22;20;12;9;9;9;8;7;6;6;3;3;2;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;UROLOGY;CARDIOLOGY;PATHOLOGY;PSYCHIATRY;INTENSIVE CARE MEDICINE;IMMUNOLOGY;ENVIRONMENTAL HEALTH;RADIOLOGY;PEDIATRICS;PHYSICAL THERAPY;CANCER RESEARCH;GENETICS;NURSING;BIOINFORMATICS;PALEONTOLOGY;ARTIFICIAL INTELLIGENCE;BIOCHEMISTRY;EPISTEMOLOGY;GASTROENTEROLOGY;LAW;MECHANICAL ENGINEERING;MEDICAL EDUCATION","132;38;37;30;23;20;18;17;15;14;13;12;11;9;9;8;7;7;6;6;6;6;6;6;6","CANCER;DISEASE;MYOCARDIAL INFARCTION;POPULATION;COHORT;LUNG CANCER;CHEMOTHERAPY;RANDOMIZED CONTROLLED TRIAL;GENE;CLINICAL TRIAL;KIDNEY;OBSERVATIONAL STUDY;BIOPSY;PROPENSITY SCORE MATCHING;RENAL CELL CARCINOMA;RETROSPECTIVE COHORT STUDY;ALTERNATIVE MEDICINE;HEALTH CARE;LUNG;MULTIPLE SCLEROSIS;URINARY SYSTEM","54;19;15;14;12;12;11;11;10;9;9;9;8;8;8;8;7;6;6;6;6","PROSTATE CANCER;PROSTATE;CLINICAL ENDPOINT;NEPHRECTOMY;COLORECTAL CANCER;REVASCULARIZATION;BLADDER CANCER;CORONARY ANGIOGRAPHY;INFECTIOUS DISEASE (MEDICAL SPECIALTY);ACUTE CORONARY SYNDROME;BREAST CANCER;CULPRIT;DOCETAXEL;HAZARD RATIO;IMMUNOTHERAPY;NEURORADIOLOGY;BIPOLAR DISORDER;MUTATION;OVERACTIVE BLADDER;TELEMEDICINE","19;16;7;7;6;6;5;5;5;4;4;4;4;4;4;4;3;3;3;3","PROSTATECTOMY;ANDROGEN DEPRIVATION THERAPY;CORONAVIRUS DISEASE 2019 (COVID-19);LOWER URINARY TRACT SYMPTOMS;ANDROGEN RECEPTOR;ARTERY DISSECTION;OXALIPLATIN;PROSTATE-SPECIFIC ANTIGEN;ACROMEGALY;CARBOPLATIN;GERMLINE MUTATION;KRAS;NIVOLUMAB;PEMBROLIZUMAB;UROTHELIAL CARCINOMA;AXITINIB;BENIGN PROSTATIC HYPERPLASIA (BPH);BLADDER TUMOR;BRUTON'S TYROSINE KINASE;CANNABINOID RECEPTOR;CEBPA;CHROMATIN REMODELING;CORE BIOPSY;CYSTECTOMY;DIFFUSING CAPACITY;DNA METHYLATION;DOUBLE BLIND;EVANS SYNDROME;FRACTIONAL FLOW RESERVE;GENE EXPRESSION PROFILING;GENETIC HETEROGENEITY;GENETIC VARIANTS;IRINOTECAN;KARYOTYPE;LIRAGLUTIDE;MANIA;MEPOLIZUMAB;MYELOPROLIFERATIVE NEOPLASM;NEUROENDOCRINE DIFFERENTIATION;NONALCOHOLIC FATTY LIVER DISEASE;OMALIZUMAB;P2Y12;PARADOXICAL EMBOLISM;PEMETREXED;PENETRANCE;PITTSBURGH SLEEP QUALITY INDEX;PROSTATE BIOPSY;RENAL MASS;SLEEP HYGIENE;STEATOHEPATITIS;SUICIDE ATTEMPT;TAKOTSUBO SYNDROME;TELEHEALTH;TELEREHABILITATION;THYMIC INVOLUTION;TRASTUZUMAB;UROTHELIAL CANCER","8;5;5;5;3;3;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;MALE;FEMALE;AGED;MIDDLE AGED;ADULT;RETROSPECTIVE STUDIES;ITALY;TREATMENT OUTCOME;AGED, 80 AND OVER;RISK FACTORS;PROGNOSIS;FOLLOW-UP STUDIES;KIDNEY NEOPLASMS;NEOPLASM STAGING;PROSTATIC NEOPLASMS;ROBOTIC SURGICAL PROCEDURES;SURVEYS AND QUESTIONNAIRES;CARCINOMA, RENAL CELL","99;68;44;36;33;32;21;19;15;13;12;9;8;7;7;6;6;6;6;5","RENAL CELL CARCINOMA;PROSTATE CANCER RESEARCH AND TREATMENT;ADVANCEMENTS IN LUNG CANCER RESEARCH;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;STANDARDISATION OF LOWER URINARY TRACT FUNCTION;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;PHEOCHROMOCYTOMA AND PARAGANGLIOMA;PREVALENCE AND MANAGEMENT OF KIDNEY STONES;ASTHMA;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;MANAGEMENT OF CARDIOVASCULAR DISEASES DURING PREGNANCY;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;ARTIFICIAL INTELLIGENCE IN MEDICINE;CANCER IMMUNOTHERAPY;DIAGNOSIS AND MANAGEMENT OF HYPERTROPHIC CARDIOMYOPATHY;DIAGNOSIS AND MANAGEMENT OF PITUITARY DISORDERS;DIAGNOSIS AND TREATMENT OF LUNG CANCER;EPIDEMIOLOGY AND MANAGEMENT OF BIPOLAR DISORDER;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS","13;9;6;6;6;5;5;4;3;3;3;3;2;2;2;2;2;2;2;2","TREATMENT;CLINICAL ENDPOINT;METASTATIC PROSTATE CANCER;PROSTATE CANCER;CARDIAC IMAGING;ADRENOCORTICAL CARCINOMA;CULPRIT;MYOCARDIAL REVASCULARIZATION;NEURORADIOLOGY;RENAL CELL CARCINOMA;STROKE (ENGINE);VIRTUAL REALITY TRAINING;2019-20 CORONAVIRUS OUTBREAK;ARTERY DISSECTION;ASTHMA;CLINICAL SIGNIFICANCE;DELPHI METHOD;DIAGNOSIS;LOWER URINARY TRACT SYMPTOMS;MYOCARDIAL PERFUSION","9;8;7;6;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3","PROSTATE CANCER;LUNG CANCER;MULTIPLE SCLEROSIS;CELL CARCINOMA;CELL LUNG;FUNCTIONAL OUTCOMES;RENAL CELL;MYOCARDIAL INFARCTION;NON-SMALL CELL;OBSERVATIONAL STUDY;RADICAL PROSTATECTOMY;URINARY TRACT;LOWER URINARY;PATIENTS PTS;TRACT SYMPTOMS;ADRENOCORTICAL CARCINOMA;ARTERY DISSECTION;CANCER SCREENING;CASTRATION-RESISTANT PROSTATE;CLINICAL MANAGEMENT;CORONARY ARTERY;METASTATIC CASTRATION-RESISTANT;PARTIAL NEPHRECTOMY;PATIENTS UNDERGOING;ROBOT-ASSISTED RADICAL;SPONTANEOUS CORONARY;ACUTE CORONARY;ADULT PATIENTS;ADVANCED HER-NEGATIVE;ADVANCED NON-SMALL","14;11;8;6;6;6;6;5;5;5;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2","PATIENTS TREATED;LUNG CANCER;ADVERSE EVENTS;HR CI;NONCULPRIT VESSELS;CLINICAL PRACTICE;EXERCISE DISCUSSION;NON-ACTIVE SPMS;NSCLC PATIENTS;PARTIAL NEPHRECTOMY;PROSTATE CANCER;SURGICAL TRAINING;ACUTE CORONARY;CLINICAL TRIALS;FVII DEFICIENCY;PRIMARY ENDPOINT;RESPONSE RATE;SEVERE ASTHMA;SPMS PATIENTS;ADRENAL HYPERPLASIA;CANCER NSCLC;CELL LUNG;CLINICAL OUTCOME;CLINICAL OUTCOMES;CORONARY ARTERY;CORONARY SYNDROMES;CROSS-SECTIONAL STUDY;DISEASE CONTROL;FAMILY SCREENING;FUNCTIONAL ASSESSMENT","16;13;9;9;9;7;7;7;7;7;7;7;6;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5",2,0.01,1,2.5,0,0,0,0,0,0,0,2.5,0,0,2.5,0,0,1,0,3,0,0,0,1.5,1.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
